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Abstract 
 
 
Mitochondria are strictly maternally inherited, with all paternal mitochondria being 
destroyed following fertilisation.  Women known to be carriers of pathogenic mtDNA 
mutations are therefore at increased risk of conceiving affected children.  These women 
are currently offered the following options to aid in genetic counselling: oocyte 
donation, prenatal genetic diagnosis (PND) or preimplantation genetic diagnosis (PGD).     
 
One of the aims of this thesis, was to examine the feasibility of PGD for mtDNA 
inherited disorders, with specific emphasis on answering the following questions: how 
accurately does the mutation load observed in the biopsied blastomeres reflect the 
mutation load in the remaining embryo, are those mutation loads initially observed in 
the biopsied blastomeres maintained throughout preimplantation embryonic 
development and do mutation loads observed in the inner cell mass reflect those 
mutation loads observed in the extra-embryonic trophectoderm cells?  In my thesis, I 
have now been able to provide data towards answering each of these questions through 
the examination of mutation loads in oocytes, embryos and blastocysts obtained from 
mitochondrial patients undergoing fertility treatment.   
 
Techniques, which have been developed in my current laboratory, have facilitated the 
characterisation of a nuclear transfer technique known as pronuclear transfer (PNT). 
This is a method to prevent the transmission of mitochondrial DNA disease from 
mother to child (Craven et al, 2010).  As part of the work for my thesis, I have 
examined the reproducibility of the PNT technique by assessing whether the procedure 
could be performed by different operators, whilst maintaining levels of efficiency, 
survival and developmental outcome.   
 
Experiments are now being performed to examine the feasibility of PNT in normally 
fertilised human zygotes, created from donated oocytes. As it is unlikely that egg 
collection will be possible from two independent donors on the same day, the final 
purpose of this study was to examine the potential and feasibility of vitrification of eggs 
or fertilised embryos at both the pronuclear (PN) and Metaphase II (MII) stage for the 
purpose of the PNT technique.   
i i  
 
 
In summary, my studies has examined the reliability of current methods to reduce the 
likelihood of having a child affected by a mitochondrial DNA disorder and new 
techniques currently being developed to prevent the transmission of defective 
mitochondrial DNA, altogether.    I hope this will provide fresh hope for patients with 
mitochondrial DNA disease.  
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Chapter 1: Introduction 
 
1.1 Mitochondrial Biology  
1.1.1 Basic Mitochondrial Biology  
 
A major function of mitochondria is to support aerobic respiration and generate energy 
substrates in the form of ATP to support intracellular metabolic pathways (Schapira, 
2006).   Here a series of enzymes catalyse the transfer of electrons along a series of 
electron carriers to a final electron acceptor (molecular oxygen, which is subsequently 
reduced to water) eventually culminating in the generation of ATP.  
 
Mitochondria have also been shown to have additional functional roles within the cell 
forming a complex branching network with other organelles rendering them as essential 
components required for normal cellular function.   Given the fundamental role of 
mitochondria in the body, defects affecting their function can have several profound 
outcomes (Schapira, 2006).   
 
Mitochondrial diseases are generally attributed as a group of disorders which result 
from malfunctioning mitochondria. Until relatively recently, their prevalence in the population 
has been relatively underestimated.   
 
1.1.2 Mitochondrial origins   
 
Mitochondria were once free living life-forms derived from the ancient α –
proteobacteria, which were taken up by the ‘host’ cells as endosymbionts and 
transformed into intracellular organelles (Reyes-Prieto, 2007; Gross and Bhattacharya, 
2009; Alcock et al, 2010).   The exact mechanism by which mitochondria were engulfed 
has yet to be fully elucidated. Several hypotheses have been proposed to attempt to 
explain how this might have occurred (Martin, 2010; Embley and Martin, 2006).  The 
most well, established of these assumes that mitochondria originated following 
engulfment via phagocytosis by an α-proteobacterium by an anaerobic organism 
(Martin, 2010).   The alternative hypothesis posits that mitochondria originated 
following the simultaneous fusion of a methanogenic Archaebacterium (host) with a 
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hydrogen producing proteobacterium (symbiont) (Gray et al, 1999) (Fig1.1).  However 
as a consequence of endosymbiosis and evolutionary pressure the mitochondrial 
genome gradually relinquished more of its genomic content, resulting in the transfer of 
genes to the nuclear genome (Roger, 1999; Embley and Martin 2006).    However 
mitochondria retained a total of 37 genes encoding 2 rRNA, 22 tRNA and 13 
polypeptides. Why these genes have not undergone transfer to the nuclear genome has 
and still is fiercely debated.  One hypothesis proposes that some proteins are too highly 
hydrophobic to be imported across the mitochondrial membranes (Papot and Vitry, 
1990).  This may also be coupled to the fact that very hydrophobic proteins might also 
be mis-routed or fail to reach their end targets.  A second hypothesis suggested for the 
retention of genes in the mitochondrion is the potentially toxic nature of the gene 
products if present within the cytosol (Martin and Schnarrenberger, 1997).   The third 
considers that genes whose products have key roles in the electron transport and energy 
coupling must be quickly and directly regulated by the redox state of the mitochondrion 
(Allen, 1993; Adams and Palmer, 2002).     It has also been suggested that the non-
standard genetic code used in the mitochondrion of many eukaryotes is also involved in 
restricting complete transfer of all genes to the nuclear genome (Adams and Palmer, 
2002).     
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Figure1. 1Primary and secondary endosymbiosis  
 
The above schematic diagram represents the two models proposed to explain the 
mitochondrial endosymbiosis theory.   (a) Primary endosymbiosis was said to involve 
the engulfment of a bacterium (α-proteobacteria) by another free-living organism. (b) 
Secondary endosymbiosis is said to have occurred when the product of primary 
endosymbiosis was engulfed and retained by another free-living eukaryote.   An 
essential part of secondary endosymbiosis has been the transfer of genes for plastid 
proteins from the endosymbiont to the host nucleus (Adapted from original taken from 
Embley and Martin, 2006).  
 
 
 
 
Primary 
endosymbiosis 
Secondary 
endosymbiosis 
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1.1.3 Mitochondrial Structure  
 
Mitochondria are unique organelles, fundamentally required by the cell in order to 
transduce energy, and are approximately 0.5-1µm in diameter and up to 7µm long.  
Their shape and number is heavily dependent upon the particular tissue they reside.  
Mitochondrial shape can also vary where they have been observed as spheres, rods and 
filamentous bodies (Campello et al, 2010).   The number, distribution and morphology 
of mitochondria, often heavily influenced by the cells function and overall energy 
demands.   
 
It is also increasingly apparent that during early embryo-foetal development 
mitochondrial structure and dynamics are considerably different to those observed in 
adult cells and tissues where the morphology of cristae within mitochondria appears 
relatively underdeveloped and sparse within the sphere-like mitochondria (Squirrel and 
Bavister, 2000; Motta, 2000).  Indeed it is not until the latter stage of preimplantation 
development due to an increase in the energy demands that the density of inner 
mitochondrial membrane folding increases in response (Sathananthan and Trounson, 
2000) (Figure1.2b).   
 
Initial observations concerning mitochondrial structure were primarily made through 
electron microscopy work (EM), which ultimately led to the proposal of two models of 
predicted mitochondrial structure (Palade, 1953 and Sjostrand, 1953).  The two models 
initially proposed were named the ‘septa’ model (Sjorstand, 1953) and ‘baffle’ model 
(Palade, 1953), with the ‘baffle’ model ultimately being accepted and now depicted in 
most text books as the perceived model for mitochondria.   This model included the 
mitochondrial double membrane, both an inner and outer membrane, which define two 
internal compartments; the intermembrane space, which is the area that lies between the 
two membranes and the matrix, which lies within the inner membrane.   The inner 
membrane is further highly convoluted with numerous folds, which give rise to the 
‘cristae’ a feature highly characteristic of mitochondria.  Cristae have a functional role 
within the mitochondria where they significantly increase the surface area on which 
ATP synthesis can occur, therefore increasing the energy tranduction efficiency of the 
organelle.   The space within the cristae folds is sometimes referred to as the ‘intracristal 
space, where relatively recently new evidence, driven by the novel process of 
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cryoelectron tomography, has revealed this space to be a unique environment (Perkins 
and Frey, 2000; Frey and Mannella, 2000) 
 
The outer membrane contains many porin molecules (voltage-dependent anion channel 
or VDAC), a type of transport protein that forms large aqueous channels through the 
lipid bilayer (Alberts et al, 2005). The outer membrane is therefore rather like a ‘sieve’ 
as it is permeable to molecules of 5000 daltons or less, including small proteins.  
However once a molecule accesses the inter-membrane space, it is normally unable to 
pass through the inner membrane, which is impermeable in comparison to the outer 
membrane.   
 
The inner membrane is highly specialised in comparison to the outer membrane and the 
primary site of the electron transport chain (ETC).   Furthermore it contains proteins 
with three different types of functions; those that carry out the oxidation reactions of the 
electron-transport chain; the actual ATP synthase that is responsible for making ATP 
and thirdly transport proteins which facilitate the passage of metabolites into and out of 
the matrix (Alberts, et al, 2005)(Fig1.2a).    
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Figure1. 2 Mitochondria within oocytes 
(a) Schematic representation depicting the traditional morphological structure of 
mitochondria.  (b) Electron microscopy (EM) images depicting mitochondria found 
within human oocytes and early cleavage stage embryos.  These mitochondria appear 
significantly different morphologically and structurally to mitochondria found at any 
other stage of development.  The organelles are sphere –like and contain fewer cristae, 
if indeed they are present at all. This is likely to be due to the reduced energy demands 
at this stage of development (Images taken from Motta et al, 2000). 
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1.1.4 The mitochondrial respiratory chain  
 
The electron transport chain comprises four complexes through which electrons are 
passed sequentially until they reach the final electron acceptor.    During electron 
transport, the enzymes of the electron transport chain create a proton gradient across the 
inner mitochondrial membrane.  This gradient is then utilised by the enzyme FoF1 ATP 
synthase to produce ATP an extremely important molecule which is often referred to as 
the ‘energy currency of a cell’ (as depicted in Fig1.3).   
 
Each respiratory chain complex is composed of multiple subunits, most of which are 
encoded by the nuclear genome, including all of the subunits of complex II (Morris et 
al, 1995).   The remaining four complexes comprise of both mitochondrial and nuclear 
encoded subunits.   Respiratory chain deficiencies are frequent causes of disease and 
result in a wide variety of diseases phenotypes (Morris et al, 1995).    
 
1.1.4.1 Complex I (NADH-coenzyme Q oxidoreductase)  
 
Complex I is the first and by far the largest and most complex protein in the electron 
transport chain   It is composed of 46 subunits (Yagi and Matsuno-Yagi, 2003; Carroll 
et al, 2006a). A total of seven subunits are encoded by mitochondrial genome and the 
remaining 39 by the nuclear genome (Hirst et al, 2003; Papa et al, 2007).  This enzyme 
catalyzes the electron transfer from NADH to ubiquinone, which is subsequently linked 
to the translocation of four protons through the inner mitochondrial membrane (Torres-
Bacete et al, 2011)    
 
1.1.4.2 Complex II (Succinate-Q oxioreductase)  
 
Complex II consists of four protein subunits (SDHA, SDHB, SDHC and SDHD), 
contains a bound flavin adenine nucleotide (FAD) cofactor, three iron-sulphur clusters 
[2Fe-4S], [3Fe-4S], and [4Fe-4S] and a heme group.  Complex II is the entry point of 
the electron transport chain for FADH2  formed as part of the citric acid cycle during the 
oxidation of succinate to fumarate by succinate dehydrogenase (Sun et al, 2005).  
Succinate dehydrogenase also forms part of the succinate-CoQ oxidoreductase complex 
otherwise known as complex II.  The two electrons are then transferred from FADH2 to 
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a series of iron-sulphur clusters which finally pass to ubiquinone (Q) and through a 
redox reaction form ubiquinol (QH2).   
 
1.1.4.3 Complex III (Q-cytochrome c oxidoreductase)  
 
Complex III was first discovered and purified from bovine heart mitochondria in 1961 
(Hatefi et al, 1961; Hatefi et al, 1962).  In mammals the enzyme is a dimer, with each of 
these sub-complexes containing 11 protein subunits, an iron-sulphur cluster and three 
heme prosthetic groups and two cytochromes (Iwata et al, 1998).  
 
The function of ubiquinol-cytochrome c oxidoreductase is to catalyze electron transfer 
from dihydroubiquinone (QH2) to oxidized cytochrome c, (Cyt c) which is subsequently 
coupled to transmembrane proton translocation (Leung and Hinkle, 1975).    The Q-
cycle, refers to the sequential oxidation and reduction of the lipophilic electron carrier, 
coenzyme Q10, whose role in the pumping of protons across the lipid bilayer, and was 
initially proposed by Peter Mitchell (1976). Here two electrons are transferred from 
QH2 to two molecules of cytochrome c (a water soluble electron carrier) as cytochrome 
c is only able to accept one electron at a time.  Two QH2 molecules bind to the complex 
consecutively, each giving up two electrons and two H
+
.  The protons are released to the 
cytosolic side of the membrane.  The first QH2 binds to the complex (via the Q binding 
site Qo) n and its electrons travel through the complex, to two different locations.  The 
first electron flows through the complex to its target oxidized cytochrome c, and 
converting it to its reduced form.  The second electron passes to an oxidized ubiquinone 
(found in a second Q binding site Qi).   Here the quinone in the first binding site is 
reduced to semi-quinone radical anion (Q.
-
) following the transfer of the first electron.  
The ubiquinione now fully oxidized leaves.  A second molecule of QH2 then binds and 
the first electron is passed to cytochrome c where it then reacts’ the same as the first 
time an electron was received.  The second electron passes to the partly reduced 
ubiquinone and subsequently takes up two protons from the matrix to form QH2.  The 
removal of two protons from the matrix leads to the formation of a proton gradient 
(Berg, Tymocozko and Stryer, 2012).   
 
 
 1 0  
1.1.4.4 Complex IV (Cytochrome c oxidase)  
 
Complex IV is the final protein complex in the electron transport chain (Calhoun et al, 
1994) and transfers electrons to oxygen, while pumping protons across the membrane 
(Yoshikawa et al, 2006).  The mammalian complex IV contains 13 subunits, two heme 
groups in addition to multiple metal cofactors (Tsukihara et al, 1996).   Complex IV 
catalyzes the transfer of electrons from the reduced form of cytochrome c to molecular 
oxygen, the final acceptor of the chain.  Furthermore it is coupled to the transfer of four 
protons across the membrane, contributing to the proton gradient.   
 
1.1.4.5 FoF1ATP synthase 
 
The mitochondrial FoF1 adenosine triphosphate synthase (FoF1 ATP synthase) is a 
membrane bound enzyme that couples the proton motive force across the inner 
mitochondrial membrane (IMM) to the synthesis of ATP in the matrix (Boyer, 1997; 
Walker, 1998; Rubinstein et al, 2003).  Electron microscopy, crystallographic and 
biochemical studies have all played pivotal roles in elucidating the function of the FoF1 
ATP synthase.  These studies have revealed that ATP synthase is a large complex which 
is composed of a proton-conducting unit and a catalytic unit (Berg et al, 2002).  These 
two subunits are more often referred to as the F1 and F0 subunits. The majority of the F0 
subunit is embedded in the inner mitochondrial membrane; this is highly hydrophobic 
and contains the proton channel.  The F1 ‘ball shaped’ subunit protrudes into the 
mitochondrial matrix and is responsible for the catalytic activity of the synthase.  These 
two subunits are then connected via ‘the central γε stalk’ and an exterior column (Berg, 
Tymoczko and Stryer, 2012) (Fig1.3).   
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1.2 Mitochondrial DNA  
 
1.2.1 Mitochondrial genome  
 
Mitochondria are unique organelles in that they contain their own genome which is 
present alongside the nuclear genome in the majority of eukaryotic cells.  Human 
mtDNA is a small double stranded molecule, 16.5kb in length and encoding 37 genes 
(22tRNA, 2rRNA and 13 polypeptides) all of which are essential for normal 
mitochondrial function (Fig1.4).  
 
Mitochondrial DNA is extremely compact. Mutation rates have been calculated as 5 to 
10 times higher than its nuclear counterpart.  This in turn explains the high degree of 
polymorphic mtDNA variants which are observed between individuals, the majority of 
which are neutral (Brown et al, 1979; 1982; Cao et al, 2009).   However occasionally 
mutations arise which are of a pathogenic nature and have the potential to cause disease 
if present in a great enough number of mtDNA molecules.  The first mutations were 
identified in 1988 (Holt et al, 1988; Wallace et al, 1988) and initially thought to be quite 
rare.  Since then, the incidence of known pathogenic mutations amongst the general 
population has increased significantly with at least 1 in 10,000 of the adult population 
affected by mtDNA disease (Schaefer et al, 2008; Turnbull et al, 2009).    Hence 
mitochondrial DNA mutations are increasingly becoming recognised as important 
causes of human disease.  
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Figure1. 4 The Mitochondrial genome  
Map depicting the, 16.5Kb mitochondrial genome.  The mitochondrial genome encodes 
22 mt-tRNAs (red circles), 2 mt-rRNA genes (red boxes) and 13 protein coding genes 
(these encode proteins involved in respiratory chain complex assembly).  Here the 
single- letter code is given to represent each of the 22 tRNA genes encoded by the 
mitochondrial genome.  (COI, Complex I; COII, Complex II; COIII, Complex III; ND1, 
NADH Dehydrogenase, subunit 1 ; ND2, NADH Dehydrogenase, subunit 2 ; ND3, 
NADH Dehydrogenase, subunit 3;ND4, NADH dehydrogenase subunit 4; ND5, NADH 
Dehydrogenase Subunit 5; ND6, NADH Dehydrogenase, subunit 6 (blue boxes)).   
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1.2.2 Mitochondrial genome organisation  
 
Mitochondrial DNA (mtDNA) was once thought to exist in an unorganised free form 
within the mitochondrial matrix however it is now clearly apparent that mtDNA is 
indeed organised into macromolecular assemblies we now refer to as nucleoids 
(Glikerson, 2009).   Nucleoids are believed to be involved in the organization and 
maintenance of mtDNA and are approximately 70nm in diameter (Iborra et al, 2007).  
The discrete nature of the mitochondrial nucleoid provides an efficient packaging of 
mtDNA for maintenance and propagation (Gilkerson, 2009).   
 
1.2.3 MtDNA Replication  
 
Currently there are two proposed models of mtDNA replication.  The initial model of 
replication termed ‘strand displacement’ or the ‘asynchronous model’   and the second 
referred to as the ‘strand-coupled model’ or ‘symmetric model’ 
1.2.3.1 Strand displacement model  
 
The ‘strand displacement’ model of replication was first proposed by Robbertson et al 
(1972) who by the use of electron microscopy (EM) demonstrated that fully duplex 
replicative intermediates were not present within the cells under observation 
(Bogenhagen and Clayton, 2003).  However the EM studies did reveal the occurrence of 
partially replicated displacement loop (D-loop) regions.   This was later mapped to a 
unique location within the mitochondrial genome to only later become referred to as the 
‘control region’ said to be generated by the delayed completion of the newly 
synthesized L-strand.   These initial studies were later confirmed by studies performed 
by Tapper and Clayton (1981; 1982) and Kang et al (1997).     
 
According to the strand displacement model of replication, synthesis of the leading 
strand is initiated at the origin of heavy (H)-strand synthesis (OH) which then proceeds 
uni-directionally, displacing the parental H-strand as single stranded DNA (ssDNA).  
The enlargement of the D-loop proceeds for a distance of about two thirds around the 
circular genome (Brown et al, 2005).    
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The origin of replication for the lagging strand, termed the origin of light (L) - strand 
synthesis (OL), is then exposed, and synthesis of the nascent L-strand proceeds in the 
opposite direction on the single stranded template of the expanded D-loop (Exp-D).   
 
With the asymmetric model of mtDNA replication one of the resulting daughter 
molecules with its new L-strand is delayed in completion with respect to the other 
daughter molecule and therefore segregates prior to fully completing replication.  This 
leaves an area of the H-strand region single stranded which is termed ‘gapped circles’ 
since they contain a gap in the newly synthesized L-strand DNA.   However there are 
those who dispute the ‘strand displacement’ model of replication on the basis that the 
model is based upon an artefact of preparation in which discontinuously synthesized 
‘lagging’ strands are preferentially degraded due to both a very high rate of 
ribosubstitution in that strand and the high RNAse H –like activity which is present as 
contaminant in the preparations (Brown et al, 2005) (Fig1.5a).   
 
1.2.3.2 Strand coupled model  
 
However several papers re-examined the proposed ‘strand displacement model’ of 
mammalian mtDNA replication and proposed a new model, referred to as the ‘strand 
coupled’ model of mtDNA replication (symmetric replication) (Holt et al, 2000; Yang 
et al, 2002; Bowmaker et al, 2003; Yasukawa et al. 2005) using a technique based on 
the ‘Brewer and Fangman 2D-gel electrophoresis method’ (Friedman and Brewer 
1995).   
 
Following these methods, Holt and coworkers (Holt et al. 2000) revealed y-arcs in 
restriction digest-generated fragments corresponding to an area between the two origins 
of replication. Replication forks of this type in this mtDNA region are inconsistent with 
the asymmetric strand-displacement model of replication (Holt et al, 2000).  Holt, 
Jacobs, and collaborators (Yang et al, 2002; Bowmaker et al, 2003) therefore concluded 
that mtDNA replicates symmetrically, with leading- and lagging- strand synthesis 
progressing from multiple, bidirectional replication forks within a broad zone (see 
Fig.1.5b).  They also proposed that the strand-displacement model of replication is 
based on an artifact of preparation in which discontinuously synthesized “lagging” 
strands are preferentially degraded due to both a very high rate of ribosubstitution in 
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that strand and an RNase H-like activity that is envisioned as a contaminant in those 
preparations (Holt et al, 2000; Brown et al, 2005) (Fig1.5b). 
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Figure1. 5Comparing asynchronous (displacement) model of replication to 
conventional strand-synchronous (symmetric) replication.   
 (a) The displacement model of replication proceeds with single-stranded replication of the 
H-strand with further expansion and displacement of the D-loop.  The intermediates are 
called expanded D-loops (Exp-D).  The Expanded D-loop intermediates continue until the 
L-strand origin (OL) becomes exposed, at which point synthesis of the new L-strand 
commences in the opposite direction.  This mode of replication ultimately results in the 
production of complete daughter molecule and one incompletely synthesized L-strand, 
called a gap circle (GpC).   (b) The Strand coupled model of replication (a-synchronous) 
assumes there to be a zone of replication intuition, which encompasses an area beyond the 
simple D-loop.  It is from within this zone that both strands are synthesized bi-directionally 
as the double-stranded replication forks proceeds through the length of the mtDNA.   
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1.3 Mitochondrial DNA Inheritance  
 
1.3.1 Maternal inheritance  
 
Mitochondrial DNA is inherited through the maternal lineage inclusively with all 
paternal mitochondria contributed at the point of fertilisation targeted for degradation by 
ubiquitin soon after their introduction into the ooplasm of the mature ovum (see below).   
 
As all mitochondria in the zygote derive from the ovum a mother harbouring an mtDNA 
mutation could potentially transmit this to future children to some varying degree, 
however only her daughters will pass it on to their progeny.  The degree to which her 
offspring are affected can vary vastly due to a phenomenon known as the ‘bottleneck 
effect’ which filters and ultimately determines which mitochondria each offspring will 
receive.   
 
 
1.3.1 Destruction of paternal mitochondria  
 
It has been estimated that human spermatozoa contain between 700 and 1200 copies of 
mtDNA (Diez-Sanchez et al, 2003) which enter the oocyte at fertilisation and are 
present within the cytoplasm.   However as mentioned previously the paternal 
mitochondria are eliminated from the oocyte, shortly after fertilization (Fig 1.6). The 
exact developmental stage at which this occurs and the precise mechanism by which the 
paternal mitochondria are removed varies between published studies.    Currently there 
are two mechanisms which have been proposed to explain the removal of paternal 
mitochondria.  The first invokes the ubiquitin tagging system in the selective removal of 
sperm mitochondria inside the fertilised egg (Sutovsky et al, 1999).  The second 
hypothesis proposes that upon fertilisation several sperm components including 
mitochondria, enter the oocyte and are rapidly degraded by autophagy (Rawi et al, 
2011). 
 
However there is some evidence which suggests that on rare occasions paternal 
mitochondria are able to evade elimination and contribute to the population of 
mitochondria which go on to populate the embryo (Bromham et al, 2003). An example 
of this extremely unusual paternal transmission is provided by a single report of a 
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pathogenic mtDNA mutation within paternally derived mtDNA in a patient with muscle 
myopathy (Schwartz and Vissing, 2002). 
 
Introduction of IVF techniques which involve the direct injection of sperm into the 
oocyte has been suggested as an artificial route of entry which could facilitate the 
contribution of paternal mitochondria to the zygote (Sutovsky et al, 2004; Spikings et al, 
2006).  However there is insufficient evidence to support this, but there is strong 
evidence to suggest the contrary (Houshmand et al, 1997; Danan et al, 1999; 
Marchington et al, 2002).   
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Figure1. 6 Destruction of paternal mitochondria  
 
This schematic diagram depicts the removal of paternal mitochondria upon fertilization, 
resulting in the strict maternal inheritance of all mtDNA.  (a) The mature oocyte 
contains many thousands of mitochondria (shown in green) whilst the sperm contains 
relatively few mitochondria (shown in purple).  (b) Shoetly following fertilisation, 
paternal mitochondria is introduced into the oocyte, are targeted for destruction.  (c) The 
resulting embryo contains only maternally-inherited mitochondria.   
 
 
 
Fertilisation 
 
Key 
Female pronuclei  
Male pronuclei  
Polar Bodies 
Male mitochondria   
Female mitochondria  
Sperm 
Spindle  
Paternal nuclear DNA    
a 
b 
c 
 2 1  
1.3.2 Mitochondrial DNA mutations  
 
Since the identification of the first mitochondrial pathogenic mutation in 1988, >300 
have been documented.  These take the form of point mutations or rearrangements 
(deletions or duplications). These either affect protein synthesis if they alter a tRNA or 
rRNA or alter the normal functioning of the respiratory chain if they lie within one of 
the genes which encode one of the subunits or enzymes of the respiratory chain 
(Turnbull et al, 2009).  
1.3.2.1 MtDNA point mutations  
 
Numerous mtDNA point mutations have been documented in protein encoding genes, 
tRNAs and rRNAs.  However the criteria for defining pathogenic point mutations from 
mere harmless polymorphic mutations has proven difficult due to the complex nature 
which exists between the lack of genotype and phenotype correlation for some 
mitochondrial diseases (DiMauro and Schon, 2001; Schapira, 2006).  Examples of 
mitochondrial DNA diseases associated with point mutations within protein coding 
genes include maternally inherited Leigh syndrome (MILS) caused by a point mutation 
in the ATP6 gene (m.8993T>C), and Leber’s hereditary optic neuropathy (LOHN) 
which is usually due to one of three mutations all found within the MTND gene of 
complex I (m.3460G>A, m.11778G>A and m.14484T>C). Point mutations within the 
mitochondrial tRNA genes may affect the function of oxidative phosphorylation by 
disrupting both the structure and function of the mt-tRNA molecule, resulting in 
impaired mitochondrial translation.  Examples of mitochondrial DNA diseases 
associated with point mutations within tRNA genes include mitochondrial 
encephalopathy, lactic acidosis and stroke-like episodes (MELAS) due to a point 
mutation within the MT-TL1 gene (m.3243A>G), and myoclonic epilepsy and ragged 
red fibres (MERRF) which is commonly caused by a point mutation in the MT-TK gene 
(m.8344A>G). 
1.3.2.2 MtDNA deletions  
 
Mitochondrial deletions are a primary cause of mtDNA disease, which can occur as 
single or multiple mtDNA deletions.  Single mtDNA deletions are a common cause of 
sporadic mitochondrial disease, with the identical mutation present within every cell of 
the individual (Schaefer et al, 2008).    Single mtDNA deletions usually occur 
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sporadically in early development, although there are several reports of mtDNA 
deletions that appear to have been maternally transmitted (Bernes et al, 1993; Shanske 
et al, 2002).    Examples of mitochondrial DNA diseases associated with single large-
scale deletions include Kearns-Sayre syndrome (KSS) and chronic progressive external 
opthalmoplegia (CPEO), which both involve deletion of several mitochondrial genes.    
However there are also patients who harbour multiple mtDNA deletions, which are 
primarily thought to arise due a defect in a nuclear encoded gene. The proteins which 
are affected are normally involved in mitochondrial nucleotide metabolism or mtDNA 
maintenance. Multiple mtDNA deletions are usually found at higher levels in the 
muscle and central nervous system (Taylor and Turnbull, 2005; Krishnan et al, 2008).    
There are also numerous reports which link mtDNA deletions with neurodegenerative 
disease (Beal, 2004; Reeve et al, 2008; Gu et al, 2002). 
 
The exact mechanism by which mtDNA deletions occur has yet to be fully resolved.   
Currently there are two primary schools of thought as to how deletions arise the first  
during replication of mtDNA and the second during repair of damaged mtDNA 
(Krishnan et al, 2008).    Currently the slipped -strand mode of replication is favoured 
by most scientists.  However there are flaws to this suggested mechanism or this to 
workthe mtDNA would not  replicati and furthermore replicating at the point where the 
single stranded 5 and 3 repeats come together to form a loop when the strand break 
occurs (krishnan et al, 2008).    Krishnan et al (2008) was the first to propose formation 
of mtDNA deletions through repair of damaged mtDNA.   This model proposed that 
mtDNA deletions are initiated by single-stranded regions of mtDNA generated through 
exonuclease activity at double stranded breaks.  The single strands generated would 
then be free to anneal with the repeat sequences present single stranded.     
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1.3.3 Homoplasmy and Heteroplasmy 
 
There are thousands of mtDNA molecules per cell, with copy number varying depending 
upon cell type and function.    Usually a cell will contain identical copies of the wild-
type mtDNA sequence.    However where there is an mtDNA mutation which arises in 
the germ line, all copies present in the cell may then contain this mutation, which would 
be referred to as a homoplasmic mutation.  Equally only a proportion of mtDNA may 
possess the mutation and this is referred to as heteroplasmy (Turnbull et al, 2009) 
(Fig1.7).  
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Figure1. 7 Heteroplasmy and Homoplasmy  
 
Schematic diagram representing the three different possible situations which may 
be observed for mitochondrial distribution.   If a cell contains copies which are all 
affected a cell would be described as ‘homoplasmic’ for this particular mutation, 
if an individual cell receives a mixture of affected and normal mitochondria this 
would be said to be ‘heteroplasmic’  and finally a cell which has a full 
complement of normal unaffected mitochondria, as wild-type.    
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1.3.4 Threshold Effect  
 
The ratio of mutant to wild type mtDNA plays a pivotal role in determining the degree 
to which an individual is affected by mitochondrial disease.  Typically between 60-90% 
mutated mtDNA is required for a clinical phenotype to develop which is usually 
referred to as the ‘threshold’ effect.  However this margin can vary depending upon the 
specific mtDNA mutation and the cell type under examination (Chinnery et al, 1997).     
 
Furthermore, in a proportion of individuals who present with a heteroplasmic mtDNA 
mutation, not all cells will show evidence of a biochemical defect, which can be the 
result of a tissue-specific pattern of segregation, where tissues which exert high energy 
demands exhibit high mutation loads (Turnbull et al, 2009) (Fig1.8).  
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Figure1. 8 The threshold effect  
Under normal conditions healthy individuals will contain one type of 
mtDNA molecule referred to as wild type mtDNA.  However wild-type and 
mutant copies of mtDNA can co-exist within the same cell. When this occurs 
a state of heteroplasmy is said to exist.  A third state can also exist, when all 
copies of mtDNA are mutated which is referred to as homoplasmy.  The ratio 
of wild-type to mutated mtDNA contained within an individual cell can vary 
between cells and often tissues within the same individual carrying a, 
mtDNA mutation.  The point at which a biochemical defect is detected 
within an individual, using molecular techniques is known as the ‘threshold’.  
The threshold often differs and is highly mutation dependent.   
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1.3.5 The mtDNA Bottleneck  
 
Females carrying a mixture of mutant and wild-type mtDNA variants run the risk of 
transmitting a variable amount of mutant mtDNA to each offspring (Cao et al, 2009).    
The exact mechanism which governs how and which mitochondria are transmitted to 
future offspring is still not clear.    However the presence of ‘genetic bottleneck’ during 
early embryonic development is believed to be responsible for the variable levels of 
mutated mtDNA observed in affected offspring from mothers with pathogenic mtDNA 
mutations (Taylor et al, 2005).   
 
Therefore although a ‘genetic bottleneck’ is known to be responsible for creating the 
variation we observe, the exact point during embryonic development at which this 
genetic bottleneck occurs is still unknown.  However there are several studies which 
have attempted to unravel the bottleneck in order to better understand why mtDNA 
inheritance is prone to such variance.  There are several different mechanisms which 
could explain the differing levels of heteroplasmy we observe within families affected 
by mitochondrial disease.  This includes; a marked reduction in the number of mtDNA 
molecules being transmitted from mother to offspring (the mitochondrial genetic 
bottleneck), the partitioning of mtDNA into homoplasmic segregating units, the 
selection of a group of mtDNA molecules to re-populate the next generation (Cree et al, 
2008). Three different studies have been performed to try and shed further light on the 
genetic bottleneck, each reaching different outcomes, which are described in greater 
detail below.   
 
The first model proposed by Cree et al (2007), suggests that the bottleneck results from 
a ‘physical’ process combined with a dramatic reduction in mtDNA copies during pre-
implantation and post-implantation development. Together this is said to create the 
genetic variation in heteroplasmy levels seen among offspring of heteroplasmic mtDNA 
mutation carriers.    The majority of the heteroplasmy variance (~70%) they were able 
to show experimentally would be created as a result of physical partitioning of the 
mtDNA molecules into daughter cells during pre- and early post-implantation 
development when the amount of mtDNA in each cell is relatively low (~200 copies).   
The remainder of the variation (~30%) is likely to occur during the intense proliferation 
of mtDNA in the exponentially expanding primordial germ cell (PGC) population (cells 
which give rise to the gametes), where the average amount of mtDNA was ~1,500 
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molecules per PGC.  This study also disputed the theory that the mtDNA genetic 
bottleneck was the result of compartmentalization of the mtDNA molecules into multi-
copy segregating units such as nucleoids or through the selection of a particular group 
of mtDNAs chosen to repopulate the next generation.   
 
However the second model proposed by Cao et al (2009) concluded that the genetic 
bottleneck is generated without a dramatic reduction in mtDNA content in germ cells 
(PGCs).   They also postulated that the genetic bottleneck is likely to result from the 
replication of a small effective number of segregating units each containing multiple 
copies of mitochondrial genomes during oocyte maturation.  This they said was likely to 
occur in combination with a strong purifying selection against severe mutations over a 
long period of time in the germ line (Cao et al, 2009).    
 
The third mechanisms proposed by Wai et al (2008) also suggests, that the genetic 
bottleneck is likely to result from replication of only a subgroup of mitochondria.   As 
they’re experiments found that only a small sub-group of mitochondria actually 
appeared to be actively undergoing replication in the primordial and primary follicles.  
From this data they therefor deduced that there were likely to be two genetic bottlenecks 
acting at different times during embryonic development. Here a physical bottleneck 
(~200 mtDNAs) occurring in the earliest PGCs, most likely enables selection against 
severely deleterious mtDNA mutations.  Whilst the second genetic bottleneck which 
would be responsible for the segregation of neutral sequence variants which they regard 
to be associated with human disease, occurring instead during folliculogenesis. This 
would most likely take place in early post-natal life, as a result of replication of a 
subpopulation of mtDNAs.   This can be explained by the high copy number in mature 
oocytes (~175,000, likely organized as 1-2 copies per organelle) which can be viewed 
as a genetic device to ensure even distribution of mitochondria to the cells of the early 
embryo at a time when mitochondrial biogenesis is arrested (Fig1.9).   
 
Understanding what how and why mitochondria are transmitted will ultimately allow us 
to greatly improve our understanding of mitochondrial inheritance.   This information 
regarding mtDNA content during early embryonic development will facilitate the 
development of therapeutic strategies blocking the mitochondrial disease transmission 
from mother to progeny.  However as we still do not as yet know why certain mutant 
mtDNA appear to segregate in a tissue specific manner and why some mutant mtDNA 
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are lost within several generations while others persist long enough to be transmitted to 
future generations the question remains unresolved (Schapira, 2006; Chinnery et al, 
1998).  
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Figure1. 9 The mtDNA bottleneck  
Schematic diagram representing changes in the number of mitochondria during 
development of the female germ line. An estimate of the number of 
mitochondria present at each stage of germ line development is given (estimates 
based on approximate numbers present in the mouse).   This diagram represents 
the potential presence of a genetic bottleneck influencing the transmission 
pattern of mtDNA during the creation of the primordial germ cells.  This model 
also suggests that the segregation of mtDNA sequence variants is essentially 
complete by the time the primary oocytes are differentiated in foetal life 
(Adapted from original image by Shoubridge and Wai, 2007).   
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1.4  Management and diagnosis of mtDNA disease  
 
1.4.1 Diagnosing mtDNA disease   
 
Mitochondrial disease can present with a wide variety of symptoms and is often 
multisystematic, or affecting specific tissues or organs dependent upon the causative 
defect (McFarland and Turnbull, 2009; Taylor and Turnbull, 2005).  Patients with 
mtDNA disease have been said to fall in to one of three groups; those with a clearly 
recognised syndrome which is associated with specific mtDNA abnormality, secondly 
those who are said to have a cluster of clinical features which suggests that they have a 
mtDNA defect and finally those who are referred with an unusual clinical presentation 
which may be the result of a pathological mtDNA mutation (Chinnery and Turnbull, 
1997).   
 
There are several common phenotypic symptoms characteristically associated with 
mtDNA disease: asymmetric ptosis, short stature, migraines/headaches, seizures, 
neuropathy, diabetes, deafness and proximal limb muscle weakness (Chinnery et al, 
1997; MacFarland and Turnbull, 2009).   A number of ‘classical’ syndromes have been 
described that are often, but not always, associated with a particular genotype 
(McFarland and Turnbull, 2009).   However the association of phenotype with genotype 
is far from straightforward in mitochondrial disease, often with mutations in mtDNA 
and nDNA resulting in similar phenotypes (McFarland and Turnbull, 2009).  Indeed 
there is often diverse variety in clinical phenotypes observed between patients known to 
harbour the same mutation, with the m.3243A>G mutation demonstrating this best, with 
at least three different phenotypes associated with this single mutation, including; 
mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), 
maternally inherited diabetes and deafness (MIDD) and chronic progressive 
externalopthalmoplegia (CPEO) (McFarland and Turnbull, 2009).   In childhood 
presentations of mtDNA disease, symptoms often tend to be more severe than those 
with onset in adult-life and can often affect life expectancy (MacFarland and Turnbull, 
2009).    Mitochondrial disease can present at any age (Moraes et al, 1989).   
  
Most patients with mtDNA disease have either a deletion or point mutation (Moraes et 
al, 1993; Chinnery et al, 1997; Chinnery and Turnbull, 1997).     MELAS 
(mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes), is 
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caused by a point mutation in the mitochondrial leucine (UUR) tRNA (MTTL1) gene 
m.3243A>G.  A set of diagnostic criteria was originally proposed for MELAS, 
including; stroke before the age of 40; an encephalopathy characterized by seizures, 
dementia or both and finally a blood lactic acidosis or ragged red fibres in skeletal 
muscle. Both, however, can be present simultaneously (Hirano et al, 1992; Goto et al, 
1990; Chinnery and Turnbull, 1997).    Another commonly diagnosed mitochondrial 
disorder is MERRF (myoclonic epilepsy with ragged red fibres) and results from a point 
mutation in the mitochondrial lysine tRNA gene m.8344A>G (Shoffner et al, 1990).  
Although there is considerable overlap in clinical presentation of MELAS and MERRF, 
they are both distinct syndromes resulting from point mutations in two different tRNAs 
(Chinnery et al, 1997).   NARP (neurogenic weakness, ataxia and retinitis pigmentosa), 
(Holt et al, 1990; Shoffner et al, 1992; Chinnery et al, 1997), is sub-acute 
encephalopathy in childhood with prominent brain stem signs (Leigh syndromes) 
(Shoffner et al, 1992).  This mutation is most commonly associated with two point 
mutations mt.8993T>G and mt.8993T>C both located within the MT-ATP6 gene.  The 
mt.8993T>G is generally associated with a more severe clinical phenotype in 
comparison to the mt.8993T>C variant, which even at similar levels of mutation is 
generally associated with a much milder and less severe phenotype.   Individuals who 
present with clinical phenotypes reminiscent of NARP syndrome most frequently carry 
the mutation at high levels; >80% and >75% for the mt.8993T>C and mt.8993T>G 
mutations, respectively (Steffann et al, 2007).  Due to these extremely high mutation 
levels the risk of recurrence for this particular mutation is often equally as high.   
 
Numerous clinical investigations are often conducted when making a clinically 
confirmed diagnosis of mitochondrial disease.  These include urinary dipstick 
assessment for blood, protein and glucose to assess potential renal involvement.  Blood 
tests can provide additional supportive evidence, ensuring analysis of creatine kinase, 
resting blood lactate, full blood count, urea and electrolytes, liver function tests, blood 
glucose and thyroxine status.  Respirometry, electrocardiogram (ECG), lumbar 
puncture,  electroencephalogram (EEG) and MRI can also all be included to aid in 
making a full clinical diagnosis  (MacFarland and Turnbull, 2009).  
 
Muscle biopsies are often performed to allow for histological and histochemical 
analysis, which still remains viewed as the ‘gold standard’ for the detection of 
mitochondrial disease (Taylor et al, 2004).  A battery of histochemical assays are, now 
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routinely performed on muscle biopsy tissue, including the Gomori trichrome stain, 
succinate dehydrogenase (SDH) assay, and cytochrome c oxidase (COX).     The 
additional information provided by these mitochondrial enzyme histochemistry assays is 
often combined and interpreted alongside clinical, personal information and results of 
biochemical respiratory chain analysis. This provides a comprehensive diagnosis.  
Increasingly, molecular genetic analysis is being employed in the investigation of 
mitochondrial disease. This is often following clinical, histochemical and biochemical 
analysis as this allows for a rational approach to molecular investigations to be 
undertaken.   
 
1.4.2 Management of mitochondrial disease  
 
Following a confirmed diagnosis of mitochondrial disease in patients, management of 
the condition is the best that can be hoped due to the current lack of therapies available 
at present to alter disease course (Chinnery et al, 1997).    
 
1.4.2.1 Pharmacological treatments 
 
Pharmacological treatments have often been considered to be of limited benefit to 
mtDNA patients providing only short lived symptomatic improvements (McFarland and 
Turnbull, 2009).   This is partly due to the multisystematic nature of mitochondrial 
disorders which means many different organ systems are affected.  Indeed those organs 
and tissues which are often worse affected by mitochondrial dysfunction are those 
which have the highest energy demands and rely upon mitochondria to function 
correctly.  This includes organs such as the heart, brain, liver and kidneys and tissues 
such as muscle.    
 
As a consequence patients who present with mtDNA disease often present with a broad 
spectrum of symptoms, which are often unique to that patient alone.   Indeed even 
patients who are known to harbour the same pathogenic mutation can be present with a 
different set of symptoms.  This has in the past made it incredibly difficult to tailor 
pharmacological treatments to suit all patients, as just as one treatment may help 
provide relief from symptoms for one patient it may not be able to do so for other 
patients due to the nature of mtDNA disease.    
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 Other issues which have hampered the success of studies examining pharmacological 
interventions, includes the relative small number of patients able to be included in trials 
(Taylor et al, 1997).   This is a result of the wide range of mtDNA mutations which can 
cause mtDNA disease, the relatively small number of patients which in-turn have been 
diagnosed with each known mutation, the diverse range of symptoms patients can 
present with, the effect of heteroplasmy and also effects of nuclear genome interactions.   
Meaning that the numbers of patients able to be included in specific drug trials is 
relatively low.   As a result it makes it difficult to assess the effectiveness and safety of 
pharmacological treatments.    
 
However mitochondrial medicine is a unique discipline that is evolving owing to 
advances in technology and knowledge regarding the role of mitochondria in disease 
development. Furthermore the unique structural and functional characteristics of 
mitochondria allow for selective intracellular targeting of drugs designed to modulate 
mitochondrial function for therapeutic gain. This is because mitochondria play a key 
role in; the regulation of energy metabolism, reactive oxygen species (ROS) production 
and apoptosis. Therefore, the specific delivery of drugs to mitochondria may provide 
the foundation to treat a variety of diseases wherein these functions are deregulated 
(Szewczyk and Wojtczak, 2002; Armstrong, 2007).  
 
Some of the potential therapeutic applications which have been proposed by utilising 
mitochondrial targeting include; the delivery of antioxidants to mitochondria to prevent 
oxidative damage associated with the neurodegenerative diseases, ischemia, tissue 
injury and diabetes. Secondly the targeting of toxic drugs or Bcl-2 proteins to the 
mitochondria to trigger apoptosis in cancer therapy.   Thirdly the delivery of drugs to 
mitochondria to inhibit the mitochondrial permeability transition (MPT) which occur 
following heart attacks and stroke. And fourthly the targeting of drugs to either 
uncouple the electron transport chain (ETC), or activate the uncoupling proteins which 
are involved in obesity and diabetes.   However, the development and implementation 
of successful therapeutic treatments targeted at disorders resulting from mitochondrial 
dysfunction are still some way off. This is due to both a lack of knowledge of the 
potential long-term toxic effects associated with some of the compounds being 
investigated for their use and secondly a current lack of efficient methods to regulate 
drug delivery to the tissue of interest (Armstrong, 2007).  
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1.4.2.2 Dietary supplementation  
 
Supplementation of diet with vitamins and minerals has shown to help in the 
management and alleviation of symptoms in patients with mitochondrial disease.  Here 
vitamins C and E, both anti-oxidants, are routinely prescribed to patients with 
mitochondrial disease although their role in ameliorating symptoms is often minor or 
absent (Sheu et al, 2006). Dietary supplementation with Ubiquinone (coenzyme Q10) 
has also shown promise (Matthews et al, 1993; Gold et al, 1996). Indeed a study 
published in 2010 (Dai et al, 2011) reported observing a reversal of mitochondrial 
dysfunction following coenzyme Q10 supplementation, however improvements were 
limited to improved endothelial function in patients with left ventricular systolic 
dysfunction (LVSD).      
 
1.4.2.3 Exercise studies  
 
Exercise intolerance in patients with heteroplasmic mtDNA mutations is predominately 
due to high ratios of mutant to wild-type mtDNA, which subsequently impairs the 
capacity to increase oxidative energy production during times of increased demand 
(Murphy et al, 2008).   Aerobic training has been suggested as a means by which to 
improve muscle oxidative capacity and compensate for the mtDNA defect (Taivassalo 
et al, 1998; Taivassalo and Haller, 2005; Murphy et al, 2008).   Studies have 
demonstrated that fatigue and tolerance to daily activities does improve as a result of 
exercise training.  However the concept of exercise training as a therapy for 
mitochondrial disease patients has been questioned due to concerns over general safety 
and efficacy (Taivassalo and Haller, 2005; Taivassalo et al, 2006).   Resistance training 
has also been examined, in order to help improve and increase muscle strength (Murphy 
et al, 2008). 
1.4.2.4 Personalised gene therapies  
 
Due to the lack of effective treatments currently available for patients with mtDNA 
disease, the prospect of selective inhibition of mutant mtDNA replication has in recent 
years been explored (Taylor et al, 1997).  Peptide nucleic acids (PNA’s) have been 
suggested as one potential means by which this could be achieved.   It was hoped that 
PNA’s could be employed to selectively inhibit the replication of the mutant mtDNA 
molecules and theoretically allow replication and propagation of only the wild-type 
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mtDNA.  However many issues concerning this approach still have as yet to be 
overcome, including the uptake of PNA’s into cells and the stability of the PNA’s once 
bound to the mutated copies of mtDNA.    
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1.5  Female Gametogenesis and Early Preimplantation Development  
 
1.5.1 Oogenesis 
 
Oogenesis is the female process of gametogenesis ultimately leading to the formation of 
an ovum (egg cell).   This is initiated when the primordial germ cells migrate to the 
genital ridge, where they then differentiate to form oogonia (Sadler, 2009).  Oogonia 
then undergo a number of mitotic divisions, where upon they form clusters, which 
become surrounded by a layer of flat epithelial cells, otherwise known as follicular 
cells. Some then arrest their cell division in prophase I and form primary oocytes.  By 
the fifth month of prenatal development (~20 weeks) oogonia reach their maximum 
number of about 7 million which is vastly reduced by birth to ~1-2 million in a process 
termed atresia. All those surviving primary oocytes have entered prophase of meiosis I.  
Near the time of birth, these primary oocytes (primordial follicles) have arrested at the 
diplotene stage, which is characterized by a lacy network of chromatin. They remain 
arrested at this stage of prophase until the onset of puberty (Sadler, 2009).      
 
During the first meiosis the primary oocyte becomes the secondary oocyte and extrudes 
its first polar body.  Following the extrusion of its first polar body the secondary oocyte 
proceeds into meiosis II. This is halted at the metaphase II stage ready to be fertilised.  
Upon fertilisation, the secondary oocyte extrudes its second polar body.  Both polar 
bodies should then degenerate, their only function being to discard the extra haploid set 
of chromosomes created at each cell division of meiosis (Fig1.10).   
 
1.5.2 Mammalian Meiosis 
 
Meiosis is the cell division which takes place in the germ cells to generate male and 
female gametes.  It is a reductional division in which the number of chromosomes per 
cell is halved, eventually resulting in the production of four haploid gametes.  Meiosis 
therefore requires two cell divisions meiosis I and meiosis II, to reduce the number of 
chromosomes to the haploid number of 23 (Sadler, 2009). 
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1. Sperm entry into oocyte 
2. Second PB extrusion  
3. Pronuclei formation 
4. Sperm aster 
formation 
6. DNA synthesis – DNA 
replicates  
7. PN membranes 
disassemble  
8. Metaphase –
maternal and 
paternal 
chromosomes align 
on first mitotic 
spindle  
9. Anaphase-
chromosomes 
separate 
10. First cleavage division 
and formation of embryonic 
nuclei  
G1-
initiated    
3-20 hpi
S-phase 
initiated 
8-14 hpi
M-phase initiated 
22-34hpi 
Cell Cycle 
G2
Completion 
of S-phase      
~10-18hpi 
5. PN migrate to 
centre of oocyte 
Figure1. 10 Events of fertilization and pronuclear formation in relation to the cell 
cycle  
 
Schematic diagram to display the key events which take place during fertilisation and 
pronuclear formation in relation to the cell cycle.  The oocyte is arrested in metaphase II 
of meiosis; sperm entry then triggers resumption of meiosis and the oocyte extrudes the 
second polar body.   The presence of the male and female pronuclei marks the transition 
of the zygote in to G1 of the mitotic cycle.   This has been shown can occur between 3-20 
hours post insemination/injection (hpi)(Balakier et al, 1993b; Capmany et al 1996; Payne 
et al, 1997; Nagy et al, 1998)(Image taken from Feenan and Herbert, 2006).  A sperm 
aster then formed in close proximity to the male pronucleus, and the microtubule 
arrangement draws the female pronucleus towards the male until the two pronuclei abut in 
the centre of the oocyte.  The cell enters the S-phase (8-14hpi) and DNA synthesis is 
completed (~10-18hpi) (Balakier et al, 1993b; Capmany et al, 1996).  Upon completing S-
phase, G2 is initiated, which lasts for around 4-6 hours (Blakier et al, 1993b).  At the end 
of G2, the pronuclear membranes disassemble, the paternally inherited centrosome 
coordinates mitotic spindle formation, and the male and female chromosomes align o the 
spindle at the metaphase.  M-phase is entered into around 22-31 hpi.  Sister chromatids 
separate at anaphase and each daughter cell inherits a set of maternal and paternal 
chromosomes.   
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1.5.3 Fertilisation  
 
The pronuclear stage represents a unique transition stage from meiotic to mitotic cell 
division.  Here sperm has entered the oocyte at which point the oocyte completes its 
second meiotic division.  In normally fertilised eggs two pronuclei exist, a maternal and 
paternal pronucleus, each containing a haploid number of maternal or paternal 
chromosomes.   The pronuclei generally exist as two separate entities until their 
membranes breakdown at the onset of the first mitotic division (Plachot, 2000; Feenan 
and Herbert, 2006) (Fig1.12).   
 
1.5.4 Abnormally fertilised human embryos  
 
In a small proportion of IVF cycles, the selection is limited to embryos that are 
abnormally fertilised, displaying one or three pronuclei.   Embryos are considered 
abnormal when they have more or less than 2PN.    These zygotes therefore contain 
either 1 or >3PN and can result from an array of scenarios; for example a 1PN embryo 
can result when the female pronucleus fails to form and a single male pronucleus may 
only be visible (Feenan and Herbert, 2006).   It is also possible however that an oocyte 
with 1PN and two polar bodies may have been parthenogenetically activated and 
resumed meiosis independently of a sperm cell (Staessen et al., 1993). This results in 
formation of a haploid female pronucleus and cytoplasm devoid of any nuclear DNA 
(Levron et al., 1995).  It has been also been reported that a proportion of 1PN embryos 
are actually diploid (Levron et al., 1995), and that such embryos could be formed by 
asynchronus pronuclear development (Munne et al., 1993) or pronuclear fusion (Tesarik 
and Mendoza, 1996). 
 
However the most frequently observed multipronucleate embryos are those containing 
3PN (Feenan and Herbert, 2006). The extra pronucleus may be either maternal or 
paternal in origin and this can be inferred by the number of polar bodies. An embryo 
with 3PN and two polar bodies is assumed to be dispermic and are formed following 
entry of two sperm in the oocyte, resulting in a single maternal pronucleus and two 
paternal pronuclei. An embryo with 3PN and only one polar body may form if the 
oocyte fails to extrude a polar body during oocyte maturation (meiosis I) or activation 
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(meiosis II), resulting in formation of two maternal pronuclei and a single paternal 
pronucleus. This may occur following intracytoplasmic sperm injection if the sperm is 
introduced in the vicinity of the meiotic spindle (Macas et al, 1996). 
 
1.5.5 Pre-implantation development  
 
Pre-implantation development in mammals involves both the development of the 
embryo and the preparation of the uterus in anticipation of blastocysts implantation 
(Stuart and Cullinan, 1997).  After the first cleavage divisions, which are under 
maternal genome control, the segmentation continues under the control of the 
embryonic genome (Tesařik, 1998).  Here the flattening of the blastomeres and the 
formation of specialised junctions amongst them characterize the foundation of the two 
different cell populations of the early blastocyst (Tesařik, 1993).  These two cell 
populations will later give rise to the inner cell mass and the trophoectoderm, which are 
finally segregated during cavitation (Tesařik, 1993) (Fig1.11).   
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Figure1. 12 Pronucleus formation  
Above diagram the series of events which take place following fertilisation to the first 
cell division. (a) Sperm enters the oocyte, which leads to the completion of meiosis, 
resulting in extrusion of the first polar body.  (b) Pronuclear envelope forms around the 
remaining oocytes chromosomes to give rise to the female pronucleus whilst the male 
chromosomes decondense forming the male pronucleus. Additionally a sperm aster 
resides in close proximity to the male pronucleus, from which a microtubule array 
extends towards the female pronucleus.   (c) Female pronucleus is pulled towards the 
male pronucleus. (d) Pronuclear envelopes breakdown. (e) Here the centrioles migrate 
to opposite poles and the chromosomes align ready for the first mitotic division. (f) 
Chromosomes segregate into two new daughter cells.  (Image adapted from original 
found in Feenan and Herbert, 2006). 
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1.5.6 Blastocyst development  
 
The human cleavage stage embryo is a unique stage during pre-implantation embryonic 
development during which the cells exist in an undifferentiated state, still as yet to 
commit to a specified cell type. This state is often referred to as ‘totipotency’.   The 
blastocyst stage embryo however is a unique stage of pre-implantation embryonic 
development, during which cells begin to adopt a cell identity, which ultimately 
culminates in commitment to a defined cell lineage.   There are two distinct cell types 
found in the mammalian blastocyst: the outer epithelial layer or trophectoderm (TE) and 
the inner cell mass (ICM) (Hardy et al, 1989) (Fig1.13a).  The TE is responsible for 
blastocoel fluid accumulation and is also specialized for implantation (Hardy et al, 
1989; Rossant, 2004).   Upon implantation the TE gives rise to components of the 
placenta and extra-embryonic membranes   The ICM however goes on to form the 
‘embryo proper’ and gives rise to three germ layers of the foetus (Gardner and 
Papaioannou, 1975).   The PE (primitive endoderm) and EPI (epiblast) cells make up 
the cells of the inner cell mass (ICM), those cells which lie within the blastocoel cavity.   
 
1.5.6.1  Lineage specification  
 
The allocation of cells to these two ‘primary lineages is said to occur following the 
fourth cleavage division (Handyside, 1981; Hardy et al, 1989)   Studies have shown that 
following commitment of cells to one of these two ‘primary lineages’ the transcriptional 
regulation of the cell is altered to allow for the precise expression of a subset of genes.  
The most important genes at this early stage of embryonic development are those 
involved in regulating the pluripotent state of cell.    A number of genes have been 
identified which are solely expressed in extra-embryonic cells (TE) Cdx2 is a caudal-
related homeodomain protein and a key regulator of the trophectoderm lineage (Rossant 
and Tam, 2009) (Fig1.13b).  Studies have shown that Cdx2 begins to be expressed 
around the eight-cell stage of embryo development before its expression begins to 
become restricted and up-regulated in the outer cells of the morula, prior to blastocyst 
formation (Dietrich and Hiiragi, 2007; Ralston and Rossant, 2008; Rossant and Tam, 
2009).  Studies have demonstrated that the promoter of the Cdx2 gene is highly 
acetylated in the trophectoderm but enriched in H3K9me2 in the ICM (O’Neill et al, 
2006).    This therefore results in suppressed expression of Cdx2 within cells of the ICM 
 4 4  
however as Cdx2 expression is not suppressed in the trophectoderm cell, we would 
expect to see if expressed widely in these cells.   
 
Another key transcription factor critically involved in maintaining cells in an 
undifferentiated, pluripotent state is Nanog (Rossant and Tam, 2009; Ozawa and 
Hansen, 2011).   Nanog is usually expressed ubiquitously in the cleavage stage 
preimplantation embryo. Its expression is gradually down-regulated as cell fate is 
adopted and consequently expression becomes restricted to a small number of cells 
found within the inner cell mass following blastocyst formation (usually around day 5-
7) (Fig1.13b).    A second transcription factor, Gata6, a zinc-finger transcription factor, 
was previously shown to be required for the development of extra-embryonic tissues, as 
demonstrated through the generation of chimeric embryos (Beddington and Robertson, 
1989; Koutsourakis, et al, 1999). In the early to mid-stage mammalian blastocyst, the 
ICM still contains a heterogeneous population of cells, composed of pluripotent epiblast 
and extra-embryonic primitive endoderm (PrE) progenitors, which is often 
demonstrated by the “salt and pepper” distribution of the key epiblast (NANOG) and 
PrE (Gata6) markers (Koutsourakis et al, 1999; Rossant et al, 2003; Chambers et al, 
2003, 2007; Mitsui et al, 2003; Chazaud et al, 2006; Silva et al, 2009) (Figure 1.19b).  It 
is not until the late blastocyst stage, that compartmentalization results in the 
establishment of two distinct expression domains for Nanog and Gata6, delineating the 
newly formed epiblast and PrE lineages (Plusa et al, 2008; Meilhac et al, 2009; Lavial et 
al, 2012). Nanog and Gata6 mutually inhibit each other and thereby segregate the two 
lineages of the ICM (Lanner and Rossant, 2010).   It has further been suggested that 
Gata6 has the ability to promote cellular properties that will allow correct sorting of PrE 
progenitors that are in the wrong position in the ICM (Rossant et al, 2003).  This would 
create a model in which the EPI and PrE precursors are specified in a random manner 
within the ICM, inferring that it is not until a later time point that they segregate to their 
respective layers (Rossant et al, 2003; Chazaud et al, 2006; Lavial et al, 2012).  
Therefore if this “salt and pepper” like distribution is to be believed, it contradicts the 
previously assumed model of cell positioning which assumed that cell position with 
respect to the blastocyst cavity is the primary determinant of PrE fate (Yamaaka et al, 
2006).     
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Figure1. 13 Cell lineage specification in the mammalian blastocyst  
 
Above images represent different cell types within the pre-implantation blastocyst and 
stains used to identify these different cell lineages(a) a DIC image of a human day 7 
hatched blastocyst, with labels marking the two cell types present at this point, the 
trophectoderm and the inner cell mass (ICM).  (b) A schematic representation of 
blastocyst, depicting both the trophectoderm cells and the ICM and blastocyst stained 
using DAPI (nuclear stain-blue) and Nanog (cells which are still pluripotent in nature-red) 
(c) A schematic representation of a blastocyst, depicting the trophectoderm cells (green) 
and Nanog cells (red) and images from blastocysts stained for the markers Gata6 (green) 
and Nanog (red).   
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1.6 Cryopreservation strategies used to preserve fertility  
 
Prior to the availability of cryopreservation technology, women producing excess 
oocytes had no choice but to discard excess non-transferred viable embryos (Veeck, 
2003).   However following the introduction of successful cryopreservation 
programmes, wastage of supernumerary embryos has and can be reduced as couples can 
instead choose to store excess embryos for future attempts (Trounson and Mohr, 1983; 
Valojerdi et al, 2009).   Consequently embryo cryopreservation has become regarded as 
an integral part of the IVF process.    
 
Cryopreservation also facilitates in the transfer of fewer embryos per cycle which can 
reduced the risk of multiple pregnancy per cycle.    However the overall chance of 
conception and the cumulative pregnancy rate in an IVF programme can instead be 
enhanced by better utilising stored embryos for future frozen embryo transfer (FETs) 
cycles.   Cryopreservation can also prove useful in situations when embryo transfer is 
unable to go ahead, for example in patients at risk of ovarian hyperstimulation 
syndrome or patients preparing to undergo radiation or chemotherapy (Shamonki and 
Oktay, 2005).   However in order for successful outcomes it is imperative that a 
successful cryopreservation strategy is in place firstly.   
 
Controlled-rate freezing has often proven to be the preferred option for embryo 
cryopreservation for the past decade within IVF laboratories.   However In recent years 
an alternative cryopreservation technique, known as vitrification has been revisited.   
The greatest benefit which has resulted from the introduction of vitrification is the high 
recovery and survival rates which can be achieved for oocytes, embryos and blastocyst 
stage embryos once not possible using conventional controlled-rate freezing (Lucena et 
al, 2006; Ciotti et al, 2009; Capalbo et al, 2010; Rienzi et al, 2010).   Both of these 
techniques will be described in greater detail in the following paragraphs.  
 
1.6.1 Controlled rate freezing  
 
Controlled rate freezing involves step-wise programmed decrease in temperature. The 
procedure is lengthy and requires the use of expensive instrumentation. However 
controlled-rate freezing has been successfully used to cryopreserve embryos at various 
different stages of embryonic development, including; pronuclear, cleavage and 
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blastocyst stage (Al-Hasani et al., 2007; Barg et al., 1990; Senn et al., 2000; Van den 
Abbeel et al., 1997a; Desai et al., 2007; Kuwayama et al., 2005; Kuwayama et al., 2005; 
Liebermann and Tucker, 2006; Menezo, 2004).    However due controlled rate freezing 
is noutourisiously associated with the risk of ice crystal formation within the cells 
during the cryopreservation procedure.   Consequently this can have extremely 
deleterious effects and often result in reduced survival outcomes (Pegg, 2005; 
AbdelHafez et al, 2010).    Indeed the successful cryopreservation of oocytes using 
controlled-rate freezing has proven impossible.  This is due to the high water content of 
oocytes which renders them prone to cryo-injuries as a result of the cryopreservation 
procedure (Toner et al. 1990, Ruffing et al. 1993, Arav et al. 1996, Zeron et al. 1999; 
Coticchio, 2007) .   
 
1.6.2 Vitrification  
 
However Vitrification literally meaning ‘to turn to glass’ frequently referred to as a 
novel technology of cryopreservation in embryology has been used as an alternative to 
‘controlled-rate freeing’ for the past decade (Loutradi et al, 2008).   Rall and Fahy were 
the first to report the successful vitrification of mammalian embryos back in 1985, with 
the first reported pregnancy from a vitrified embryo following in 1990 (Valojerdi et al, 
2009).   However there were several issues associated with the vitrification technique 
which resulted in controlled-rate freezing taking president as the preferred method of 
cryopreservation within IVF laboratories.   This primarily concerned the solutions and 
devices employed to perform vitrification, which were sub-optimal and exposed 
embryos to high concentrations of cryoprotectants for prolonged periods of time in large 
volumes (Fig1.14).   
 
Although in recent years there has been a resurgence of the vitrification technique with 
an increasing number of IVF clinics now opting to replace controlled-rate freezing 
cryopreservation strategies with vitrification based systems.  This has been attributed to 
the vast improvements which have been made with regards to the solutions and devices 
used to perform the vitrification procedure.  The majority of these solutions and devices  
have been designed with several key principles in mind which are fundamental to 
achieving successful cryopreservation outcomes, including; using a combination of 
cryoprotectants, employing multiple-step protocols, minimal loading techniques and 
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high cooling rates.   Whereby ensuring these criteria are met, vitrification is able in 
many cases to guarantee survival.    
 
The reinvention of vitrification has indeed revolutionized the cryopreservation of 
embryonic samples within IVF laboratories worldwide.   Embryos are now able to be 
successfully vitrified at all stages of embryonic development resulting in improvements 
in clinical pregnancy rates for frozen embryo transfers compared to that once achievable 
with conventional controlled-rate freezing (Mukaida et al, 1998; El-Danasouri et al, 
2001; Mukaida et al, 2003; Liebermann et al, 2002; Vanderzwalmen et al, 2002; 
Liebermann et al, 2004; Huang et al, 2005; Kumasako et al, 2005; Kuwayama et al, 
2005; Raju et al, 2005; Zech et al, 2005; Liebermann and Tucker, 2006; Kuwayama, 
2007; AbdelHafez et al, 2010).   Huge leaps in survival outcomes have been observed 
for cleavage and blastocyst stage embryos  which due to their high water content and 
large surface areas were often fraught by the risk posed from cryoinjuries, induced as a 
result of the sub-optimal conditions associated with controlled-rate freezing (Balaban et 
al, 2008; Papanikolaou, et al, 2008).   Using vitrification it is also now possible to 
successfully cryopreserve oocytes once not feasible using controlled-rate freezing (this 
will covered in greater detail in chapter 6) (Lucena et al, 2006; Ciotti et al, 2009; 
Capalbo et al, 2010; Rienzi et al, 2010).   This has proved extremely important for 
women requiring fertility preservation.  As previously oocytes were often fertilised 
using either partner or doner sperm and subsequently cryopreserved at the single cell-
zygote or cleavage embryo stage of embryonic development due to an inability to 
successfully cryopreserve oocytes.    However this was often not ideal for young 
oncology pateints in particular who have not yet found a partner they wish to begin a 
family with; often having to resort to using donor sperm to create embryos which could 
be stored.   However now they are able to cryopreserve oocytes which they can then use 
at a later date when they find a partner whom they want to start a family with.   
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before loading onto cryoleaf
4.  Following loading of embryo 
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2. Warming 
LN2
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containing embryos to 
initial warming solution 
(3mins at 37oC)
5. Finally transfer to culture dish 
and left to recover min 2hrs 
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Figure1. 14 vitrification: cooling and warming  
(a) Schematic representation of the cooling procedure.  Here embryos are passed 
through a series of solutions, which act to prepare the oocyte before they are plunged 
rapidly into liquid nitrogen and stored for indefinite periods in liquid nitrogen storage 
tanks. (b) Schematic representation of the warming procedure - Here devices containing 
embryos are removed from liquid nitrogen storage before the device containing the 
embryos are transferred to the initial warming solution to begin the warming procedure.  
Embryos are then passed through a series of sequential solutions which act to remove 
the cryoprotectants gradually in a step-wise manner so as to not shock the embryos.   
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1.7 Current and future approaches for the treatment and prevention of mtDNA 
disease  
 
Due to the lack of data regarding the rules of segregation of wild type and mutant 
mtDNA species and tissues in the developing embryo, it is difficult to predict the 
resulting phenotype of a child (Steffann et al, 2006).  However there are several tests 
available which have the ability to assess the likelihood of a couple having a child 
affected by a life threatening disease. These tests should be explained to the couple 
through genetic counselling within the clinic.  These include oocyte donation, prenatal 
screening, prenatal genetic diagnosis, and pre-implantation genetic diagnosis (DiMauro 
et al, 2001; Thorburn et al, 2001; Poulton et al, 2000; Poulton et al, 2002; Taylor et al 
2005).  Although these techniques have the potential to indicate the potential degree by 
which a child is likely to be affected by a disease, they are by no means error proof.   
 
1.7.1 Genetic counselling  
 
As previously discussed, mitochondrial DNA defects can be transmitted by maternal 
inheritance (Chinnery, 2006).  Whilst the majority of mtDNA deletions occur de novo 
and therefore usually only affect one single family member harbouring no potential 
threat to other family members, point mutations can be transmitted down the maternal 
line.  Therefore a mother harbouring a mtDNA point mutation may transmit a variable 
amount of mutant mtDNA to her offspring due to the phenomenon of heteroplasmy.  
This can result in considerable clinical variability amongst siblings within the same 
family.  Therefore patients who have been found to harbour a pathogenic mtDNA 
mutation must be made fully aware of the future risk when considering a family and be 
made aware of the options available to them, including prenatal and preimplantation 
genetic screening as now discussed.   
 
1.7.2 Oocyte donation  
 
Oocyte donation is the process whereby a women consents for her eggs to be donated 
for use in reproductive purposes.   Oocyte donation is therefore the equivalent to sperm 
donation, as both procedures depend upon the donation of gametes (Baetens et al, 
2000).  Oocyte donation is somewhat more controversial, as oocyte donation can 
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involve some invasive medical procedures, including ovarian stimulation and retrieval 
of mature oocytes under local anaesthetic (Baetens et al, 2000).    Oocyte donation has 
become a standard treatment for women with diminished ovarian reserve, those who are 
of advanced reproductive age, women affected by or are carriers of a significant genetic 
defect, and women with poor oocyte quality (Cameron et al, 1989; Beatens et al, 2000; 
Cobo et al, 2010).   
1.7.3 Prenatal genetic diagnosis   
 
Prenatal diagnosis (PND) is generally defined as testing for diseases or conditions in a 
foetus or embryo before it is born.  This can be performed as early as 11 weeks into the 
pregnancy by chorionic villus sampling (CVS) and as late as 20 weeks by amniocentesis 
however both of these are invasive procedures which can cause additional 
complications (White et al, 1999) (Fig1.15a).   
 
PND is now available for mitochondrial disorders, however molecular analysis and 
interpretation of results is somewhat complicated by the phenomenon of mtDNA 
heteroplasmy (White et al, 1999; Chinnery, 2006).    Heteroplasmy refers to the 
coexistence of at least two mtDNA molecules within one cell.  This is also sometimes 
referred to as the ‘mutant load’ which is the proportion of mutant mtDNA molecules 
present within an individual (White et al, 1999).  The ability to predict how a mutation 
may be transmitted to a future offspring is not only influenced by heteroplasmy but also 
due to the presence of a genetic bottleneck during pre-or postnatal development.   There 
are also concerns that the mutant load may vary among tissues and may change over 
time, which has observed in adults with mitochondrial disease (Harding et al, 1992; 
Poulton and Morten, 1993; Poulton et al, 1998; Chinnery, 2006).   
 
This has therefore raised concern that the percentage levels of mutant mtDNA observed 
in the extra-embryonic tissues sampled via PND may not truly reflect those levels 
present in the foetal tissues at birth (White et al, 1999; Bredenoord et al, 2010).   
However there are a limited number of studies which have reported a uniform 
distribution of mutation load among different tissues from two heteroplasmic 24-and 
25-week-old human fetuses obtained from a carrier of the m.3243A>G mutation 
(Cardaioli et al., 2000; Matthews et al., 1994). Indeed PND has now been reported to 
have been performed successfully for a number of different mtDNA inherited mutations 
(Harding et al, 1992; White et al, 1999; Thorburn and Dahl, 2001; Chou et al, 2004; 
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Bouchet et al, 2006).  Although one disadvantage to the PND procedure is that it is only 
able to be performed once a pregnancy has been established.  Patients must therefore be 
aware that dependent upon results this may lead to a selective termination if the foetus 
is determined to have a high proportion of mutant mtDNA and they wish to prevent the 
birth of an affected child.    
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Fig3.1 Procedures performed for prenatal genetic diagnosis (PND) versus Preimplantation 
genetic diagnosis (PGD)  
 
(a) Images representing the process performed to obtain a PND samples.  This can be performed 
as early as 14 weeks into the pregnancy by chorionic villus sampling (CVS) and as late as 20 
weeks by amniocentesis however both of these are invasive procedures which can cause 
additional complications.  (b) Image represents the biopsy process, performed in order to obtain 
a single blastomere, upon which molecular analysis can be performed.   
a
. 
b
. 
 
 
Figure . 15 Procedures per m d for pr natal genetic diagnosis (PND) and Pre-
implantation genetic diagnosis (PGD)  
 
(a) Images representing the processes performed to obtain a PND sample.  This can be 
performed as early as 14 weeks in the pregnancy by chorionic villus sampling (CVS) 
and as late as 20 weeks by amniocentesis.  However these are both invasive procedures, 
which so carry additional risks and complications.  (b) Image represents the biopsy 
procedure, performed in order to obtain a single blastomere.  Samples obtained from 
both procedures are then sent for diagnostic molecular analysis (Images taken from 
http://www.learningdigitally.org/Science/GeneticsSites.html).  
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1.7.4 Preimplantation genetic diagnosis  
 
Preimplantation genetic diagnosis (PGD) is now conducted on a routine basis for 
couples who are at a heightened risk of transmitting a genetic or chromosomal 
abnormality to their children. This can include autosomal recessive, autosomal 
dominant and X-linked disorders (Thornhill et al, 2005).    
 
PGD requires the use of assisted reproductive technology (ART) in order to create 
enough embryos which can go on to be analysed via genetic testing.   This ensures that 
only those embryos which do not test positive for the specific condition tested for, are 
transferred back to the mother (Thornhill et al, 2005).   Traditionally PGD is conducted 
on embryos which are cultured in vitro to the 6-8 cell stage (which us usually around 
day 3); at this stage it is possible to perform an embryo biopsy.  This usually involves 
the removal of at least 1 blastomere, although it also possible to remove two 
blastomeres, however as the number of blastomeres removed is increased, the likelihood 
of impaired development also increases (Cohen et al, 2007; Goossens et al, 2008; A 
DeVos et al, 2009; Van de Velde, et al, 2000)(Figure 1.15b).  Following blastomere 
biopsy, molecular analysis is then performed to determine which if any embryos can be 
returned.   Generally the two least affected embryos are returned on day 5 or day 6 post-
analysis (Thornhill et al, 2005) (Fig 1.16).   
 
However trophectoderm biopsy is now increasingly being used in place of conventional 
cleavage stage biopsy, since the trophectoderm gives rise to the extra-embryonic tissues, 
this is regarded as a safer procedure (Dokras et al, 1990).  This change of direction is 
also a result of the vast improvements which have been made in blastocyst culture and 
freezing, which together with the advantage of an increased number of cells available 
for analysis make this an ideal stage to perform PGD (Lalic et al, 2001; De Boer et al, 
2002; McArthur et al, 2005; Schoolcraft et al, 2011).    
 
PGD is a relatively new option for women who carry heteroplasmic mtDNA mutations 
and involves identifying suitable embryos that have undetectable or low levels of 
mtDNA mutation associated with a lower risk of the offspring developing severe 
disease. Indeed this technique has been successfully applied to a small number of 
maternally inherited mtDNA mutations (Steffan et al, 2006, Thorburn et al, 2009, 
Monnot et al, 2011, Treff et al, 2012, Sallevelt et al, 2013) but as experience is still 
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limited, more information is required to determine the suitability of PGD for different 
pathogenic mtDNA mutations (Fig1.16).   
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Transfer only ‘low risk’ biopsied embryos to the patient 
High 
mutation 
load  
Wild-type/ low 
mutant load 
Wild-type/ low 
mutant load 
High 
mutation 
load  
Figure1. 16 Preimplantation genetic diagnosis (PGD)  
The diagram represents the process behind PGD.  Here embryos are created by 
IVF, which are subsequently biopsied on day 3 and sent for molecular analysis.  
The results of this analysis determine which of the embryos are safe to be 
transferred back.  A maximum of two embryos are able to be transferred back to 
the patient per cycle (Adapted from original image taken from Braude et al, 
2002).   
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1.7.5 Currently explored IVF strategies to prevent the transmission of 
mitochondrial disease  
 
Due to the lack of currently available treatments for mitochondrial disease and the 
unpredictable nature regarding mtDNA segregation during early embryonic 
development, several alternative strategies have been developed to try and help any at 
risk families.  These are based upon nuclear transfer techniques, which involve the 
removal and transfer of genetic information providing a means by which couples could 
conceive healthy children free of mtDNA disease.   
 
1.7.5.1 Germinal vesicle transfer  
 
Germinal vesicle transfer is one particular nuclear transfer technique which has been 
proposed.  This is similar to the pronuclear transfer technique whereby the GV is 
removed from the affected oocyte and transferred to the enucleated recipient oocyte 
(Spikings et al, 2006).  Indeed studies using human oocytes have shown that GVT can 
overcome oocyte aneuploidy, with the majority of reconstructions having normal 
karyotypes (Zhang et al, 1999; Takeuchi et al, 2001; Spikings et al, 2006).  However the 
success of GVT in human oocytes appears to be limited, as in vitro maturation 
following manipulation is fairly low (Zhang et al, 1999; Takeuchi et al, 2001).  The in 
vitro maturation has been associated with essential removal of cumulus cells prior to 
manipulation procedures, as cumulus cells are considered important for oocyte 
maturation (Ge, et al, 2008).  Therefore without improvements to in vitro culture 
conditions, it is unlikely that this technique could be used to prevent transmission of 
mtDNA disease.   
 
1.7.5.2 Metaphase II spindle transfer  
 
An alternative strategy proposed to prevent transmission of mitochondrial disease is 
‘Metaphase II spindle–chromosomal complex transfer’ or ‘maternal spindle transfer’ as 
it is otherwise referred.   Several studies have reported upon the MII spindle transfer 
procedure, which have so far been conducted in mouse, primate and human oocytes 
(Wang et al, 2001; Tachibana et al, 2009; Tachibana et al, 2010; Tachibana et al, 2012; 
Paull et al, 2012).    Wang et al (2001) were the first to report the use of MII meiotic 
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spindle transfer performed in mouse oocytes.   Metaphase II karyoplast transfer with 
human in-vitro matured oocytes has been proposed as a potential strategy to rescue aged 
oocytes (Tanaka et al, 2009).    Here the authors demonstrated, using the ICSI 
technique, that these could be successfully fertilised and subsequently compatible with 
onward development as demonstrated by the blastocyst formation rates (Tanaka et al, 
2009).  Chromosome analysis was also performed upon a selection of the reconstructed 
oocytes following fertilisation and all analysed were found to contain normal diploid 
sets of 46 chromosomes, confirming the feasibility of the technique in human oocytes.   
A later study then reported upon the use of maternal spindle transfer for the preventing 
the transmission of mtDNA disease to offspring which they performed in mature non-
human primate oocytes (Macca Mulatta) (Tachibana et al, 2009).   Here they showed 
that the reconstructed oocytes were capable of supporting normal fertilisation, embryo 
development and producing healthy full term offspring.    Subsequent genetic analysis 
confirmed that the nuclear DNA in the three infants originated from the spindle donor 
and the mtDNA from the egg donor. They were also able to demonstrate no detectable 
level of mtDNA carryover originating from the spindle donor (Tachibana et al, 2009) 
(Figure 1.17b).  The same group later reported performing the same experiments this 
time using human oocytes (Tachibana et al, 2012).  They were able to demonstrate the 
potential to perform MST in human oocytes however they did report observing 
abnormal fertilization for a number of embryos which underwent MST.  Although the 
remaining embryos which were found to have undergone normal fertilization (as 
determined by the presence of two pronuclei) were capable of developing to blastocyst 
stage embryos.   A second study published in the same year also examined the potential 
of MST in human oocytes.  However they opted to use parthenogenetic activation 
instead of fertilization using ICSI, to overcome legality issues associated with creating 
embryos for the purpose of research.  However they were still able to attain 
developmental efficiency to the blastocyst stage and undetectable levels of mtDNA 
carryover.  Therefore providing further support for the MST technique, which they 
referred to as nuclear genome transfer to prevent the transmission of mtDNA disease in 
humans.     
 
1.7.5.3 Pronuclear transfer  
 
McGrath and Salter (1983) were the first to report the successful use of the pronuclear 
transfer manipulation technique which they performed in mouse embryos.  They 
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described how using microsurgical apparatus they were able to remove the pronuclei 
from a donor mouse embryo and using a virus-mediated cell fusion technique 
reintroduce this into a previously enucleated recipient mouse embryo.    Since this initial 
report, several groups have attempted to utilise the technique for different purposes.   
These include studies performed in mice to examine mitochondrial genotype 
segregation during preimplantation development (Meirelles and smith 1997; Meirelles 
and Smith 1998).  One further study also examined the potential use of this technique as 
a possible method to prevent the transmission of mitochondrial disease to future 
generations in a mouse model (Sato et al, 2005).  This technique has since been 
suggested as a possible method which could be used to prevent transmission of 
mitochondrial disease from mother to child in humans.   This would involve the 
removal of both the female and male pronuclei from an embryo known to contain 
affected mitochondria to an enucleated, disease-free, donor embryo (Craven et al, 2010) 
(Fig1.17a).   These studies performed in abnormally fertilised PN stage embryos were 
able to demonstrate that the transfer of pronuclei between human zygotes was indeed 
compatible with onward development and resulted in minimal carryover of mtDNA to 
the donor zygote (Craven et al, 2010).   
 
1.7.5.4 Comparison between metaphase II spindle transfer and 
pronuclear transfer  
Although the two techniques have each separately been shown to be technically feasible 
to perform and lead to low levels of carryover mtDNA, the question which has been 
asked is which is the better technique  for patients with mtDNA disease (Craven et al, 
2011).  One other approach which may help in making this decision is to compare and 
contrast the two techniques, in order to fairly assess which approach should be 
favoured.   
MST is performed using unfertilized oocytes, where only the female spindle 
chromosome complex is present.   As a result the karyoplast produced using this 
technique is smaller, than possible with PNT, there is therefore potential for less 
carryover of mtDNA.   However studies performed using both the MST and PNT 
technique have demonstrated equivalent levels of mtDNA carryover, indicating the risk 
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of offspring developing the disease is likely to be minimal (Craven et al, 2010; 
Tachibana et al, 2012; Paull et al, 2012).    
However as the chromosomes of the metaphase II oocyte are not enclosed within a 
nuclear membrane concern has been raised that this could result in incomplete transfer 
of generic material to the recipient donor oocyte.  At this stage the chromosomes are 
attached to a spindle which is only able to be visualized using polarized light 
birefringence (Oldenbourg, 1998; Liu et al, 2000; Konc et al, 2004; Rienzi et al, 2005; 
Montag et al, 2006).   This is the only means by which the chromosomes can be 
visualized indirectly and safely without the use of a fluorescent dye, which could 
potentially affect future embryo viability and developmental potential.  However there 
is evidence from studies performed in human oocytes that chromosome scattering can 
occur, which would not be able to be observed when using this imaging technique alone 
(Battaglia et al, 1996).  Chromosome scattering has been associated with ageing and 
also sub-optimal environmental condition (Almeida et al, 1995; Cassimeris et al, 1988).  
It will therefore be important to ensure all experiments are performed with these points 
in mind.  It may be that oocytes must be used for MST in the period immediately 
following oocyte retrieval and manipulations are performed in a controlled environment 
to overcome issues regarding spindle scattering. 
PNT therefore offers the advantage of having the maternal and paternal genomes 
enclosed in clearly visible membrane bound structures, known as pronuclei.   This 
overcomes issues associated with the MST technique regarding spindle integrity.  
However there are other problems which are associated with performing the nuclear 
genome transfer in the fertilized zygote.   One such issue concerns the centrosome, 
which in humans is paternally derived (Sathananthan et al, 1991).   It is possible that 
when removing the pronuclei from the patients zygote that the centrosome which is 
found tightly apposed to the male pronuclear membrane could be left behind, as a result 
of efforts made to reduce the size of the karyoplast the pronucleus is removed in.   The 
centrsome plays an essential role in the first mitotic division, ensuring the assembly of a 
normal bipolar spindle (Sathananthan et al, 1996; Munne and Cohen, 1998; Craven et 
al, 2011).  It will therefore prove important to ensure that the reconstituted zygote 
contains two centrioles.  However by performing nuclear genome transfer before 
fertilization this issue can be avoided (Paull et al, 2012).  Furthermore, pronuclear 
transfer requires the fertilization of both donor and recipient oocytes, resulting in the 
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destruction of half of the embryos. By contrast, human oocytes would only be fertilized 
after successful genome exchange (Paull et al, 2012).    
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1.8 Ethical issues associated with the IVF based reproductive 
techniques  
 
1.8.1 Ethical issues associated with Preimplantation genetic diagnosis 
(PGD)  
 
Preimplantation genetic diagnosis (PGD) is an adjunct to asscited reproductive 
technology, and requires a patient to undergo ovarian stimulation in order to obtain 
oocytes or embryos for evaluation.  The objective of the PGD technique is to screen for 
specific disorders in embryos from patients who are at risk of passing a life-limiting 
condition to their unborn child.  Its main advantage is that it avoids selective pregnancy 
termination as the method used to select embryos makes it highly likely that the baby 
will be free of the disease under consideration.  However since the first reported 
application of preimplantation genetic diagnosis (PGD) to the study of deleterious gene 
mutations in an embryo, there has been debate regarding the ethical acceptability of the 
IVF based procedure (Coutelle et al, 1989; Holding et al, 1989; Verlinsky, 2007).    
 
There are two main sets of ethical objections against the use of PGD.   The first arising 
from the requirement to create and then select embryos on chromosomal or genetic 
grounds, with the deselected embryos then usually discarded.   The second concerns the 
process of selection itself (Robertson et al, 2003).  The PGD technique also attracts 
religious objection and disapproval since some believe that it involves the destruction of 
human life.    
 
The potential misuse of PGD has also been discussed extensively, with several different 
areas highlighted.  Firstly the fear that PGD could be used for prenatal sexing of the 
embryo, and thus potentially used to select embryos of one sex in preference of the 
other in the context of "family balancing".   A second fear is that it may prove possible 
to make other "social selection" choices in the future that introduce socio-economic 
concerns.   A  third concern is the potential to screen for genetic issues unrelated to 
medical neccesity, such as intelligence and beauty, and against negative traits such as 
disabilities. There is concern that this technique could result in the creation of ‘designer 
babies’ and this is often referred to as the ‘slippery slope’ argument.   
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Also there is concern regarding the reliability of the PGD technique, as PGD operates 
under the assumption that the mutation load observed in the cell removed at biopsy is 
representative of the mutation load in the remainder of the cells of the embryo. This 
may not be the case, as the incidence of mosaicism is often relatively high (Munne et al, 
1998a).   Therefore on occasion PGD may result in a false negative result leading to the 
acceptance of an abnormal embryo, or in a false postitive result leading to the de-
selection of a normal embryo.   However despite given these objections, there is a 
strong consensus that PGD is justifiable, at least for severe genetic disorders 
(Fasouliotis and Schenker, 1998; Buchanan et al, 2000; Verlinsky and Kuliev, 2000; 
Steinbock, 2002; Robertson, 2003, Klipstein, 2005; Kuliev and Verlinsky, 2005, a; 
Dresser, 2006; Bredenoord, 2008).    
1.8.1.1 Ethical issues associated with the use of PGD for 
mtDNA inherited disorders  
 
The use of PGD for mtDNA disorders raises several ethical questions in clinical 
practice (Bredenoord et al, 2008a, b, 2009).    This is because diseases caused due to 
mtDNA-defects are more complicated to assess, due to the combined effects of 
heteroplasmy and the genetic bottleneck, which make it difficult to estimate the 
recurrence risks correctly and to provide an accurate prognosis for some mtDNA 
mutations (Bredenoord et al, 2008).       
 
The concerns when performing PGD for mtDNA inherited disorders specifically relate 
to the effect of heteroplasmy.   The possibility of having a large number of embryos 
with intermediate levels of mtDNA mutation loads results in what is deemed the ‘grey 
zone’ (Bredenoord et al, 2008).   The exact threshold level of mtDNA mutation should 
be discussed  during counselling of each individual couple, since it also depends on 
other factors such as disease manifestation and clinical severity on the family, 
perception of risk, the availability of embryos below the threshold and general fertility 
issues associated with IVF  (Hellebrekers et al, 2012; Smeets, 2013)    
 
A further strategy which has been suggested is the use of ‘sex selection’, for selecting 
male foetuses in order to eliminate the risk for future generations (Bredenoord et al, 
2010).  Sex selection in this particular approach is not intended to help a couple avoid 
having a child with a severe genetic disorder, but to avoid possible health risks in 
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further generations. Sex selection may be put to this use in the context of preventing 
mitochondrial DNA disorders by means of preimplantation genetic diagnosis (PGD) 
(Bredenoord et al, 2010).    Sex selection against healthy female carrier embryos would 
have a two-fold advantage; firstly it would avoid difficult reproductive decisions for the 
future child and secondly avoid transmission of the mutation to a possible third 
generation.   As Bredenoord et al (2011) writes, sex selection would still be done for 
reasons of health therefore this application should not give rise to the moral concerns 
associated with sex selection for non-medical reasons. 
  
1.8.2 Ethical issues surrounding the nuclear transfer technique pronuclear 
transfer (PNT)  
 
In view of the limitations posed by current reproductive techniques targeted at mtDNA 
patients (which at best are able to minimize the risk of mtDNA transmission from 
mother to child), the scientific community is searching for ‘radical’ alternatives, 
including ooplasmic transfer and pronuclear transfer (PNT).  These approaches are often 
viewed as radical as they do not entail ‘genetic selection’ but instead ‘genetic 
intervention’ in order to correct the genetic cause of the disease (Bredenoord et al, 
2009).     There are a number of issues raised when considering the ethics of 
mitochondrial replacement techniques such as PNT. 
 
1.8.3 Are PNT and other nuclear transfer techniques being explored for their 
ability to prevent the transmission of mtDNA disease, forms of cloning?  
 
The question often posed when discussing the potential of the PNT technique and other 
nuclear transfer techniques aimed at preventing the transmission of mtDNA disease, is 
whether it amounts to ‘human cloning’.     This question can usually be answered both 
affirmatively and negatively depending on what is determined as the defining 
characteristic of cloning (De Wort, 2000; Jacobs et al, 2006; Bredenoord et al, 2008).      
Cloning is defined as the ‘production of a genetic copy, genetically identical organism 
or individual’ (‘genetic duplication’).      The procedure of cloning can be further 
classified as either; embryo cloning (when the original cell is derived from an embryo) 
or adult cloning (when the original cell is derived from an adult).   However the aim of 
nuclear transfer procedures currently being explored is not targeted at the conception of 
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genetically identical individuals but at the prevention of severe genetic disorders.  It 
therefore seems unreasonable to view such therapeutic nuclear transfer procedures as 
approaches to cloning.    
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1.9  Aims  
 
 To examine mtDNA mutation loads in oocytes, embryos and blastomeres 
obtained from patients undergoing preimplantation genetic diagnosis (PGD). 
 To learn and develop the skills to perform the pronuclear transfer technique. 
Examine potential modifications which could be made to the PNT technique to 
improve efficiency. 
 
 To optimise a vitrification protocol for human zygotes and oocytes.  
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Chapter 2 Materials and Methods 
 
2.1 Collection of oocytes and embryos 
 
Human oocytes and embryos were obtained from patients undergoing fertility treatment 
at the Newcastle Fertility Centre at Life following informed consent. The projects were 
licensed by the Human Fertilisation and Embryology Authority (HFEA) 
(see Appendix 1) and approved by the Newcastle and North Tyneside Local Ethics 
Committee. 
 
2.1.1 Human Oocytes 
 
Immature oocytes used in the study were obtained at the time of oocyte collection 
(day 0 of the IVF or ICSI cycle). These included both germinal vesicle (GV) stage 
oocytes, which were identified at the time of oocyte collection by a visible GV, and 
oocytes arrested at the metaphase I stage, which were identified by the absence of a first 
polar body. Mature oocytes used included freshly harvested metaphase II oocytes and 
metaphase II oocytes that failed to fertilise following intracytoplasmic sperm injection 
(ICSI) ~48hrs post-fertilisation. Failed fertilisation was determined by lack of visible 
pronuclei on day 1 of the IVF or ICSI cycle and failure to cleave by day 2. Immature 
oocytes were also cultured in G-FERT (Vitrolife, Sweden) at 37°C with 7% CO2 until 
they reached the metaphase II stage (determined by extrusion of the first polar body) 
and were used in the study. 
 
2.1.2 Abnormally Fertilised Human Embryos 
 
Embryos used in the study included abnormally fertilised embryos collected on day 1 of 
the IVF or ISCI cycle. These embryos were identified as abnormal by the presence of 
either 1 pronucleus (monopronucleate) or 3 pronuclei (tripronucleate) 18-19 hours after 
insemination. These embryos cannot be used in fertility treatment and are routinely 
rejected from the IVF program. 
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2.1.2.1 Blastomere biopsy 
 
Embryo biopsy was performed using an inverted microscope (Nikon Eclipse TE2000-
U) equipped with a micromanipulation system (Integra Ti, Research Instruments).  To 
obtain individual blastomeres, embryos were placed in G-PGD medium (Vitrolife, 
Sweden) at 37
o
C with 7% CO2 and immobilised with a holding pipette.  A small hole 
was made in the zona pellucida using a microsurgical laser (Saturn Active, Research 
Instruments) and a biopsy pipette used to gently aspirate the individual blastomeres.  
The blastomeres were transferred to sterile microfuge tubes for analysis and the 
biopsied embryo cultured in G2v5 Plus medium (Vitrolife) at 37ºC with 7% CO2. 
 
2.1.2.2 Whole embryo disaggregation to obtain individual 
blastomeres 
 
Embryos were placed briefly in Acid tyrode’s solution (<1 minute) to remove the zona 
pellucida and transferred to G-PGD medium.  Blastomeres were obtained by continual 
pipetting of the embryo to disaggregate individual cells.  Blastomeres were washed 
through several drops of PBS and transferred to sterile microfuge tubes for analysis. 
 
2.2 Molecular Biology Techniques  
2.2.1 DNA isolation  
2.2.1.1 DNA extraction from single cells  
 
 Samples (Oocytes, embryos and blastomeres) were centrifuged at 13,000rpm for 
10mins and 15µl cell lysis buffer (50mM Tris-HCl pH8.5, 1mM EDTA, 0.5% Tween-
20, 200µg/ml proteinase K) added to each tube.  The samples were incubated at 55
o
C 
for 2 hours and at 95
o
C for 10 minutes so as to inactive enzyme activity (method 
referenced Craven et al, 2010).    
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2.2.1.2 Follicular fluid DNA extraction  
 
Follicular Fluid was collected at the time of oocyte retrieval and the ovarian cells 
pelleted at 13,000rpm for 10 minutes.  The pellets were resuspended in a volume of 
~200µl and stored at -20
o
C until required.  DNA extraction was completed using 
QIAsmp® DNA Mini Kit according to manufacturer’s instructions (Qiagen).  20µl 
QIAGEN Protease was added to a 1.5ml centrifuge tube followed by 200µl Buffer AL.  
The sample was vortexed for 15seconds and incubated at 56
o
C for 10 minutes.  200µl of 
100% ethanol was then added and the sample vortexed for 15 seconds before being 
applied to a QIAamp Spin Column. The spin column was centrifuged at 13,000rpm for 
1 minute and transferred to a clean collection tube.  500µl Buffer AW1 was added and 
the spin column centrifuged at 13,000rpm for 1 minute.  Te spin column was transferred 
to a clean collection tube and 500µl Buffer AW2 added.  The column was then 
centrifuged at 13,000rpm for 3 minutes and transferred to a clean collection tube.  The 
DNA was eluted by adding 50µl Buffer AE and centrifuged at 13,000rpm for 1 minute 
(method referenced Craven et al, 2010).    
 
2.2.2 PCR  
 
In PCR reactions, 1µl of sample DNA was amplified in 25µl volumes containing 5µl, 
5x reaction buffer, 1 unit Go Taq DNA polymerase (promega, UK), 3µl MgCl2, 2µM 
dNTPs, of 125ng each primer (100µM ).  PCR was performed with one cycle of 10min 
at 95
o
C, 30 cycles of 45s at 95
o
C, 45s at the appropriate annealing temperature (as 
detailed in figure), 45s at 72
o
C, and finally followed by one cycle of 10mins at 72
o
C.  
All standard PCR reactions were carried out on a Thermal Cycler (GeneAmp PCR 
system 9600). The annealing temperature differed depending on the primer pair and the 
extension time varied depending on the length of the amplified product.  (A list of all 
primers is included in Appendix 2). 
 
2.2.3 Gel electrophoresis, visualization and analysis 
 
Four µl of loading dye was added to the PCR products, which were subsequently 
separated on 2% agarose gels (prepared by adding 1g agarose (Roche, diagnostics, UK) 
to 50ml1xTAE buffer (0.04M Tris-acetate, 0.01MEDTA), including 1.5µlethidium 
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bromide (l0mg/ml) (Sigma) to allow subsequent visualization].  A 1kb DNA ladder was 
loaded onto the gel to allow sizing of the DNA products.  Electrophoresis was 
performed for 30-35 minutes in a electrophoresis tank (Bio-Rad) at 85V until adequate 
separation of the DNA was observed.  The PCR products were then visualized and 
imaged using a UV light illuminator (Alphaimager™2200, Alpha Innotech).     
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Chapter 3 Analysis of embryos for pre-implantation genetic diagnosis 
for mitochondrial DNA point mutations 
 
3.1 Introduction  
 
Pathogenic mutations within mitochondrial DNA (mtDNA) are now commonly 
recognised as important causes of genetic disease (Elliot et al, 2008; Schaefer et al, 
2008).  MtDNA mutations are maternally inherited (Wallace, 2007) the risk of 
transmitting mtDNA disease is difficult to predict due to the co-existence of wild-type 
and mutant mtDNA within an individual (known as heteroplasmy).  The presence of a 
genetic bottleneck during early development complicates matters further and results in 
considerable variation in the mtDNA mutation load transmitted to offspring.  This 
makes genetic counselling extremely challenging and because of a lack of effective 
treatments, pre-implantation genetic diagnosis (PGD) is increasingly being offered to 
women who carry pathogenic mtDNA mutations (Figure 3.1).  However unlike PGD 
performed for Mendelian inherited disorders, where the presence or absence of the 
specific mutation is detected from the nuclear DNA, PGD for mtDNA disease aims to 
detect the proportion of mutant mtDNA within the embryo which has limited its 
application.  This technique therefore aims to identify those embryos with low mutant 
loads to be selected and has been used successfully for only a small number of mtDNA 
mutations (Steffan et al, 2006; Thorburn et al, 2009; Monnot et al, 2010).  Therefore In 
view of the fairy limited evidence available for different mtDNA mutations I have 
looked at levels of heteroplasmy for a total of seven different mtDNA mutations in 
oocytes, blastomeres, inner cell mass (ICM), trophectoderm and whole embryos.    
 
3.1.1 Mitochondrial segregation during pre-implantation development in 
mouse heteroplasmic embryos  
 
Most available data regarding mtDNA segregation during pre-implantation embryo 
development has come from animal studies.  Mouse strains have been constructed 
which are heteroplasmic for two neutral mtDNA polymorphisms (Jenuth et al, 1996; 
Meirelles and Smith, 1997).   These studies have demonstrated that mtDNA 
polymorphisms are transmitted to the offspring with levels of heteroplasmy largely 
determined by random genetic drift.    Resulting in identical levels of observed 
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heteroplasmy within individual blastomeres of cleaved embryos throughout each of the 
cleavage stages examined (Dean et al, 2003).  However they did report wide variations 
in the proportion of mtDNA variants in cleaved embryos compared with levels on the 
mother (Dean et al, 2003).  Similar dramatic shifts of mtDNA populations between 
mother and her off-spring have been reported in cattle models as well (Laipis et al, 
1988).   
 
3.1.2 Mitochondrial segregation studies in the human pre-implantation 
embryo  
 
Few data exist on mtDNA segregation during early human embryonic development.  
Studies have instead used polymorphisms to mimic the study of pathogenic mtDNA 
mutations in human pre-implantation embryos (Steffann et al, 2005, 2006).  Here 
reporting relatively little variation in mitochondrial heteroplasmy amongst most pre-
implantation embryos (<8%) with variation observed in the distribution of 
polymorphisms among embryos from a given mother, judged to be fairly small (14-
17%).   Studies examining mutation load segregation for the NARP (m.8993T>G) 
mutation in pre-implantation embryos demonstrated the virtually identical distribution 
of mutant species between blastomeres, which they were able to examine for 3 different 
embryos (Steffann et al, 2005).  Another study also examining the m.8993T>G mutation 
in individual blastomeres revealed limited variation between blastomeres ranging from 
2-11% (Tajima et al., 2007).   A study examining segregation of the m.3243A>G 
mutation also reported observing equal partitioning of the mutant species between 
blastomeres (Monnot et al, 2011).   The observed inter blastomere stability of the 
mutant load, which has now been reported for at least two different mtDNA mutations 
has led to the suggestion that the embryonic heteroplasmy determined for a single-cell  
provides an accurate estimate of the mutant load of the whole embryo ( Steffann et al, 
2006; Craven et al, 2010; Monnot et al, 2011).   
 
3.2 Background to mutations included in analyses    
3.2.1  m. 8993T>C 
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NARP syndrome is most commonly associated with two point mutations m.8993T>G 
and m.8993T>C both located within the MT-ATP6 gene.  The m.8993T>G is generally 
associated with a more severe clinical phenotype in comparison so the m.8993T>C 
variant which even at similar levels of mutation is generally associated with a milder 
and less severe phenotype.   Individuals who present with clinical phenotypes 
reminiscent of NARP syndrome most frequently carry the mutation at high levels >80% 
and >75% for the m.8993T>C and m.8993T>G mutations respectively (Steffann et al, 
2007).  Due to these extremely high mutation levels the risk of recurrence for this 
particular mutation is often equally as high.  Indeed several studies have reported 
extreme variances in mutation loads during embryofetal development although 
predominately for the m.8993T>G variant which is known to demonstrate characteristic 
skewed patterns of segregation  (<10% or >80%)(Blok et al, 1997; White et al, 1999; 
Leshinsky-Silver et al, 2003; Steffan et al,2006; Steffan et al 2007).    Indeed the first 
successful reported case of PGD for a mitochondrial disorder was reported for the 
m.8993T>G NARP mutation, which resulted in the successful birth of a healthy baby 
boy (Steffann et al, 2007). 
 
3.2.2 m. 9176T>C 
 
The m.9176T>C mutation is located within the MT-ATP6 gene, the same gene the two 
NARP associated mutations (m.8993T>G and m.8993T>C) are located.  Indeed it has 
been shown to bare similar resemblance in clinical symptoms to the NARP syndrome 
mutations (Dionisi-Vici et al, 1998).  However the m.9176T>C mutation is a less well 
characterized mutation and the mutation load threshold for clinical expression has 
therefore proven more difficult to judge.   Although of those cases reported in the 
literature most patients presenting with severe symptoms generally possess mutation 
loads above 90% in various tissues (Jacobs et al, 2005).   
 
3.2.3 m. 10158T>C 
 
The m.10158T>C mutation is located in the MT-ND3 gene (NADH dehydrogenase 
subunit 3), which encodes a subunit of complex I.  Mutations in the MT-ND3 gene are 
commonly associated with complex I deficient Leigh Syndrome (LS) and Leigh-like 
syndrome (Wong, 2007; Malfatti et al, 2007; Bugiani et al, 2004).  Leigh syndrome is 
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usually fatal during infancy (Huntsman et al, 2005; Wang et al, 2009.  This mutation 
does appear to demonstrate quite consistent patterns of segregation although clinically 
affected tissues in patients often display very high levels of the mutation.  The 
consistent pattern of segregation observed for this particular mutation is encouraging for 
patients and its prospective suitability for PND and PGD.    
 
3.2.4 m. 14487T>C 
 
The m.14487T>C is a mis-sense mutation found within the ND6 subunit of complex I 
of the mitochondrial respiratory chain.  Similarly to the m.10158T>C mutation it is also 
associated with isolated cases of Leigh syndrome (LS) and or in addition to bilateral 
striatal necrosis (BNS) (Solano et al, 2003; Wang et al, 2009).  Variable levels of 
heteroplasmy are often reported for carriers of the m.14487T>C mutation (65-95%) 
(Wang et al, 2009) where mutation loads >90% are associated with a disease phenotype 
and onset of clinical symptoms typical of Leigh syndrome (Santorelli et al, 1993; 
DiMauro and Schon, 2001; Wang et al, 2009). It has therefore been said to display a 
similar pattern of inheritance to the NARP mutations (m.8993T>G, m.8993T>C and 
m.9176T>C) which also only become clinically apparent at high levels of heteroplasmy 
(Tatuch et al, 1992; Oritz et al, 1993; Degoul et al, 1995; Mäkelä-bengs et al, 1995; 
Santorelli et al, 1997; White et al, 1999).   
 
3.2.5 m. 14709T>C  
 
The m.14709T>C mutations is a well characterised mutation which has been found in 
several families with patients presenting with a proximal myopathy and diabetes (Hao et 
al, 1995). In some family members ataxia can also be an important and disabling feature 
(Van Hove et al, 2008; McFarland and Turnbull, 2008; Lax, 2012).  The mutation is 
interesting because there is usually a fairly high threshold for disease and the level of 
mutation is pretty evenly spread throughout the tissues (Meulemans et al, 2007).  
Previous studies have demonstrated a correlation between the amount of mutant 
mtDNA and clinical severity within family pedigrees (Hanna et al, 1995).   
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Figure3. 1 Procedure performed for Preimplantation genetic 
diagnosis (PGD)  
 
Image represents the biopsy process, performed in order to obtain a 
single blastomere, upon which molecular analysis can be performed.   
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3.3 Materials and Methods 
 
3.3.1 Collection of oocytes and embryos 
 
3.3.1.1 Human oocytes  
 
Immature oocytes were included as part of this study.  These were obtained 
following oocyte collection (day 0 of the IVF or ICSI cycle) and included germinal 
vesicle stage (GV) oocytes identified at the time of oocyte collection by a visible 
GV, and oocytes arrested at the metaphase I (MI) stage, which were identified by 
the absence of a first polar body.   Mature oocytes used included freshly harvested 
metaphase II oocytes and metaphase II oocytes that failed to fertilise following 
intracytoplasmic sperm injection (ICSI) ~48hrs post-fertilisation. Failed fertilisation 
was determined by lack of visible pronuclei on day 1 of the IVF or ICSI cycle and 
failure to cleave by day 2. Immature oocytes were also cultured in G-IVF (Vitrolife, 
Sweden) at 37°C with 7% CO2 until they reached the metaphase II stage 
(determined by extrusion of the first polar body) and were used in the study.    
 
3.3.1.2 Human Blastocysts 
 
Following blastomere removal (see section 2.1.3.1), biopsied embryos were cultured 
in vitro to the blastocyst stage (day 5-7) and used in the study. Embryos not suitable 
for transfer or cryopreservation were cultured in G1 medium (Vitrolife, Sweden) at 
37°C with 7% CO2 until the 8-cell stage (day 3 of the IVF or ICSI cycle) and were 
then transferred to G2 medium (Vitrolife, Sweden) at 37°C with 7% CO2 until they 
reached the blastocyst stage (day 5-7). 
 
3.3.1.3 Cleavage stage thawing  
 
Straws were removed from the liquid N2 and held in the air for 30 seconds.  Straws 
were incubated at 37
o
C for 1 minute.  The end of the straw was snipped off using 
sterilised scissors, and the contents were transferred to a 4-well nunc dish (NUNC, 
Thermofisher, Roskilde, Denmark).  Using a denudation pipette embryos were 
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transferred to 500µl of TS1 (thawing solution) and left for 5 minutes at room 
temperature.  Embryos were then transferred to the next solution TS2 (500µl) and 
left for a further 5 minutes, TS3 for 10 minutes and finally TS4 and incubated at 
37
o
C in a non-CO2 incubator for 10 minutes.   The thawed embryos were moved 
using a denudation pipette to a pre-equilibrated culture dish (37
o
C and 7% CO2).   
 
3.3.2 Individual Blastomeres from Human Embryos 
 
3.3.2.1 Blastomere biopsy 
 
Embryo biopsy was performed using an inverted microscope (Nikon Eclipse 
TE2000-U) equipped with a micromanipulation system (Integra Ti, Research 
Instruments).  To obtain individual blastomeres, embryos were placed in G-PGD 
medium (Vitrolife, Sweden) at 37
o
C with 7% CO2 and immobilised with a holding 
pipette.  A small hole was made in the zona pellucida using a microsurgical laser 
(Saturn Active, Research Instruments) and a biopsy pipette used to gently aspirate 
the individual blastomeres.  The blastomeres were transferred to sterile microfuge 
tubes for analysis and the biopsied embryo cultured in G2v5 Plus medium 
(Vitrolife) at 37ºC with 7% CO2. Embryo biopsies were performed by Mrs Sam 
Byerley, Dr Lyndsey Butterworth and myself.   
 
3.3.2.2 Whole embryo disaggregation to obtain individual blastomeres 
 
Embryos were placed briefly in Acid tyrode’s solution (<1 minute) to remove the 
zona pellucida and transferred to G-PGD medium.  Blastomeres were obtained by 
continual pipetting of the embryo to disaggregate individual cells.  Blastomeres 
were washed through several drops of PBS and transferred to sterile microfuge 
tubes for analysis. This was performed by Dr Lyndsey Butterworth and myself.   
 
3.3.3 Samples included in analysis  
 
After receiving informed consent from the donors, we obtained a number of samples 
from carriers of the m.3688G>A, m.3243G>A, m.8993T>C, m.9176T>C, 
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m.10158t>C, m.14487T.C, m.14709T>C mutations, all undergoing fertility 
treatment at the Newcastle Fertility Centre at Life.  The project was licensed by the 
Human Fertilization and Embryology Authority (HFEA) and approved by the 
Newcastle and North Tyneside Local Ethics Committee.   
 
3.3.3.1 m. 3688G>A 
 
The samples included a previously biopsied cleavage stage embryo which was able 
to be disaggregated into individual blastomeres (n=12).   Additionally several whole 
blastocysts (n=4) and a single blastocyst which was able to be successfully to give 
individual inner cell mass (ICM) and trophectoderm samples.   
 
3.3.3.2 m. 8993T>C  
 
Samples included two embryos, which blastomere biopsy revealed harbored high 
levels of mutation (>90%) and later went onto subsequently arrest development.   
Unfortunately both embryos contained considerable fragmentation and individual 
blastomeres were unable to be obtained and therefore embryos were collected as a 
whole for mutation load analysis.    
 
3.3.3.3 m. 9176T>C 
 
Here samples included two embryos biopsied on day 3, which arrested development 
on day 5.  Both embryos were disaggregated manually and individual blastomeres 
obtained for both (n=5 and n=6).   
 
3.3.3.4 m. 10158T>C  
 
Samples included two embryos which had undergone blastomere biopsy and 
arrested development to be obtained (these were analyzed as whole embryos).   An 
in vitro matured MII oocyte which had undergone polar body biopsy was also 
acquired for analysis.   
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3.3.3.5 m. 14487T>C  
 
A number of frozen embryos were obtained from a carrier of the m.14478T>C 
mutation who had previously undergone fertility treatment at the Regional Fertility 
Program, Canada (Hewko, Calgary, Canada).  A total of 5 embryos frozen at the 8-
cell stage of development were thawed and cultured.  One embryo was cultured to 
the blastocyst stage (day 7) and the trophectoderm and zona pellucida collected for 
mutation load analysis.  The remaining embryos failed to reach the blastocyst stage 
and arrested development between the 8 to 18-cell stage (Fig3.2).  These embryos 
were disaggregated into individual blastomeres for analysis. 
 
3.3.3.6 m. 14709T>C 
 
Samples included immature oocytes (GV and metaphase I stage) and a mature 
oocyte that failed to fertilize following IVF (metaphase II stage).  A total of 3 
fertilized embryos not suitable for transfer or cryopreservation were cultured to the 
6-8 cell stage (day 3) and an embryo biopsy performed to remove a single 
blastomere for mutation load analysis.  Two embryos were subsequently cultured to 
the blastocyst stage (day 7) and the trophectoderm and zona pellucida collected for 
analysis.  The remaining embryo arrested development prior to the blastocyst stage 
and was disaggregated into individual blastomeres for analysis. 
 
3.3.4 Single cell lysis 
 
Individual oocytes and embryos were lysed for 2 hours in a standard lysis buffer 
(50mM Tris-HCl, pH 8.5, 1mM EDTA, 0.5% Tween-20 and 200μg/ml proteinase 
K) at 55ºC.  The enzyme was inactivated by incubation at 95ºC for 10 minutes. 
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Figure3. 2 Thawed embryos analysed for the m.14487T>C mutation 
which successfully developed to blastocyst stage embryos  
 
Above images represent embryos thawed at the 8-cell stage.  These were then 
cultured and a number (n=4) successfully developed to blastocyst stage 
embryos (between days 5-7).   These were then manually dissected so as to 
separate the inner cell mass (ICM) from the remaining trophectoderm cells.   
All blastocysts were found to contain relatively large ICM (as indicated by 
arrows), which assisted when performing the manual dissections of the 
blastocysts. Scale bars, 50µm.    
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Figure3. 3 Above schematic diagram represents the principle methodology 
behind pyrosequencing  
 
Here (step 1) the sequencing primer anneals to the single stranded PCR 
amplicon.  Every time a new nucleotide is incorporated into the sequence a 
molecule of pyrophosphate is released (step 2).  The pyrophosphate molecule 
released reacts with APS through a reaction catalysed by sulfurylase resulting in 
the production of ATP.  The ATP generated then reacts to with luciferase 
supplied in the reaction reagents in so resulting in the generation of light (Step 
3), which is detected and represented as a peak on the program trace generated 
(Step 4) (The height of each peak is proportional to the number of nucleotides 
incorporated at that specific part of the sequence being processed at the time.  
(Adapted from original images at www.qiagen.co.uk) 
 
 
 
 
 
 
Step4  
Step1  
Step3 
Step2 
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3.3.5 Pyrosequencing 
 
We developed specific pyrosequencing assays employing a mutation-specific 
pyrosequencing primer to detect and quantify samples for the m.3688G>A, 
m.3243A>G, m.8993T>C, m.9176T>C, m.10158T>C, m.14709T>C and m.14487T>C 
mtDNA mutations.  Primers were designed using PyroMark Assay Design Software 
version 2.0   Assays were designed by myself and Mrs Charlotte Alston.   
 
PCR amplicons were generated from single cell lysate.  Reactions were 25μl in volume 
and contained 1µl cell lysate, 5µl 5x reaction buffer, 1 unit Go Taq DNA polymerase 
(Promega, UK), 3µl MgCl2, 2µM dNTPs and 125ng forward and reverse primer 
(100µM)(Please refer to, Appendix 2 Supplementary table1for full list of primer 
sequences).  PCR reactions were performed on a Thermal Cycler (GeneAmp PCR 
system 9600) using the following amplification conditions: 95
o
C for 10 minutes, 
followed by 30 cycles of 95°C for 45 seconds, annealing temperatures were assay 
specific for 45 seconds and 72°C for 45 seconds.  The final extension was at 72°C for 
10 minutes. 
 
Pyrosequencing assays were performed in triplicate using the PyroMark Q24 instrument 
according to the manufacturer’s instructions (Qiagen) (Figure3.3).  Mutation load was 
quantified using the allele quantification PyroMark™Q24 Software (Figure3.4).  To 
determine the sensitivity, specificity and accuracy of the assays, patient samples with 
known levels of the specific mutation previously quantified by hot last cycle-PCR 
RFLP were included in the analysis. 
 
3.3.5.1 Validation of pyrosequening assays for the 
determination of mutation loads in preimplantation embryos  
 
Pyrosequencing on the Pyromark Q24 platform was used to quantify the mtDNA 
mutations.  PyroMark assay design software v2.0 (Qiagen, Hilden, Germany) was used 
to design mutation-specific pyrosequencing (PSQ) primer trios (as detailed in 
supplementary table).   In order to determine the accuracy of the pyrosequencing assays, 
samples for which mutation load had previously been quantified using last hot-cycle 
RFLP were examined for each specific pyrosequencing assay.  These samples were of 
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varying levels of heteroplasmy and with homoplasmic mutant mtDNA.  Control 
samples were also included within runs from patients who were known to not carry the 
mutation of interest (WT-wild-type).  These samples were also included in runs when 
analyzing embryonic samples to ensure assay accuracy.  The allele quantification 
application of Pyromark's proprietary Q24 software was used to calculate mtDNA 
heteroplasmy levels.   
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Figure3. 4 Pyrograms generated following pyrosequencing to determine mutation loads. 
 In each assay a number of internal controls specific to each assay were included.  This included 
where possible a sample obtained from the mother which had previously been quantified, 
heteroplasmic mutant and wild-type sample were included to ensure correct validation and 
accuracy through consecutive runs.   
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3.4 Results  
 
3.4.1 Mutation load analysis conducted for embryonic samples obtained 
from a carrier of the m.3688G>A mutation  
 
3.4.1.1 Studies examining mtDNA mutation loads in embryos  
 
Several samples were obtained from a patient recently confirmed as a carrier of the 
m.3688G>A.   Previously the first child born to this patient died aged 3 months, from a 
complex I deficiency and Leigh syndrome, leading to an establishing a diagnosis of the 
m.3688G>A mutation in the mother.   She was determined to carry the mutation load at 
20% and 50% in blood and urine samples respectively, whilst her son was found to 
harbour the mutation at ~98%.   Knowing the risk of potentially conceiving a second 
child also harbouring similarly high levels the couple opted to undergo pre-implantation 
genetic diagnosis (PGD).    Several samples which were left over from her treatment 
programme and were not suitable to be cryopreserved were obtained via informed 
consent for mutation load analysis.    This included a cleavage stage embryo biopsied on 
day three as part of the PGD programme here the mutation load was determined for the 
biopsied blastomere (4%) by the NCG mitochondrial diagnostic service.  The embryo 
later arrested development and individual blastomeres were manually disaggregated 
(n=12 blastomeres) with mutation loads ranging from 1-7%, (mean= 5%) (Fig3.5). A 
number of the biopsied embryos successfully developed to blastocyst stage (n=5).   
 
3.4.1.2 Studies examining mutation loads in blastocyst stage 
embryos  
 
Here mutation levels were determined for the biopsied blastomeres obtained from three 
embryos on day 3 (by the NCG mitochondrial diagnostic service) as 16%, 8% and 2% 
and later for the corresponding blastocysts which were not transferred back to the 
patient (n=3) as 4, 6 and 3% (Fig3.15) (Table3.6).   It was possible to manually dissect 
the inner cell mass (ICM) from the surrounding trophectoderm cells for one of the 
embryos which successfully developed to a blastocyst.  Here the mutation load was 
determined for the ICM as 2% and the trophectoderm cells also as 2% (Fig3.6b).  To 
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our knowledge this the first study we know of, which has attempted to successfully 
examine mutation loads in separate ICM (goes onto form embryo-proper) and 
trophectoderm (extra-embryonic tissues) samples.  This was performed in order to 
determine if any variation in mutation loads existed between the two cell types.  
However no apparent preferential segregation was observed, although mutation loads 
were relatively low compared to wild-type levels.   The mutation load was also 
determined for one blastocyst as a whole (3%) (Fig3.6a). No further information was 
available for this embryo as the biopsied cell acquired on day 3 failed to amplify.   
 
3.4.1.3 Studies examining mtDNA mutation loads in oocytes  
 
Mutation loads were also analysed for several oocytes obtained which were either found 
to be immature at egg collection or failed to fertilise (n=3).   Here mutation loads were 
determined as 13% in the GV stage oocyte (Fig3.7a), 4% in the metaphase II stage 
oocyte (* with large polar body) (Fig3.7b) and 3% in the metaphase I stage (zona-free 
oocyte) (Fig3.7c).  The corresponding empty zona pellucida was also included in 
analyses and mutation load determined as 42%* (*however this was attributed to 
cumulus cell attachment).  
 
3.4.1.4 Studies examining mtDNA mutation loads for polar 
body biopsied oocytes  
 
Two MII stage oocytes from the carrier of the m.3688G>A mutation which failed to 
fertilise and underwent polar body biopsy (performed by Ms Byerley) were also 
analysed.  Mutation loads of 4% and 2% were observed in each polar body and the 
respective oocytes were determined as 3% and 3% (Fig3.8a and b)(Table3.1).   
Representing variation of ~1% between polar bodies and there corresponding oocyte, 
without taking into consideration errors in PCR and pyrosequencing.   
 
 
 
 
 
 
9 0  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
m. 3688G>A 
Figure3. 5 Analysis of mutation loads for individual blastomeres obtained 
for the m.3688G>A mutation  
 
Above schematic diagram represents a cleavage stage embryo obtained from a 
carrier of the m.3688G>A mutation (12-cell stage) which subsequently 
arrested development and was able to be disaggregated into individual 
blastomeres (n=12).  The mutation load was subsequently determined for the 
individual blastomeres with mutation loads ranging from 1-7%, (mean= 5%).  
This embryo had previously been biopsied on day 3 as part of the PGD 
programme (run between the Newcastle upon Tyne NHS Fertility Centre at 
Life and the NCG mitochondrial diagnostic service).  Here the mutation load 
had been determined as 4% (analysis performed by Mrs C. Alston).   
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Figure3. 6 Determination of mutation loads in pre-implantation blastocysts 
for the m.3688G>A mutation  
 
 Two embryos which were biopsied on day 3 as part of the PGD programme for the 
m.3688G>A mutation but failed to amplify, so were excluded from the treatment 
cycle, successfully developed to blastocyst stage embryos.  Here mutation load was 
determined for the whole blastocyst.  (a) ~3% (b) for the second blastocyst the 
inner cell mass (ICM) and the trophectoderm cells were able to be dissected apart 
manually and collected for mtDNA mutation load analysis.  Here the mutation load 
was determined for the ICM (2%) and trophectoderm cells (2%).    
 
 
 
b. 
a. 
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Figure3. 7 Schematic diagrams represent mutation load determined in 
samples obtained from a carrier of the m.3688G>A mtDNA mutation.  
 
 (a)  Mutant load was determined for an immature oocyte (13%). (b) 
Metaphase II stage oocyte with large polar body (~4%) (c) Zona free oocyte 
(3%) and also corresponding empty zona pellucida (~42%).  Here we believe 
the mutation load determined for the empty zona pellucida was influenced by 
the presence of cumulus cells which we know (following analysis) contained 
a higher mtDNA mutant load.  
a. 
m. 3688G>A 
  
 
c. 
b. 
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Figure3. 8 Schematic diagrams represent mutation load determined for two MII 
stage oocytes which underwent polar body biopsy from a carrier of the 
m.3688A>G mtDNA mutation.   
 
For the two oocytes obtained from the carrier if the m.3688A>G mutation the oocyte 
mutant load was determined as (a) 4% and (b) 2% whilst the mutant load in the 
respective polar bodies was determined as 3% for both.   For the m.10158T>C 
mutation (c) a single MII oocyte had a mutant load of 1% and this corresponded to the 
polar body which had an identical mutant load of 1%.  
 
  
 
m.10158T>C 
a. b. 
c. 
m. 3688G>A 
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3.4.2 Mutation load analysis conducted for embryonic samples obtained 
from a carrier of the m.9176T>C mutation  
 
3.4.2.1 Studies examining mtDNA mutation loads in embryos  
 
Several samples were obtained from an asymptomatic carrier of the m.9176T>C 
mutation who previously had one affected child known to carry the mutation at high 
levels (>97%) and therefore opted for PGD to minimise the likelihood of conceiving 
another child affected by such high levels.  Indeed previous studies have reported cases 
where maternal relatives of the patients either do not carry the mutation or carry the 
mutation at varying percentages (Jacobs et al, 2005).   Here a number of embryos were 
created following IVF treatment. Those embryos which successfully fertilised were 
biopsied ideally on day 3 (p.f) involving the removal of a single cell.   A number of 
these embryos arrested development (n=2) following biopsy procedures.   Here the 
mutation was found to be undetectable in the biopsied cells (0%) (Mutation loads of 
blastomeres analysed by Mrs C. Alston as part of the NCG mitochondrial diagnostic 
service).   Individual blastomeres were disaggregated for the arrested embryos (n=2) 
and mutation loads determined for each (1-4% and 2-4% respectively) (Fig3.9).  
Relatively low levels were detected in both of the embryos over all, which correlated 
with previous reports for mutation loads observed in the biopsied blastomeres.   
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Figure3. 9 Schematic diagrams represent mutation load analysis performed 
upon individual blastomeres disaggregated from the same embryo both for the 
mt.9176T>C. 
 
 Above schematic diagram represents two cleavage stage embryos which arrested 
development and were able to be manually disaggregate in order to obtain individual 
blastomeres (a) n=5 and (b) n=6 for the m.9176T>C mutation.  The mutation load 
was determined for the individual blastomeres with mutation loads ranging from 1-
4% (mean=3%) and 2-4% (mean=3%) respectively.   These two embryos had 
previously been biopsied on day 3 as part of the PGD programme (ran between the 
Newcastle upon Tyne NHS fertility centre at Life and the NCG mitochondrial 
diagnostic service).  Here no mutation was detected in either of the blastomeres 
analysed (analysis performed by Mrs C. Alston).   
 
 
m. 9176T>C 
B 
A 
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3.4.3 Mutation load analysis conducted for embryonic samples obtained 
from a carrier of the m.8993T>C mutation  
 
3.4.3.1 Studies examining mtDNA mutation loads in embryos  
 
Several samples were obtained from a patient known to be a carrier of the m.8993T>C 
mutation.    The patient had been found to carry the mutation load at 96% and 98% in 
blood and urine samples respectively.  Due to carrying the mutation at such high levels 
the couple opted to undergo PGD.   Several embryos were created following IVF 
treatment (n=4) and biopsied on day 3.  Unfortunately all biopsies blastomeres were 
found to possess the mutation to virtual homoplasmic levels  (99%, 98%, 99% and 99% 
respectively) (Mutation loads for biopsied blastomeres analysed by Mrs C.Alston, 
clinical scientist at the NCG mitochondrial diagnostic service). Later mutation loads 
were analysed for the whole embryos, which were previously biopsied (99%, 98% and 
99% respectively) (Table3.1) (Fig3.10a).   Again mutation loads observed in the 
embryos were reflective of mutation loads observed in the earlier blastomere biopsied 
samples, demonstrating the accurate value of biopsied cell (It should be noted that the 
fourth embryo failed to amplify successfully therefore was not included in analyses).  
 
3.4.4 Mutation load analysis conducted for embryonic samples obtained 
from a carrier of the m.10158T>C mutation  
 
3.4.4.1 Studies examining mtDNA mutation loads in embryos  
 
Mutation loads were determined for n=2 embryos unable to be disaggregated into 
individual blastomeres and therefore analysed as whole embryos.  Here mutation loads 
determined for the whole embryos (18% and 4%)  were similar to those levels 
previously determined for the biopsied blastomeres (18% and 0%) (Fig3.10b) (mutation 
loads determined by Mrs C.Alston for biopsied blastomere).  
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3.4.4.2 Studies examining mtDNA mutation loads for polar 
body biopsied oocytes  
 
 A single in vitro matured MII stage oocyte was biopsied allowing mutation loads to be 
determined for the oocyte (1%) and polar body (1%) separately (Fig3.8c).   The 
corresponding values observed between the polar body and its corresponding oocyte 
were identical demonstrating the predictable value of the polar body.  
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Table3. 1Mutation loads determined in individual blastomeres for the 
8993T>C mutation.  
 
 Mutation loads were determined for a total of n=3 whole embryos which were 
had been biopsied on day 3 as part of the PGD programme(run between the 
Newcastle upon Tyne NHS Fertility Centre at Life and the NCG mitochondrial 
diagnostic service) and the mutation loads determined for the biopsied single 
blastomeres (99%, 98% and 99%).  Unfortunately these embryos contained a high 
degree of fragmentation and therefore were unable to be disaggregated in order to 
obtain individual blastomeres, consequently all three embryos were analysed as 
whole embryos (96%, 98% and 98%).  
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m.8993T>C 
Figure3. 10 Mutation load analysis for whole embryos for the m.8993T>C 
and m.10158T>C mutation  
 
Here we were able to analyse mutation loads in a total of three whole embryos 
which were unable to be disaggregated into individual blastomeres due to the 
high degree of fragmentation.  (A) Mutation loads were determined for those 
embryos analysed for the m.8993T>C mutation (96%, 98% and 98%).  All three 
embryos had previously been biopsied on day three and a single blastomere 
obtained for mutation load analysis via pyrosequencing (99%, 98% and 99%).   
(B)  Mutation loads were determined for two embryos for the m.10158T>C 
mutation (18% and4 %).  Both embryos had previously been biopsied on day 
three and a single blastomere obtained for mutation load analysis via 
pyrosequencing (18% and 0%).    
m.10158T>C 
a 
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3.4.5 Mutation load analysis conducted for embryonic samples obtained 
from a carrier of the m.14487T>C mutation  
 
3.4.5.1 Studies examining mtDNA mutation loads in embryos  
 
A number of embryos (n=8) cryopreserved at the eight cell stage were received from a 
patient undergoing fertility treatment at an IVF centre in Canada (Hewko, Calgary, 
Canada).   All embryos had been frozen at the 8-cell stage and were warmed at different 
points using medicult thawing solutions and protocol (as fully described in material and 
methods section).     An attempt was made to biopsy the first thawed embryo following 
appropriate recovery. This resulted in the successful retrieval of one single blastomere 
(9%) which was analyzed together with the remaining fragmented embryo (7%).   Three 
further embryos were thawed and disaggregated manually to obtain individual 
blastomeres (n=34).  The heteroplasmy levels were low in all blastomeres analysed and 
ranged from 1 to 11% (mean ~4%) overall (Table3.3) (Fig3.11).      
 
3.4.5.2 Studies examining mutation loads in blastocyst stage 
embryos  
 
 The remaining four embryos thawed were cultured and developed to blastocysts 
(Figure3.2).    An attempt was made to separate the inner cell mass (ICM) from the 
trophectoderm for those blastocysts with clearly visible ICM (n=3).    The mutation 
levels determined for the trophectoderm samples (17%, 2% and 4%) correlated with 
levels found in the ICM (12%, 3% and 3%) for all three embryos analysed in this way 
(Fig3.12a, b and c).   In so revealing no preferential segregation of mtDNA species 
between the two cell lineages at least in samples analysed for these two particular 
mutations.     It was not possible to isolate the ICM cells from the remaining 
trophectoderm cells for one of the thawed embryos which developed to a blastocyst 
therefore the mutation load was determined for the entirety of the blastocyst (ICM + 
trophectoderm); this was determined to be 20% (Fig3.12d).   
 
Samples which we analysed for this particular mutation were from a lady who had an 
affected family member and wanted to determine her risk of having an affected child.  
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We were only able to detect very low levels of the mutation (>10%) within individual 
blastomeres, whole embryos and blastocyst stage embryos which would all have been 
within minimal risk.  This would fit with previous reports in the literature where 
variable levels of heteroplasmy have been detected between affected and unaffected 
members of the same family with only those with very high levels of heteroplasmy 
actually displaying clinical symptoms (Wang et al, 2009). 
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3.4.6 Mutation load analysis conducted for embryonic samples obtained 
from a carrier of the m.14709T>C mutation  
 
3.4.6.1 Studies examining mtDNA mutation loads in embryos  
 
Several samples were received from a patient undergoing fertility treatment at the 
Newcastle upon Tyne NHS Fertility centre at life.   These embryos (n=3) had been 
biopsied on day 3 by Dr Lyndsey Butterworth.     One arrested development at the 8-9 
cell-stage and individual blastomeres were obtained by manual disaggregation (n=8, 
including 2 blastomeres that could not be disaggregated into individual blastomeres and 
were therefore analysed together),  a maximum intra-blastomere variation of 7% was 
observed with mutation loads ranging from 41-48%, (mean=45%).   The mutation load 
determined for the biopsied cell was 45%, which correlated with loads detected in the 
disaggregated blastomeres (Fig3.13).     
 
3.4.6.2 Studies examining mutation loads in blastocyst stage 
embryos  
 
The two other biopsied embryos successfully developed to blastocyst stage embryos 
therefore here it was possible to determine mutation loads were for combined 
trophectoderm and zona pellucida samples (collected day 7)    Mutation loads detected 
in the biopsied blastomeres (34 and 39%) for these two embryos which developed to 
blastocysts were reflective of those detected in the trophectoderm and zona pellucida, 
(33 and 31% respectively).    Interestingly mutation loads observed within the 
individual blastomeres and later stage blastocyst samples were similar to loads 
previously observed in samples analysed for the female carrier of the mutation when  
both skeletal and urine (40 and 49%)(Fig3.15).   
 
3.4.6.3 Studies examining mtDNA mutation loads in oocytes  
 
Mutation loads were also determined for several unfertilised oocytes obtained from the 
carrier of the m.14709T>C mutation at various stages of maturation (n=3) here the 
mutation loads were determined as: 4% in a GV stage oocyte, 28% in a metaphase I 
1 0 7  
 
stage oocyte and 33% in a metaphase II stage oocyte (Fiigure3.14).   Much greater 
variation was observed between the oocytes we analysed in comparison to the 
blastomeres we analysed for the same mutation.    
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Figure3. 13 Schematic diagrams represent mutation load analysis 
performed upon individual blastomeres disaggregated from the same 
embryo for the m.14709T>C mutations 
 
Above schematic diagram represents a cleavage stage embryo obtained from a 
carrier of the m.14709T>C mutation.  Following manual disaggregation (n=8, 
including 2 blastomeres that could not be disaggregated into individual 
blastomeres and were therefore analysed together),  a maximum intra-
blastomere variation of 7% was observed with mutation loads ranging from 41-
48%, (mean=45%).  This embryo had previously been biopsied on day 3 as part 
of the PGD programme (run between the Newcastle upon Tyne NHS Fertility 
Centre at Life and the NCG mitochondrial diagnostic service).  Here the 
mutation load had been determined as 45% (analysis performed by Mrs C. 
Alston).   
 
m. 14709T>C 
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Figure3. 14 Schematic diagrams represent mutation load determined in 
oocytes sampled from a carrier of the m.14709T>C mtDNA mutation.   
 
Here a number of oocytes (n=3) at various stages of maturity were obtained 
from a carrier of the m.14709T>C mutation.  Mutation loads were subsequently 
determined for each (a) Germinal vesicle (GV) stage oocyte (4%). (b) 
Metaphase I (MI) stage oocyte (MI) (28%) and (c) Metaphase II (MII) stage 
oocyte (31%).   
b. c. a. 
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3.5 Discussion 
 
 
The lack of available treatment for mitochondrial disease means that many 
families with inherited mtDNA disease are left with difficult reproductive choices. 
Until recently these choices were limited to genetic counselling, ovum donation 
and chorionic villus biopsy/amniocentesis. The work of Steffann et al, have shown 
that PGD is now feasible for some families with mtDNA disease, where the high 
copy number of mtDNA makes the analysis less prone to artefacts like 
amplification failure and allelic-drop-out (Thorburn, 2004).    Although the 
number of children born following PGD for mtDNA disorders remains limited and 
the data regarding the distribution of mutation loads within embryos minimal and 
available for very few mtDNA mutations.  Therefore the data we have gathered 
has allowed us to gain an insight into mtDNA distribution within oocytes and pre-
implantation embryos for several different mtDNA point mutations.  This 
provided a unique opportunity to broaden our current understanding regarding 
mtDNA segregation, during these critical early pre-implantation stages of 
development.   
 
Here I employed pyrosequencing technology to analyze mtDNA mutation loads in 
oocytes, single blastomeres, pre-implantation and blastocyst stage embryos 
received from a total of seven patients undergoing pre-implantation genetic 
diagnosis at the Newcastle upon Tyne NHS trust fertility Centre at Life.   For 
samples which were not able to be included as part of their treatment cycles (refer 
to materials and methods section for further sample collection details).   
 
The analysis of individual blastomeres obtained for four different mtDNA 
mutations (m.3688G>A, m.9176T>C, m.14487 and m.14709T>C) demonstrated 
the even distribution of mutation loads between blastomeres originating from the 
same embryo.  Minimum variation was observed between blastomeres, ranging 
from as low as 1-10% maximum (Table3.5).    This is in-line with previous studies 
which have examined mutation loads in individual blastomeres obtained from 
human embryos for the m.8993T>G and m.3243A>G mutation who reported 
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observing limited variation ranging from 2-11% and 0.5% to 2.9% (Tajima et al, 
2007; Treff et al, 2012).  Our observations are therefore entirely compatible with 
the even spread of mutation previously reported (Steffann et al, 2006; Tajima et al., 
2007; Treff et al, 2012).  This is important as previously it had been suggested that 
mutation loads observed in biopsied cells may not portray an accurate 
representation of the mutation load in the remaining cells of the embryo 
(Bredenoord et al, 2008) due to the unpredictable manner in which mitochondria 
are inherited and segregate making screening procedures such as pre-implantation 
genetic diagnosis (PGD) impossible to perform.   However my data suggests this 
is not the case.  As those mutation loads I observed in both the individual 
blastomeres and whole embryos both agreed with mutation loads determined for 
the biopsied blastomeres obtained on day 3 as part of the PGD programme 
(Table3.5).  This is in agreement with previous reports made for two different 
mutations (m.8993T>G and m.3243A>G) (Gigarel et al2011; Monnot et al, 2010; 
Steffann et al, 2006; Treff et al, 2012).  It would appear that mutation loads 
observed within biopsied blastomeres provides an accurate representation of the 
mutation loads within the remaining cells of the embryo, providing much needed 
evidence in support of PGD for mtDNA inherited disorders.   
 
Although it is important to ensure that the mutation load observed for the biopsied 
cell on day 3 accurately reflects the mutation load in the remaining cells of the 
embryo.  It is also equally important that we are certain that the mutation load 
observed following biopsy is not subject to not change during the pre-implantation 
period. This type of analysis is often difficult to perform in clinical practice, as 
non-essential biopsy is often avoided due to the negative effect this can exert on 
future developmental potential.   However after obtaining a number of samples 
obtained from patients undergoing fertility treatment or PGD at the Newcastle 
Fertility Centre at Life, which were unsuitable for use in treatment or 
cryopreservation this material was made available for mutation load analysis and 
so making such analyses possible to perform.  A total of 5 embryos were able to 
be included in this particular analysis, which were obtained from two patients each 
a carrier of a different mtDNA mutation, including the m.3688A>G (n=3) and 
m.14709T>C (n=2).   A high degree of similarity was observed between the 
biopsied blastomere (obtained on day 3) and the pre-implantation trophectoderm 
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(obtained between day 5-7) for samples obtained for both mutations. These studies 
support the work from Monnot et al (2011) who showed similar levels of the 
m.3243A>G mutation in individual day 3 blastomeres and corresponding day 5 
trophectoderm samples.  This suggests that mtDNA segregation is not skewed 
across embryonic and extra-embryonic cells at least at this developmental stage 
(Monnot et al, 2011).   
 
However the trophectoderm only represents those cells which will give rise to the 
placental tissues, whose role it is to support the embryo during uterine 
development. Instead it is the cells which comprise the ‘inner cells mass’ (ICM) 
which go onto give rise to the ‘embryo proper’.  Therefore ensuring that the 
mutation load present in these cells would more likely provide more useful 
information as to the levels of mtDNA we might expect to see in the resulting 
child at birth.    Therefore more recently efforts have been made to examine 
mutation loads in blastocyst stage embryos obtained from carriers of mtDNA 
mutations and through the use of micromanipulation techniques, manually 
separate the ‘trophectoderm cells’ from those cells which comprise the ‘ICM’.  
This particular form of analysis allows to see how accurately representative 
mutation loads observed in the trophectoderm are of the actual mutation load 
found within the cells of the ‘ICM’.   As part of this study I was able to perform 
such analyses, which revealed that the mutation load observed in the 
trophectoderm was indeed highly comparable with the mutation loads observed 
for the cells of the ‘ICM’ for two different mtDNA mutations (m.14487T>C and 
m.3688G>A), suggesting that mutant mtDNA is uniformly segregated between all 
cells of the premiplantation embryo up to the blastocyst stage.   This is supported 
by results obtained from embryos carrying the m.3243A>G mutation, which 
showed a maximum variation of 9% mutant load between the ICM and TE (Treff 
et al, 2012).  In addition, multiple biopsies from the ICM and TE of the same 
embryo revealed highly consistent heteroplasmy levels across the embryo, with 
mutation loads differing by 2-4% in the ICM and 3-11% in the TE (Treff et al, 
2013).  The low variation within the ICM supports the observation that mutant 
load remains relatively stable across fetal tissues (Matthews et al, 1994, Ferlin et 
al, 1997, Cardailoi et al, 2000, Monnot et al, 2010) and suggests that the mutant 
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load determined at the time of biopsy will remain unchanged during embryo-fetal 
development. 
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Indeed trophectoderm biopsy is now increasingly being viewed as a preferred in favour 
of the traditional approach of cleavage stage biopsy (Dokras et al, 1990; Montag et al, 
1998; De Boer, et al, 2004).   This is because it offers several important benefits.  Firstly 
it an increased number of cells are able to be analysed from a trophectoderm biopsy (2-5 
cells v 1cell).  Secondly it is often regarded as a safer procedure, as it avoids removing 
cells which could contribute to the embryo proper. Many argue that it is much safer to 
remove a small number of cells from a blastocyst which can contain up to 300 cells, in 
comparison to an 8-cell cleavage stage embryo.  Thirdly embryos which attain 
development to the blastocyst stage, have demonstrated developmental potential and 
therefore this increases the chances of a successful transfer (De Boer et al, 2004; Braude 
et al, 2002).  Therefore if mutation loads observed in the trophectoderm is 
representative of mutation levels observed in the ICM then blastocyst stage biopsy 
should not be discouraged for mtDNA disease PGD patients.   However there is a 
disadvantage to performing trophectoderm biopsy for PGD, due to the time required for 
molecular analysis to be performed before samples can be selected for transfer.   As the 
molecular analysis required to assess mutation loads often takes between 24-48 hours, 
blastocysts must be able to be cryopreserved, until the required mutation load 
information has been obtained.   Vitrification at the blastocyst stage is possible, 
although it is imperative that an efficient vitrification programme is put in place before 
commencing a trophectoderm biopsy PGD programme.    
 
Following the 74
th
 ENMC meeting a set of criteria were agreed which a patient should 
meet prior to consideration for PND or PGD, this includes: a close correlation between 
the mutant load and disease severity, a uniform distribution of mutant load across 
tissues and no major change in mutant load with time.    By meeting these criteria it was 
hoped that successful outcomes would be achievable for patients opting to undergo 
PND and PGD.  In our recent study we found that levels observed in the female carriers 
we had access to samples for (m.3688G>A, m.10158T>C and m.14709T>C) reflected 
the mutation loads detected in her embryonic samples, and in some instances 
(m.3688G>A) to a much lesser or even undetectable levels.    This allowed us not only 
to determine the efficiency of the pyrosequencing assays used to quantify levels of 
heteroplasmy in the samples but also allowed us to determine the relationship with 
levels observed in her embryonic samples.    This is important as the complex genetic 
and phenotypic variability characteristic of mtDNA inherited disorders has previously 
 
1 1 8  
 
compounded attempts to identify potential relationships between the levels of mutant 
mtDNA observed in the mother and the clinical features likely to be expected in her 
offspring (Chinnery et al, 1998).    Indeed a number of studies have attempted to obtain 
a more accurate description of the inheritance of pathogenic mtDNA mutations through 
the study of large pedigrees (Chinnery et al, 1998).  However the majority of these 
studies conducted have cautioned that by no means do the conclusions reached provide 
absolute given risks regarding the likelihood of them conceiving a child with a given 
clinical phenotype.    Instead the outcome of pregnancy is likely related to the level of 
mutant mtDNA observed in the mother under discussion and that the risks of having 
affected offspring may differ between mtDNA mutations.    
 
3.5.1 Preconception genetic diagnosis (PCD) for mtDNA inherited disorders  
 
Preconception genetic diagnosis (PCD) is now routinely performed for a number of 
nuclear encoded genetic diseases.   Here the first or second polar body is biopsied and 
the mutation load analyzed without altering the integrity of the oocyte of embryo.   It is 
increasingly being employed in countries where cleavage-stage embryo selection is 
legally not possible to perform and ever more sought after by couples whom are 
concerned by potential embryo wastage issues associated with conventional cleavage 
stage biopsy (Gigarel et al, 2011).  However two recent publications reported rather 
conflicting data regarding the predictive value of the polar body in relation to the oocyte 
(Gigarel et al, 2011; Vandewoestyne et al, 2011).   The study published by 
Vandewoestyne et al (2011) reported observing a strong correlation in levels detected 
between oocytes and their respective polar bodies for the m3243A>G mutation.  This 
was in contrast to the study results published by Gigarel et al (2011) who demonstrated 
the lack of predictive value the polar body represented in relation to the oocyte 
following examination of mutation loads in 50 polar bodies and their corresponding 
oocytes.  Indeed this same study was further able to demonstrate that this discrepancy 
they observed between mutation loads observed in the polar body and corresponding 
oocyte was more apparent at high mutation loads (>60%)    This could be due to the 
lower amount of mtDNA found within polar bodies which could make analysis 
susceptible to allelic drop-out or indeed preferential amplification.  This therefore 
questioned the potential effectiveness of PCD for mitochondrial disease however it does 
not fully discount its potential to select ‘mutation free’ oocytes, in so reducing embryo 
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wastage.   However our own recent examination of mutation loads in oocytes and their 
corresponding biopsied polar bodies, for the two mutations: mt.3688G>A and 
mt.10158T>C revealed a high correlation between the mutation load observed between 
the polar body and its corresponding oocyte.  Again however it must emphasized that 
the mutation loads we observed within these samples was relatively low in comparison 
to the spectrum of mutation loads samples contained in the study reported by Gigarel e 
et al (2011).   This study state that the correlation which was present between the two 
samples was indeed lost when a threshold value of >60% was observed within the 
oocyte.  This may indeed to the difference in mtDNA copy number between the oocyte 
body and the polar body, which results in a loss of predictive power by the biopsied 
polar body.   
 
3.5.2 Studies of mutation loads in oocytes from carriers of mtDNA mutations  
 
Several studies have now examined mutation loads in oocytes obtained from carriers of 
mtDNA point mutations (Blok et al, 1997; Dahl et al, 2000; Brown et al, 2001: Jacobs 
et al, 2007; Monnot et al, 2011).  The variation in mutation loads we have observed 
amongst the oocytes analysed thus far for both the m.3688G>A and m.14709T>C 
mutation is in-line with previously published data (Brown et al, 2001; Jacobs et al, 
2007), which demonstrate the vast degree variance in mutation loads amongst the 
oocyte population. 
 
Indeed a study performed just over a decade ago (Brown et al, 2001) looked to examine 
mutation loads in several primary oocytes (~82) obtained from a woman who harboured 
the m.3243A>G (MELAS) mutation.  The woman was asymptomatic but known to 
carry the mutation at varying levels (18.1% in quadriceps and 7.24% in leukocytes).  
The proportion of mutant mtDNA found within her oocytes ranged from 0% to 45% 
(mean 12.64%).   This study inferred that random genetic drift was likely to be 
responsible in this instance for determining the level of mutant mtDNA observed within 
primary oocytes.   A similar study recently reported examination of mutation loads in 
oocytes for a carrier of the MELAS (m/3243A>G) mutation with mutation loads 
ranging from 9% to 90% (Treff et al, 2012). Others have reported observing between 
<5% to >50% variation in mutation loads between oocytes (Jacobs et al, 2007).   Indeed 
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I also observed variation in mutation loads for those oocytes I analysed for both the 
m.3688A>G (3% to 13%) and m/14709T>C mutation (4% to 31%).    
 
As this study was only able to analyse mutation loads for a small number of oocytes due 
to the scarcity and availability of this material, it is encouraging that other groups have 
also been able to demonstrate the similar variability in mutation loads within the oocyte 
population of mtDNA mutation carriers as this substantiates the data presented here 
within this thesis.  Taking all current data into account it would therefore appear that the 
oocyte population does harbour the greatest degree of variability in mtDNA mutation 
loads.   This is most likely due to random genetic drift during germ cell development.  It 
is not possible as yet to say if there is some underlying mechanism which may influence 
which oocytes are likely to possess best fertilization potential and if indeed those 
oocytes carrying the mutation possess a selective advantage against those which do not 
and if indeed this is in some way mutation specific.   However the variability observed 
within the oocyte population may reflect the variability observed between siblings born 
from mitochondrial DNA mutation carriers.    
 
3.6 Conclusion  
 
Our results presented here support similar observations made by other studies for 
different mutations whereby the level of mutation is very evenly spread throughout the 
embryo and thus is supportive of both antenatal and pre-implantation diagnosis as 
valuable approaches for families with different heteroplasmic point mtDNA mutations.   
However whether PGD is suitable for all heteroplasmic mtDNA mutations remains to 
be seen but it is essential that we continue to collect information on additional mtDNA 
mutations so that we can provide best possible advice to women exploring the different 
reproductive options.  
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Chapter 4 Identifying key factors involved in successful Pronuclear 
Transfer (PNT) 
 
4.1 Introduction  
 
Mitochondrial disease is now recognised as a common cause of genetic disease 
(Schaefer et al, 2004).  Current estimates show a minimum of 1 in 10,000 adults in the 
UK are affected by mtDNA disease (Schaefer et al, 2008), with 1 in 6,000 women in the 
UK heteroplasmic for a particular mtDNA mutation (Schaefer et al. 2008).  At present 
there are no successful treatments for mitochondrial disease and current strategies are 
predominately targeted at minimising symptoms.  Due to the lack of available treatment 
for these patients and their families, preventing the transmission of mitochondrial 
disease is a priority (Chinnery et al, 2006; Craven et al, 2010).   
 
One strategy currently being explored with the aim of preventing transmission of 
mitochondrial disease is the nuclear transfer technique, pronuclear transfer (PNT).   
Studies conducted in the lab have successfully demonstrated that the transfer of 
pronuclei between abnormally fertilised human embryos results in minimal carry-over 
of donor zygote mtDNA and is importantly compatible with onward development 
(Craven et al, 2010).    
 
The efficiency and feasibility of PNT to prevent transmission of mtDNA disease has 
been successfully demonstrated using the abnormally fertilised human zygotes.   
However it is recognised that these abnormally fertilised zygotes have a limited 
potential for development therefore it will be essential to perform these same 
experiments in normally fertilised human zygote, which are known to contain only two 
pronuclei.   This it is hoped will allow for improved potential for onward development 
to the blastocyst stage, further demonstrating the potential of the technique.   However 
just as these experiments will have to be performed in normally fertilised human 
zygotes it is highly likely that other operators, will have to be trained to perform the 
procedure to demonstrate.  However first it will be important to establish that the 
technique can be reproduced with similar results.  Therefore the purpose of this chapter 
was to establish important factors which are key to performing the PNT procedure 
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successfully and efficiently and also determine if polar body removal may improve 
outcomes.   
4.2 Aims:  
 
 Establish factors involved in successful pronuclear transfer manipulations.   
 Monitor onward development following pronuclear transfer and contrast with 
previously gathered published data.  
 Maximise development of post-manipulated embryos  
 Examining the potential and feasibility of polar body removal  
 
4.3 Materials and Methods  
 
4.3.1 Collection of Human Oocytes and Embryos  
 
In this study all embryos were obtained from patients undergoing routine fertility 
treatment at the Newcastle Fertility Centre at Life, following informed consent.  The 
project had previously been approved by the Human Fertilisation and Embryology 
Authority (HFEA).   
 
4.3.2 Abnormally Fertilised Human Embryos  
 
Embryos used in this study included abnormally fertilised human embryos collected on 
day 1 of the IVF or ICSI cycle.  These embryos were identified as abnormal by the 
presence of either 1 pronucleus (mono-pronucleate) or 3 pronuclei (tri-pronucleate) 18-
19 hours post insemination.  These embryos were unable to be used for fertility 
treatment and are routinely rejected from the IVF programme.   
 
4.3.3 Embryo Manipulations performed between abnormally fertilised PN 
stage embryos 
 
Embryos were transferred to a manipulating dish containing 4µl sized drops of G1v5 
plus media (vitrolife AB, Kungsbacka, Sweden) supplemented with 0.5µl of 
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cytochalasin B (1µg/ml) and 1µl nocodazole (2µg/ml) (Sigma-Aldrich, UK)   Embryos 
were left to equilibrate in the manipulation media for between 15-30 minutes prior to 
manipulation.  Manipulations were subsequently performed using an inverted 
microscope (Nikon Eclipse TE2000-U) equipped with a micromanipulation system 
(Integra Ti, Research Instruments).  Both holding and biopsy pipettes were lowered into 
a drop in the manipulating dish not containing an embryo and both pipettes primed 
before the embryo was immobilised by gentle suction with the holding pipette 
(Figure4.1a).   Subsequently all manipulations were carried out at the x40 
magnification, the objective to which the laser was fitted.   The embryo was moved 
towards the laser target (XYclone laser, clonetech) and a small hole was created in the 
zona pellucida.   Using the biopsy pipette pronuclei were gently removed from the 
embryo, after which embryo was released from holding pipette (Figure 4.1b, c and d). 
 
4.3.4 Embryo enucleation and karyoplast transfer  
 
Following successful removal of the PN karyoplast, the biopsy pipette containing the 
PN karyoplast (s) was taken to the HVJ-E (GenomONETM-CFEX HVJ Envelope Cell 
Fusion Kit, Cosmo Bio Co) drop.   The PN karyoplasts were then expelled into the drop 
of HVJ-E to coat the karyoplast in a sufficient amount of HVJ-E.    The PN 
karyoplast(s) were then aspirated back into the biopsy pipette together with a small 
amount of HVJ-E in a volume equal to the size of karyoplast.  The biopsy pipette was 
then moved to the drop containing the enucleated recipient embryo and holding pipette 
re-introduced into drop and recipient embryo immobilised.   Using the same hole 
initially made to allow removal of the PN karyoplasts, the biopsy pipette was the 
lowered into the enucleated recipient embryo and the karyolpast expelled together with 
a small volume of HVJ-E to assist with fusion.   Here it is important to ensure good 
contact is made between the karyoplast membrane and the membrane of the embryo 
cytoplasm to encourage fusion (Figure 4.1e).  The embryo is then left within the 
manipulation drop to allow the karyoplast to fuse with the recipient embryo (Figure4.1f) 
(can take between 10-60 minutes) (method referenced from Craven et al, 2010).   
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4.3.5  Embryo culture  
 
When fusion had occurred, embryos were transferred to a fresh culture dish containing 
G1V5 plus media (Vitrolife, Kungsbacka, Sweden) (50µl drops overlaid with 4ml 
Ovoil).   On the third day of culture manipulated embryos were then transferred to G2v5 
plus media (Vitrolife, Kungsbacka, Sweden) (50µl drops).   Embryos may be cultured to 
day 7 where at this time all embryos must be discarded (in 10x EBSS solution) or 
fixed/frozen for further analysis (Fig4.2).  
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Figure4. 2 Images representing development observed for embryos 
following pronuclear transfer  
 
Above images represent the different stages of embryo development following 
manipulation from the initial PN stage embryo though to the blastocyst stage 
at day 5.  Pronuclear stage embryo (a),  day 2 4-cell embryo (b), day 3, 8-10 
cell embryo (c), 16-24-cell compacting embryo (morale stage) (d), and day 5  
early blastocyst (e).  Scale bar, 50µm.   
a 
e d 
c b 
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4.4 Results  
 
4.4.1 Factors that influence success in pronuclear transfer (PNT)  
 
4.4.1.1 Priming of pipettes  
 
One important aspect of the pronuclear transfer technique is ensuring that both the 
holding and biopsy pipettes are primed correctly before beginning the manipulation 
procedure.     By priming we refer to ensuring both the holding ad biopsy pipettes have 
been washed thoroughly so as to remove any old media which or air pockets before then 
loading the pipettes with fresh media from the manipulating drop.  Here care must be 
taken so as to not overload the biopsy and holding pipettes with media from the 
manipulation drops as this can result in loss of suction.    Conversely a lack of media 
within the pipette allows air to flow freely and often results in air bubbles flooding the 
drop the pipettes are currently held within at the time.   Ensuring the pipettes are 
correctly primed is a relatively important aspect of the technique to safeguarding the 
zygotes during the manipulation procedure.   
 
4.4.1.2 Finding the best plane of view  
 
Another important aspect central to the pronuclear transfer technique is the need to be in 
the correct plane of focus, before attaching the embryo to the holding pipette and 
importantly before making a small hole in the zona pellucida using the clinical grade 
laser.  As once a hole has been made in the zona pellucida you have committed yourself 
to using that hole as the point of entry for the biopsy pipette, both to limit the number of 
holes made so as to not damage the integrity of the zygote and limit the number of times 
you use the laser due to the effect this could pose with regards to onward development 
potential.   Furthermore pronuclei are easier to remove when they are in the correct 
focus, often resulting in less, disturbance to the cytoplasm hence ensuring the integrity 
of the embryo and pronuclei are maintained.  However it can sometimes be more 
complicated to ensure that all pronuclei within the zygote lie within the same focus 
when working with the abnormally fertilised human zygotes (Fig4.3c).    The best one 
can often hope to achieve in this situation is focusing the zygote so that the majority of 
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pronuclei are within focus, which can often be judged by the sharp contrast of the 
ooplasmic membrane (Fig4.3c).  The focus can then be adjust slightly using the fine 
focus control during the manipulation procedure so as to assist in the removal of the 
remaining pronuclei if not possible on the current focus. 
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Figure4. 3 Finding the best plane of focus  
 
Prior to beginning the manipulation procedure it is essential that the pronuclei lie within the 
best plane of focus before attaching the zygote to the holding pipette.  However as the 
images above demonstrate this is not always easy to achieve.  (a) tri-pronucleate (3PN) 
abnormally fertilized zygote in which all 3 pronuclei are visible (as indicated by arrows) 
the sharp outline of the cytoplasmic membrane and zona pellucida  (as indicated by the 
arrow) would also indicate that this zygote is orientated in the best possible plane of focus 
to attempt PNT (b) a mono-pronucleate zygote in which the pronucleus is only just visible, 
indeed faint pronuclei can also make pronucleus removal more difficult (ci) a tri-
pronucleate  abnormally fertilised zygote in which only two of the three pronuclei can be 
clearly visualized , however the sharp edge of the ooplasmic membrane (as indicated by 
arrow) would suggest this zygote is orientated in the best plane of focus (cii) the same a tri-
pronucleate zygote (as displayed in image c), in which all 3 pronuclei can be clearly seen 
however to achieve this the zygote has been orientated so that it is slightly out of focus as 
demonstrated by the blurry nature outline of both the cytoplasmic membrane ad inner wall 
of the zona pellucida (indicated by arrow). Scale bar, 50µm.    
 
 
 
 
a b 
C i. C ii 
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4.4.1.3 Accounting for the presence of polar bodies  
 
Another factor which must also be considered when orientating the zygote is the 
position and location of the first and second polar bodies within the zygote.   The 
position of the polar bodies must be considered in order to ensure that they do not 
interfere with the manipulations or pose a risk of fusing back with the zygote following 
introduction of HVJ-E.   Therefore the zygote is usually orientated so that the polar 
bodies are located at either the 6 or 12 o’clock position (Fig4.3a and Fig4.4a).  However 
by ensuring the polar bodies are located a safe distance from the site of the hole made to 
allow the PNT biopsy pipette to enter the zygote, the location and focus of the pronuclei 
can often be compromised.  It is also often the case that the polar bodies are located in 
areas of increased perivitelline space (Figure4.4b) (the area between the ooplasmic 
membrane and inner wall of the zona pellucida) which would prove ideal areas to place 
the biopsy hole,  as the hole is made using a laser diode.  The laser is equipped with 
isothermic rings (Fig4.5) which can be used to ensure that the laser is being used at safe 
enough distance so as not to inflict damage or detrimentally affect the zygote.  However 
it is often preferential to place the hole in an area of increased perivitelline space, 
therefore a compromise must be made regarding the location of the polar bodies and the 
chosen area to make the biopsy hole in the zona pellucida.   
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Figure4. 4 Orientating, the zygote with respect to the first and second polar 
bodies  
The position of the polar bodies must be considered in order to ensure that they do not 
interfere with the manipulations or pose a risk of fusing back with the zygote 
following introduction of HVJ-E.   Therefore the zygote is usually orientated so that 
the polar bodies are located at either the (a) 6 or 12 o’clock position (indicated by 
arrow, above).  However it is often the case that the polar bodies are located in areas of 
increased perivitelline space (a and b) also ideal areas to place holes using the laser 
diode so as to allow the biopsy pipette to gain entry.  This ensures that the zygote is 
not at risk of the laser misfiring and hitting the zygote and also from heat dissipation 
emitted when the laser is fired.   Therefore by placing the holes in areas where there is 
increased distance between the zona pellucida and the outer membrane of the 
cytoplasm (c) (as indicated by boxed area), it is less likely that the integrity of the 
zygote could be harmed.   However occasionally polar bodies degenerate or are not 
present, therefore the zygote can be orientated more easily (c). Scale bars, 50µm.   
 
a 
 
b 
 
c 
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Figure4. 5 The importance of Isotherm rings  
Isotherm rings help prevent potential harmful effects posed to the zygote adjacent to 
the zona due to heat dissipation resulting from laser drilling. The isotherm rings 
appear on the screen as a series of six concentric circles of varying colours (isothermic 
colour key, above) and indicate the maximum temperature reached at the ring 
diameter at various laser pulse durations (right). At longer pulse duration, it is 
apparent that temperatures radiate farther into the centre of the embryo, increasing the 
likelihood of damage to the zygote. The orange ring (second from centre) is also a 
useful indicator of the drill hole, size at the selected pulse duration. 
(http://www.hamiltonthorne.com/products/lasers/zilostk/safety.htm) 
 
 
 
 
 
Isotherm Colour Key  
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4.4.1.4 Problems encountered during karyoplast removal, 
transport and fusion  
 
Another issue concerned control over the fine balance of both the biopsy and holding 
pipettes when removing the pronuclei from the zygote.   Once the zygote was adhered to 
the holding pipette and the biopsy pipette in place to remove the pronuclear karyoplasts 
it was essential that only fire adjustments were made in the air pressure controlling 
movement of media within both the holding and biopsy pipette.  Sudden increases in air 
supply to the biopsy pipette can lead to the pronuclei rushing into the biopsy pipette 
accompanied by a large amount of cytoplasm.   However after removal from the zygote 
it is possible to further manipulate the PN karyoplasts to remove additional cytoplasm 
and in so reduce the size of the karyoplast before fusing with the recipient zygote.   This 
is usually achieved using the biopsy pipette and applying gentle suction with the air 
syringe controlling the biopsy pipette whilst the karyoplast is pressed against the side of 
the zygote and the excess cytoplasm nipped off as a cytoplast and discarded to the edge 
of the manipulation drop.   
 
The next step is to pick the PN karyoplasts up using the biopsy pipette.   However once 
the karyoplasts have been removed from the zygote they are only surrounded by a small 
volume of cytoplasm, making them extremely fragile in nature.   Great care must 
therefore be taken when picking up the karyoplasts for this reason, due the potential risk 
for the karyoplasts to lyse at this time.    Several steps can be taken to help minimise the 
risk of the karyoplasts lysing including reducing the amount of media in the biopsy 
pipette to prevent the pipette from becoming overloaded with media, this in turn can 
help increase the overall control over the biopsy pipette.   Small incremental increases 
in air flow can also help prevent karyoplasts from lysing (Fig4.6a).    
 
Once the karyoplasts have been picked up by the biopsy pipette they are then carried to 
the drop of HVJ-E within the manipulation dish and brought to the end of the biopsy 
pipette, taking care to not entirely release them into the drop of HVJ-E.   Once at the 
end of the biopsy pipette the karyoplasts are rolled so as to ensure they are coated with 
sufficient HVJ-E before they are then brought back fully into the biopsy pipette with the 
addition of a small amount of HVJ-E equal to the size of the PN karyoplast.    
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The final step, involves transferring the karyoplast accompanied by a small volume of 
HVJ-E to the recipient embryo.  By this time the karyoplasts have been out of the 
zygote for a considerable amount of time and are now more susceptible to the potential 
risk of lysing.  Therefore great care must be taken when placing the karyoplast into the 
recipient zygote.  To minimise the risk of the karyoplast lysing at this point, the amount 
of media within the biopsy pipette should be kept to a minimum (the biopsy pipette 
should contain enough media so that the meniscus is also visible within the pipette), this 
in turn helps to increase control over the contents of the biopsy pipette.     By reducing 
the volume of media within the biopsy pipette the karyoplast should move towards the 
mouth of the biopsy pipette (Fig4.6b and c), eventually leaving only a small volume of 
HVJ-E in front of the karyoplast.  The biopsy pipette at this point should be taken 
towards the biopsy hole of the recipient zygote and gently expelled into the zygote 
ensuring good contact is made between the karyoplast and cytoplasm of the recipient 
zygote (Fig4.6d).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 3 6  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
b 
 
c 
Figure4. 6 Karyoplast removal, transport and fusion 
 
Above images represent different stages during karyoplast removal, transport and 
fusion. Once the karyoplast has been removed from the donor zygote, it consists of the 
pronuclei surrounded by a small volume of cytoplasm (so as to minimise the amount 
of mtDNA which could potentially be carried over to the recipient zygote).  Therefore 
the pronuclear karyoplast has relatively little protection and is highly fragile during the 
transfer procedure.  (a) Great care must be taken when picking up the karyoplast, as 
sudden increases in air pressure to the biopsy pipette can result in the karyoplast 
rushing into the pipette and lysing as a consequence.  (b and c)  Furthermore when 
preparing to introduce the karyoplast into the recipient zygote it is best to ensure the 
karyoplasts are relatively close together In the biopsy pipette (b) and ensure that only a 
small volume of media is presents within the pipette, including to increases control 
over karyoplast movement (including a small volume of HVJ-E in front of the 
karyoplasts if possible equal to the size of the pronuclear karyoplasts).The karyoplasts 
at this point can then be slowly released into the recipient zygote ensuring good 
contact is made with the cytoplasm to allow for efficient and successful fusion to 
occur (d).  Scale bars, 50µm.    
 
a 
 
 
 
d 
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4.4.2 Embryo Development  
 
The aim of this chapter was develop the appropriate skills required to perform 
Pronuclear Transfer (PNT).   Overall I attempted to manipulate a considerable number 
of abnormally fertilized human zygotes (n=89) during a 6 month period.   Here zygotes 
either received one (n=38) or two pronuclei (n=51) from an enucleated corresponding 
embryo and development was monitored for all embryos which survived following 
manipulation.    Initially a considerable number of embryos degenerated (n=33) either 
during or following manipulation procedures due to: removal of karyoplasts before 
cytoskeletal inhibitors have taken affect, lysing of PN karyoplasts during 
removal/fusion back with zygotes, loss of control over air syringe controlling the biopsy 
pipette, resulting in degeneration of the cytoplasm.    
 
Development in vitro was used to assess improvement and ability to perform PNT 
following the few first months from initially being introduced to the technique (April-
July).  Initially the majority of embryos surviving the PNT manipulation procedure 
attained development to the <4cell stage 26.3% (April) before finally arresting 
development (Figure 4.7 and Table 4.1).     However with further practice and improved 
manipulation skills, after performing an increased number of transfers the overall 
number of zygotes which survived the manipulation procedure did improve.   This was 
marked by the reduction in the number of PNT manipulated embryos attaining 
development to the <4cell stage 23.5 % (May) and 15.4% (June).    In turn the number 
of embryos attaining development to the 4-8 cell stage and >8 cell stage increased, with 
the number of embryos developing to >8-cell stage peaking at 70.6% (May).   Indeed 
over the four month learning period data I gathered developmental data for PNT 
manipulated embryos,  I was able to demonstrate a positive trend in regards to 
development stage attained with a significant number of embryos attaining development 
to >8-cell stage in comparison to the number who arrested development at the <4-cell 
stage (Figure 4.7 and Table 4.1).    
 
However there are several factors independent of those associated with operator errors 
when learning the PNT technique which could also have impacted upon embryo 
development. This includes issues associated with the equipment used to perform the 
PNT technique and the fact the embryos utilised for this study were abnormally 
fertilized human zygotes, which are known to demonstrate a reduced potential for 
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development which I will discuss in greater detail later in this chapter.  However factors 
associated with the equipment include, the impact of the laser used to make a hole in the 
zona pellucida, the impact of incubation within solutions containing cytoskeletal 
inhibitors, the fusing agent HVJ-E, extended exposure to non-natural light.   This is only 
a small list of the many technical associated factors which could have contributed to 
development potential following PNT manipulation.   Unfortunately it is difficult to 
control for all of these factors during each individual manipulation and therefore it is 
impossible to know how each of these factors independently affect development 
potential.    
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Figure4. 7 Initial experience of learning the pronuclear transfer 
procedures with embryonic development as the main outcome measure  
 
(a)Above graphical representation of development data acquired to 
demonstrate progress during learning the pronuclear transfer technique (PNT) 
for abnormally fertilised human zygotes which successfully survived the PNT 
procedure and went onto cleave after.   
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Figure4. 8 Development of unmanipulated abnormally fertilized zygotes 
following pronuclear transfer  
 
(a) Development data obtained by Dr L Butterworth for pronuclear transfer 
embryos (b) Above graph represents current development outcomes for both 
manipulated and unmanipulated embryos.   Here we compared development 
following manipulation where embryos received either 1 (blue) (n=38) or 2 PN 
(red) (n=51) karyoplasts from a donor zygote.  We also compared development 
in comparison to those embryos which were not manipulated (green) (n=56).  
 
a 
b 
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4.4.3 Overall development of pronuclear transfer (PNT) embryos with 
previously acquired developmental data following PNT  
 
After establishing that I was able to perform the PNT technique, with a significant 
number of embryos surviving the manipulation procedure intact the next stage involved 
determining the developmental capacity of pronuclear transfer embryos containing 
either one or two pronuclei.   Here overall development observed was encouraging 
(Fig4.8) with 10/38 (26.3%) of those embryos receiving one transferred pronucleus and 
16/51 (31.3%) embryos receiving two transferred pronuclei going onto develop to at 
least the eight-cell stage.   Furthermore these results are consistent with previous 
published data for the same technique (Craven et al, 2010) (Fig5.8a) published from our 
lab which showed that following pronuclear transfer around one quarter (n=10/44) of 
embryos receiving one transferred pronucleus and around the same number/percentage 
of those (n=8/36) embryos receiving two transferred pronuclei successfully went onto 
develop to more than the eight-cell stage (Fig4.8).    The development data that I 
attained from these abnormally fertilised zygotes successfully demonstrates the 
reproducibility of the PNT technique when performed by different operators.  This is 
very important because if the PNT technique becomes available as a clinically 
recognised procedure it is highly likely that several operators will be required to be 
trained in the technique.   Due to the highly delicate nature of the material involved and 
the skill required to ensure zygotes survive the procedure given adequate time and 
experience, it does appear that it is possible to perform the PNT procedure  by different 
operators and importantly achieve highly similar levels of onward development,   
 
Interestingly it was found that a significant number of zygotes which received only one 
single pronucleus failed to develop beyond the four-cell stage, which was slightly less 
consistent with previous data.    Obviously those embryos only receiving one 
pronucleus are more likely to have a reduced developmental capacity as they are lacking 
either the maternal or paternal genome and therefore only contain a haploid set of 
chromosomes.  However previous studies examining abnormally fertilised embryos 
have shown that some 1PN embryos which contain a rather large single pronucleus can 
actually be representative of two-fused pronuclei.    Here previous studies examined a 
number of abnormally fertilised embryos and found that a proportion of 1PN 
abnormally fertilised embryos had a normal diploid karyotype, suggesting the premature 
fusion of both the maternal and paternal pronuclei in so forming  one visible pronuclei 
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(Feenan and Herbert, 2006) .  This could therefore influence the rates we have been 
observing with regards to compatibility with onward development following 
manipulation.   
4.4.4 Pronuclear transfer (PNT) in normally fertilised zygotes  
 
Experiments to determine the efficiency and feasibility of pronuclear transfer between 
normally fertilised human zygotes, created from oocytes donated by altruistic donors 
and fertilised using donor sperm are now underway.   This was made possible following 
the passing of legislation through parliament to the 1990 HFEA ACT so as to allow the 
creation of normally fertilised human zygotes for the purpose of research.  This is 
essential as all previous experiments to demonstrate proof of principle of the PNT 
technique have been performed in abnormally fertilized human zygotes.  However as 
development is known to be impaired in abnormally fertilized human zygotes, it is 
essential that experiments be performed using normally fertilised human zygotes, which 
contain only two pronuclei and therefore have the correct chromosomal constitution and 
a greater developmental potential in comparison to their abnormally fertilised 
counterparts.   
 
Unfortunately one of the altruistic egg donors only managed to produce 1 oocyte and 
therefore it was not possible to perform reciprocal transfers between the oocytes.  
However the second altruistic egg donor did produce a significant number of oocytes 
(n=13), a significant number of which were able to fertilised (n=9), using normal IVF, 
as these were fresh oocytes unlike the vitrified oocytes, which we will cover in a later 
chapter (chapter 7) which require intracytoplasmic (ICSI) fertilisation due to zona 
hardening following cryopreservation and storage in liquid nitrogen.  However 
fertilisation achieved was good, with a number of normally fertilised zygotes (n=8/9) 
produced, judged by the presence of two pronuclei following fertilisation checks the 
morning after fertilisation was performed (Fig4.9).       Four normally fertilised zygotes 
were used for the PNT experiment the pronuclei were either removed before they were 
then fused back with the same zygote or removed from one zygote and fused back with 
another enucleated zygote obtained from the same patient.   Although it was not 
possible to perform reciprocal transfers between zygotes obtained from two different 
patients, this did allow us however to ascertain if development observed following PNT 
may be improved as a result of performing the transfers in normally fertilised zygotes, 
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known to only contain 2 pronuclei as opposed to all transfer proceeding this, which 
were performed in abnormally fertilised human zygotes.   
 
The majority of zygotes used for PNT that subsequently survived the procedure, went 
onto to show signs of onward development in vitro (n=3/4) (Fig4.10).   At least one of 
the embryos demonstrated signs of compaction (Fig4.10e), however unfortunately none 
of the embryos developed to blastocyst stage embryos.    As these zygotes were created 
from oocytes donated by one of the altruistic egg donors, and none of the normally 
fertilised zygotes created were cultured without manipulating as controls it was not 
possible to determine if development was undermined due to the PNT procedure or if 
indeed the quality of the oocytes was responsible for the relatively poor development 
observed here.    This is on-going research and outside the scope of this thesis.  
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Figure4. 9 Normally fertilised zygotes (containing two pronuclei) 
following fertilisation checks  
 
Images of normally fertilised human zygotes, as denoted by the 
appearance of two pronuclei (as indicated by red arrows).  These 
zygotes were created from oocytes donated by an altruistic egg donor 
which were subsequently fertilised by IVF using donor sperm.  Scale 
bars, 50µm.  
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4.5 Discussion  
 
At present there is no means available for mothers with homoplasmic or high 
heteroplasmy mtDNA mothers to conceive healthy offspring which are biologically 
genetically related.   Two nuclear transfer techniques have been proposed to overcome 
issues associated with risk of transmission from mother to child including; metaphase II 
spindle transfer (MST) and pronuclear transfer (PNT) (Tachibana et al, 2009; Craven et 
al, 2010).   
 
Proof of principle studies were performed to examine the feasibility of PNT to prevent 
the transmission of mtDNA using abnormally fertilised human zygotes.  The results of 
these studies, published in 2010, showed low level of carryover of mtDNA between 
donor and recipient zygote (Craven et al, 2010).   Therefore the aim of this chapter was 
to examine the reproducibility of the PNT technique between different operators.   In 
order to determine if similar survival and developmental outcomes could be achieved.   
I was able to develop the appropriate micromanipulation skills required to successfully 
perform pronuclear transfer (PNT).    This technique requires excellent manual 
dexterity, accuracy and control.  Similar micromanipulation is also used to perform, 
embryo biopsy and intracytoplasmic sperm injection (ICSI).     
 
All manipulations were performed using a Nikon microscope, equipped with the Integra 
Ti micromanipulation workstation.   This uses fine glass pulled pipettes; one holding 
pipette to secure zygotes and a biopsy pipette to allow removal of pronuclei.  The 
pipettes are controlled by air syringes which allow for suction to be increased/decreased 
for the correct degree of pressure to be applied to allow pronuclei to be removed 
effectively and intact.   In addition to developing the appropriate skills required to 
perform the technique, I wished to determine the operator reproducibility.   
 
In developing the appropriate skills required to perform the PNT technique, I identified 
several key observations and issues associated with performing the PNT technique.  
This included orientation polar bodies of the zygote, the presence of fragmentation 
within the perivitelline space, visibility of the pronuclei within the zygote, the 
orientation of the pronuclei and also the efficiency of the cytoskeletal inhibitors.   
Together these factors were able to complicate the nature of the procedure and also had 
the ability to affect outcomes following manipulation.  For example the efficiency of the 
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cytoskeletal inhibitors during the procedure, impacted upon both the ability to remove 
karyoplasts efficiently and intact and also the ability to manipulate karyoplasts further 
once outside of the zygote.   The production of larger karyoplasts inevitably means they 
will contain more cytoplasm and so would also be expected to contain more 
mitochondria from the donor embryo, resulting in the potential for higher levels of 
mtDNA carry-over. 
 
However a number of the issues I identified to be associated with the technique was due 
to the fact that abnormally fertilized human zygotes were used as the main sample 
source for these studies.   These embryos are the result of abnormal fertilization and 
therefore do not contain the correct chromosome complement.   The majority of the 
zygotes I used in this study contained either 1 or 3 pronuclei. Some multipronuclear 
zygotes contained >4 pronuclei and these proved incredibly difficult to remove 
successfully.   This is because the pronuclei were often orientated in different planes of 
the zygote.   Furthermore the time at which the abnormally fertilized human zygotes 
were obtained from the clinical IVF laboratory after fertilization checks meant that 
sometimes the pronuclei in some zygotes were already faint.  Therefore by the time I 
attempted to use the zygotes to manipulate not all of the pronuclei were still visible. 
This was a particular problem associated with the multipronuclear zygotes and on 
occasions meant that it was not possible to remove all pronuclei.    
 
It took several months to acquire the appropriate skills required to successfully perform 
the PNT technique.   Overall survival and developmental potential during this time was 
low with a considerable number of zygotes degenerating during and following the 
procedure.  However both survival and potential for development began to increase with 
further experience with the technique.    
 
However analysis showed that a number of zygotes demonstrated potential for onward 
development to the 4-8 cell-stage (n=33).     However, development to the blastocyst 
stage in vitro was low at ~3% compared to the previous blastocyst development rate 
achieved of 6.8% for single pronuclear and 8.3% of double pronuclear transfers (Craven 
et al, 2010).  This could be a result of differences in technique between operators as 
mentioned previously however all manipulation were performed using abnormally 
fertilised human zygotes, which would never be replaced due to doubts over 
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chromosome complement. It is also known that abnormally fertilised zygotes 
demonstrate a limited potential for development (Fennan and Herbert, 2005).    
 
However issues associated with using abnormally fertilized human zygotes for the 
purpose of the PNT technique could be overcome if it was possible to use normally 
fertilised human zygotes instead.  Performing transfers in normally fertilized zygotes  
would allow for more reliable examination of the effect of the PNT technique and the 
effect it alone has on embryo development.     Indeed experiments are now underway to 
examine the potential of PNT in normally fertilised human zygotes.   A number of 
altruistic donors have been recruited to donate oocytes, which will then be fertilised 
using donor sperm and in so, if all goes well lead to the creation of normally fertilised 
zygotes, containing two pronuclei.   Following the creation of these zygotes they are 
then utilised for PNT experiments and there compatibility and potential for onward 
development.   As this embryos will only contain one maternal and one paternal 
pronuclei, theoretically they should contain the correct chromosomal constitution and 
therefore development potential able to be attained should reflect this.    
 
The impact and general use of cytoskeletal inhibitors is also something which may be 
worth investigating further.  Currently two cytoskeletal inhibitors are used during the 
PNT prcocedure, each of which inhibits different parts of the cytoskeleton.  This 
includes Cytochalasin B (CB) and nocodazole (noc).  CB has been shown to bind to 
actin filaments and block polymerization and elongation of the actin disrupting 
microfilament structure.  CB has also able to induce polyploidy and also prevent polar 
body extrusion (Snow, 1973; Siracusa et al., 1980; Bos-Mikich et al., 1997).   
Nocodazole is an inhibitor of tubulin polymerization and causes breaks in the 
metaphase spindle and, thus, is often used for cell cycle synchronization experiments 
(Johnson et al., 1988).   There is evidence that treatment with these cytoskeletal 
inhibitors, provided at the correct concentration and exposure time, development to the 
blastocyst stage is unaffected in vitro (Siracusa et al., 1980; Epstein, 1986; McGrath and 
Solter, 1984b; Surani et al., 1984).   However given the cytotoxicity of the current 
inhibitors used (cytochalasin B and nocodazole) for the PNT procedure it may indeed be 
important to investigate the potential of other cytoskeletal inhibitors.   It is also worth 
noting that neither; CB or Noc are available in clinical grade forms this would therefore 
prevent their use if PNT were to be translated into clinical treatment.    
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Indeed there are several features which can influence the choice of cytoskeletal 
inhibitor, including; low toxicity, fast acting and reversibility. These characteristics 
should be considered when exploring other potential inhibitors.  Other compounds 
which could include be investigated includes other member of the Cytochalasin family 
(A, B, C, D, E, F, H and J) or even different compounds altogether including colchicine, 
colcemid and Latrunculin.  Several studies have now examined the function and effect 
of two of the members of the latrunulin family, including; Latrunulin A (Lat A) and 
Latrunculin B (Lat B) (Walter et al, 2000).  Both of these compounds have been shown 
to demonstrate similar modes of action, inducing actin depolymerization both in vitro 
and in vivo (Spector et al, 1983; Morton et al, 2000).  There is also evidence of Lat A 
treatment of embryos (Himaki et al, 2010).  They studied embryos treated with either 
Lat A or CB and found that cleavage rate following exposure to Lat A was significantly 
higher than that achieved for embryos exposed to CB (Hikami et al, 2010).  It would 
therefore prove interesting to examine the use of Latrunculin as an alternative 
cytoskeletal inhibitor in place of cytochalasin and nocodazole.  Although it would be 
important to assess its effect on subsequent embryo development and mtDNA 
carryover, in order to determine its efficiency compared to currently used cytoskeletal 
inhibitors.     
 
However the main aim of this part of work was to demonstrate that the PNT technique 
can be reproduced between different operators and furthermore similar levels of 
development observed for these manipulated zygotes.    This was important to 
demonstrate as if the PNT procedure is ever allowed to be used a clinical IVF 
procedure, it will be important to train others in the procedure so that it can be 
reproduced.    Other groups have examined other variants of the nuclear transfer 
technique for the purpose of preventing the transmission of mtDNA disease.   This of 
course refers to meiotic spindle transfer (MST).   This has now been reported to have 
been performed in both primates from which live offspring resulted and also more 
recently human oocytes.   Reproducibility has been demonstrated for the MST nuclear 
transfer technique, demonstrating that both techniques are able to be performed by 
different operators.    
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4.6 Summary  
 
 Here I was able to develop the appropriate micromanipulation skills required to 
successfully perform pronuclear transfer (PNT).    This was a technique which I 
had no previous experience in and required excellent manual dexterity, accuracy 
and control.     However with further practice and gaining experience in the 
technique, the number of zygotes which survived the manipulation procedure 
gradually improved (n=89).   After demonstrating  I was able to successfully 
perform PNT as judged by the number of zygotes which survived following 
manipulation the next stage involved determining the developmental capacity of 
pronuclear transfer embryos containing either one or two pronuclei.  For those 
embryos which successfully survived the pronuclear transfer procedure a 
significant number showed onward development.     
 
 As part of developing the appropriate skills to perform the PNT procedure I 
identified a number of key factors involved in attaining successful PNT 
manipulations.  Hopefully by identifying a series of key factors it may facilitate 
in the training of future individuals in the PNT technique.  
 
 I was also able to perform pronuclear transfer experiments between normally 
fertilized human zygotes, which showed potential for onward development.  
These are experiments which are now being explored in greater depth and on a 
larger scale which are out of the scope of this current thesis.   
 
 There are several aspects of the PNT technique which still require optimisation.  
This includes the fate of the polar bodies following PNT.  Here inactivated viral 
envelope protein of the Hemagglutinating virus of Japan (HVJ-E) is used to 
mediate fusion between the pronuclear karyoplast and the recipient zygote.  
However it has been suggested that if the HVJ-E was able to persist within the 
perivitelline space following karyoplast fusion that this may allow for the polar 
bodies to fuse back with the zygote.  Therefore I was involved in conducting a 
pilot study to determine if polar body removal could prevent this additional risk.  
The results of which may have consequences for how the PNT technique is 
performed in the future.   
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Chapter 5 Modifications to Pronuclear Transfer Technique - Polar body biopsy 
 
5.1 Introduction  
 
Polar bodies are sometimes referred to as the ‘genetic dustbin’ of the oocyte.   They are 
the structures formed following the first and second meiotic divisions, into which the 
extra set of chromosomes, are extruded, allowing the oocyte to maintain a haploid state 
in readiness to be fertilised (Magli et al, 2004).     
 
Polar bodies are unique in that they provide a reciprocal image of the chromosomal 
make-up of the MII oocyte, which is increasingly being used as a diagnostic screening 
tool to assess not only the ploidy of an oocyte but also test for single gene disorders 
prior to fertilisation (Verlinsky et al, 1990).   This gives couples with a high 
reproductive risk a better chance of delivering a healthy infant (Magli et al, 2004).  
Unfortunately neither paternally derived defects nor aneuploidy events, generated at 
fertilization or after the first cleavage divisions can be diagnosed using the polar body 
(Kuliev et al., 2003; Magli et al, 2004).    
 
Several studies have evaluated the effect of second polar body removal on the viability 
and developmental potential in vitro, with the majority demonstrating no significant 
differences in the percentage of morphologically normal blastocysts produced following 
PB biopsy (Kaplan et al, 1995).  This indicates the relatively low impact polar body 
biopsy exerts upon development and successfully maintaining the integrity of the 
oocyte.  However the exact method used to remove the polar body can influence future 
outcomes.    Despite the independent nature of the polar bodies with respect to the 
embryo great care must always be taken not to damage the oocyte/embryo during 
biopsy procedures, as doing so could lead to loss or induced damage to the 
chromosomal material (Montag et al, 1998).  Indeed it has been reported that an 
estimated 28% of oocytes which undergo polar body biopsy for genetic screening 
procedures  have to be discarded  as a result of technical failures during the biopsy or 
following analytical procedures (Reubinoff and Shushan, 1996).    
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The type of instrument or pipette used to retrieve polar bodies can also vary between 
labs.  Sharp aspiration needles have routinely been used as the tool of choice to 
mechanically breach the zona pellucida (ZP) and retrieve the polar body 
simultaneously.   However laser-assisted microdissection is now viewed as the preferred 
method, as this allows for the ZP to be breached in a more controlled manner.     
Furthermore the use of a laser to breach the ZP enables the use of blunt-ended 
micropipettes, which reduces risk of potential damage to the oocyte (Montag, 1998).   
However there was concern raised that the use of a laser diode may result in longer 
lasting effects which could subsequently impair embryo development.     Several studies 
have now successfully demonstrated that use of a 1.48µm diode laser system is a safe an 
efficient method to use for laser microdissection of the ZP; which does not impair later 
embryo development (Rink et al, 1996; Germond et al, 1995; Montag et al, 1998).   
 
Oocytes and embryos in which the zona pellucida has been breached manually has been 
shown to facilitate in the hatching process (Montag et al, 1998).   The hole made using 
the laser/acid Tyrode’s to allow for polar body removal frequently results in embryos 
hatching earlier than would normally be expected if the process was to occur naturally 
as a result of the zona pellucida thinning to allow hatching of the blastocyst.   However 
this does not appear to affect the embryo developmentally or otherwise other than to 
assist it to hatch occasionally in advance of those embryos which do not have a hole in 
their zona pellucida.   Indeed laser assisted hatching is a technique employed within 
many embryology clinics to aid in blastocyst hatching, primarily in those cases where 
the zona pellucida does not appear to be thinning as would be expected (with respect to 
expected development) and therefore intervention is required.   This is often the case in 
frozen/vitrified embryos, where the ZP hardens as an artefact of the cryopreservation 
process.     
 
5.1.1 Explanation for removing the polar bodies  
 
Current work is examining the potential of pronuclear transfer (PNT) as a potential 
means by which to prevent transmission of mtDNA disease to future offspring in those 
women whom carry mtDNA mutations at high levels.     Proof of principle experiments, 
already conducted within the lab using abnormally fertilised human zygotes 
demonstrated that these PNT embryos were compatible with onward development, even 
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when complicated by the fact that abnormally fertilised zygotes have limited potential 
for development to the blastocyst stage (Craven et al, 2010).  The PNT technique 
involves the removal of pronuclei from a donor zygote within a karyoplast containing a 
small volume of cytoplasm.  Karyoplasts are then placed under the ZP of a recipient 
(previously enucleated) zygote and fused using inactivated viral envelope proteins of 
the Hemagglutinating virus of Japan (HVJ-E).   
 
HVJ-E is a purified product prepared through complete inactivation of Sendai virus 
(HVJ Hemagglutinating Virus of Japan) through which only the cell membrane-fusing 
capability of the envelope protein of Sendai virus is retained.  The genomic RNA of the 
Sendai virus contained in HVJ-E has been inactivated completely and therefore has 
neither infective nor proliferative potentials in cells (as demonstrated schematically in 
Fig5.1).  Studies have previously reported the removal of polar bodies when performing 
nuclear transfer experiments (Li Meng et al, 1997; Dinnyes et al, 2000; Simerly et al, 
2004).  As it was suspected that following the addition of HVJ-E to assist in cell fusion, 
polar bodies with fully intact membranes could also potentially fuse back if sufficient 
HVJ-E was present.  This was determined by the presence of two pronuclei following 
fertilisation checks.  However in order to ensure sufficient activation is achieved 
electrofusion is often also employed, this it has been said would be enough to allow 
polar bodies to fuse back with the oocyte.   I therefore performed a pilot study to 
determine if polar body removal could prevent this additional risk incurred by the 
procedure.   
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HVJ HVJ Envelope 
Inactivation
purification 
F protein HN protein 
 
Cell A
Cell B
Fused 
Cell 
Figure5. 1 Hemagglutinating Virus of Japan (HVJ-E)  
Above schematic diagram demonstrates how the genomic RNA of the Sendai 
virus contained in HVJ-E has been inactivated completely and has neither 
infective nor proliferative potentials in humans.    The HN protein of the HVJ 
envelope binds specifically to the sialic acid receptor on the cell membrane of 
the target cell.  Membrane fusion is induced by the F protein contained in the 
HVJ envelope.  Allowing fusion to occur between the two, membrane 
enclosed cells (Adapted from original image www.cosmobio.co.jp).   
 1 5 7  
 
5.2  Materials and Methods  
5.2.1 Removal of polar bodies  
 
Zygotes were transferred to a manipulation dish containing 4µl drops of G1v5plus 
(Vitrolife, Sweden) overlaid with 3-4ml of Ovoil (Vitrolife, Sweden).   The holding and 
zona drilling pipette were lowered into the manipulation dish and both pipettes primed 
before use in a spare side drop within the dish.    A small hole was made in the zona 
pellucida (ZP), enough to allow the zona drilling pipette to enter the perivitelline space.  
Once the polar bodies were in the best plane of focus, we could move to the laser 
objective (x40).  The zona drilling pipette was moved towards the first polar body and 
very slight suction applied using the air syringe.  At this point great care must be taken 
not to apply too much suction as this can result in damage to the embryo.  Once the 
polar body was in the mouth of the zona drilling pipette, we began to ease the pipette 
out of the zygote, at the same time gently applying suction so as to not lose the polar 
body or allow it to traverse back towards the zygote (Fig5.2).  Once in the pipette the 
polar body was placed at the outer edge of the drop and the procedure repeated to 
remove the second polar body.   
 
5.2.2 Embryo culture  
 
When fusion had occurred embryos were transferred to a fresh culture dish containing 
G1V5 plus media (Vitrolife, Kungsbacka, Sweden) (50µl drops overlaid with 4ml 
Ovoil).   On the third day of culture manipulated embryos were then transferred to G2v5 
plus media (Vitrolife, Kungsbacka, Sweden) (50µl drops).   Embryos may be cultured to 
day 7 where at this time all embryos must be discarded (in 10x EBSS solution) or 
fixed/frozen for further analysis   
 
5.2.3 Immunostaining of blastocysts  
 
Blastocysts were fixed in 4% paraformaldehyde (PFA) for 30 minutes at room 
temperature and then transferred to 1% PBS (can be stored once fixed in PBS for 3-4 
months).   Blastocysts were permeablised for 1 hour at RT using 0.2% Tween and 0.2% 
Triton X solution in PBS and then blacked in 1% milk in PBS for a 1 hour.   Blastocysts 
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were incubated in the primary goat anti Nanog antibody (Abcam ab21603). (1:1000) 
overnight in the fridge.    The following morning blastocysts were washed three times in 
PBS, 5 minutes each.  Incubated with donkey anti- goat secondary Alexa fluorophores 
(Invitrogen) diluted 1:1000 in PBS.   Sequential washes were then performed (5mins, 
10mins and 30mins) in PBS.    Finally they were transferred to a 3µl drop (PBS 1:1000 
DAPI) overlaid with 1 ml of oil in a glass bottom viewing dish, for viewing. 
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5.3 Results 
5.3.1  Problems encountered when learning the PNT technique 
 
5.3.1.1 Difficulties in orientating the zygotes  
 
Our aim was to remove the polar bodies, prior to attempting removal of the pronuclei.   
However we soon encountered several problems when beginning to examine the 
potential to remove the primary and secondary polar bodies from the abnormally 
fertilised human zygotes.    Initially we found that as these were abnormally fertilised 
human zygotes, the morphology of the embryos and their subsequent polar bodies, was 
occasionally very poor, which complicated the situation.    The location of polar bodies 
within the perivitelline space was irregular, polar bodies were often found on different 
planes within the zygote and occasionally at different locations (Fig5.3).   The often 
random location of the polar bodies made it incredibly difficult to orientate the zygotes, 
so that both polar bodies were in a position which they could easily be removed without 
causing potential damage to the zygote.   Furthermore of those abnormally fertilised 
zygotes we received some had been fertilised using IVF and others using 
intracytoplasmic sperm injection (ICSI) (Fig5.3).  This induced additional problems as 
those oocytes which had been fertilised using ICSI often contained polar body-like 
structures at the 6 and 9 o’clock positions of the perivitelline space.   This we believed 
to be an artefact of the ICSI technique since when oocytes are orientated so they are in 
the correct position to inject with the sperm, they are positioned in so the polar body is 
out of the way, either at the 12 or 6 o’clock position.    The needle used for ICSI is thin 
and sharp, allowing it to penetrate the zona pellucida without the need for a hole.    The 
sperm is therefore injected once a cytoplasmic ‘snap-back’ is observed, which signifies 
that the oolema (membrane around the cytoplasm) has sealed back trapping the sperm in 
the cytoplasm.    However on withdrawal of the ICSI pipette from the cytoplasm of the 
oocyte, a cytoplasmic bridge is sometimes formed which can create ‘polar body-like’ 
structures within the perivitelline space (Fig5.3b).    It is these structures which we 
believe were making it difficult to orientate the zygotes, as we could not be sure which, 
were the actual polar bodies.   
 
As the aim of the study was examine the potential to remove the pronuclei following 
removal of the polar bodies, whilst minimising the number of holes made in the zona 
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pellucida of the zygote.   This influenced the orientation the zygote was positioned in 
prior to attaching to the holding pipette.  The ideal scenario would allow for a single 
hole to be made in the zona pellucida which would allow to, firstly remove the polar 
bodies and then secondly remove the pronuclei.   However t due to the varying positions 
of the polar bodies in the perivitelline space and the varying planes within the zygote 
the pronuclei resided this often proved difficult.   
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Figure5. 3 Morphological differences observed in polar bodies found in IVF 
inseminated zygotes versus ICSI fertilised zygotes.   
 
Above images represent observational differences made regarding polar body 
morphology and position between embryos which were inseminated using 
straightforward IVF (in vitro fertilization) and those fertilised using ICSI (intra 
cytoplasmic injection) (a) Polar bodies found in those embryos created following 
IVF insemination often were found to contain atypical polar bodies, with the first 
and second polar bodies in approximately the same location (indicated by arrow). 
(b) However in those embryos created following ICSI, we often found that at least 
one of the polar bodies was fragmented  (indicated by arrow) and often further 
apart within the perivitelline space (indicated by arrow), making them incredibly 
more difficult to remove.  Scale bar, 50µm.   
 
a 
 
b 
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5.3.1.2 Fragmented polar bodies  
 
A number of zygotes contained fragmented polar bodies, an issue which related to both 
these being abnormally fertilised zygotes and the time span in which we received them.   
In particular the primary polar body is formed before the oocyte is fertilised and 
therefore we would expect this to be more fragmented than the secondary polar body 
due to the extra time this has been present for (Fig5.4).  
 
Another problem encountered, when removing some of the polar bodies was the ability 
to tease the polar bodies into the zona drilling pipettes (used for their removal), due to 
what appeared to be ‘cytoplasmic like-bridges’ invisible ties existing between the polar 
body and the zygote.   Once the polar body had been successfully navigated the zona 
drilling pipette it often began to drift back out of the pipette and towards the zygote.   
To overcome this issue the air flow from the air syringe attached to the biopsy pipette 
was gradually increased in an attempt to counterbalance the pull back towards the 
zygote.  However on several occasions when the air flow was increased too suddenly 
the polar body often flew up the zona drilling pipette but also with accompanying 
cytoplasm from the zygote.    Most of those embryos in which the cytoplasm of the 
zygote was nicked by the pipette went on to degenerate (n=10/39).   
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Figure5. 4 Polar body biopsy of fragmented polar body  
 
Above image represents a typical fragmented polar body we attempted to 
biopsy from an abnormally fertilised human zygote.  Scale bar, 50µm.   
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5.3.2 Polar body biopsy prior to PNT  
 
I attempted to perform polar body biopsy immediately prior to performing PNT on the 
same zygote.   Two different approaches were taken to examine the possibility of 
performing polar body removal in conjunction with PNT.  As part of the first approach 
polar bodies were removed in media supplemented with cytoskeletal inhibitors 
(cytochalasin B (1µg/ml) and 1µl nocodazole (2µg/ml) (Sigma-Aldrich, UK)).  This 
allowed for PNT to be performed immediately following polar body removal.    For the 
second approach, zygotes were placed into un-supplemented G1v5plus media for polar 
bodies removal.  Following successful polar body removal these zygotes were then 
transferred to a different drop of media within the manipulation dish containing media 
supplemented with the cytoskeletal inhibitors to allow for PNT to be attempted.  A 
comparison was then made between the two different approaches so as to determine, 
which approach was most feasible to perform ad gave best survival outcomes.   
 
5.3.2.1 Orientation of the zygotes for optimum polar body 
combined with sequential pronucleus removal  
 
Prior to beginning the procedure (polar body removal followed by PNT) it was often 
found incredibly difficult to orientate the zygote so that both the polar bodies and the 
pronuclei were all roughly within the same focus.  This was made more difficult when 
the polar bodies were fragmented and located in different areas within the perivitelline 
and present in multiples (Fig5.4).    It was therefore decided that the primary aim was to 
ensure that the pronuclei were removed intact and therefore were in the best possible 
focus.  Once the zygote had been orientated in to an acceptable working position, the 
zygote was attached to the holding pipette, using suction.  The zona drilling pipette used 
for the polar body biopsy procedure was then lowered into the drop of media containing 
the zygote.   A small hole was made in the zona pellucida using the laser and the biopsy 
pipette brought to the mouth of the hole.   Using the air syringe controlling the biopsy 
pipette light suction was applied to encourage the polar body into the mouth of the 
biopsy pipette.  For those zygotes which polar bodies had successfully been removed 
using the zona drilling pipette,  it was necessary to remove the pipette from the pipette 
holder and attach and prime the PNT pipette before attempting PNT (Please refer to 
previous materials and methods section chapter 5 or full PNT method).    
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5.3.2.2 Polar body removal performed in the absence of 
cytoskeletal inhibitors followed by PNT  
 
PNT was attempted on a number of zygotes (n=19) which had undergone polar body 
removal but in un-supplemented G1v5plus media (media lacking cytoskeletal 
inhibitors).   Polar bodies were therefore removed in G1v5plus media before they were 
transferred to another drop within the same manipulation dish containing media 
supplemented with the cytoskeletal inhibitors.   The zygotes were then incubated in the 
drop containing the supplemented media for between 10-15 minutes prior to attempting 
PNT.  This allowed time to take off the zona drilling pipette and replace it with the PNT 
pipette.   However this did increase the time taken to perform the entire procedure, 
given to the time required to move the zygote between drops of media in the 
manipulation dish, change biopsy pipettes, primer biopsy pipettes and orientate the 
zygote so as to find the hole originally made to remove the polar bodies.  For those 
zygotes which polar bodies were successfully removed in G1v5plus media, PNT was 
subsequently attempted a significant number survived both procedures and 
demonstrated potential for onwards development (n=14/19).   
 
5.3.2.3 Polar body removal performed in media supplemented 
with cytoskeletal inhibitors immediately prior to performing 
PNT   
 
Those zygotes for which polar bodies were successfully removed in the presence of 
cytoskeletal inhibitors (n=10) were also used to attempt PNT. Here the zona drilling 
pipette used to remove the polar bodies was taken off the pipette holder and the PNT 
pipette attached in its place.    It was possible to successfully remove the pronuclei 
intact from these zygotes (n=8).  However we did find that those zygotes which had 
previously undergone polar body removal in the presence of cytoskeletal inhibitors were 
more ‘leaky’ which we believe was due to the prolonged exposure to the cytoskeletal 
inhibitors.  Two zygotes which lost a considerable amount of cytoplasm did go on to 
degenerate.     
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5.3.3 Issues associated with performing polar body removal and PNT in the 
presence/absence of cytoskeletal inhibitors  
 
Initial experiments performed to examine the feasibility of polar body removal had 
primarily been performed in G1v5plus media, with initial results proving encouraging, 
although on several occasions the zona drilling pipette used to remove the polar bodies 
inadvertently breached the cytoplasm of the zygote, which usually resulted in the zygote 
degenerating during the recovery period (Fig5.55b).   Also due to the limited time that 
pronuclei remain visible for following fertilization until pronuclear breakdown (~17-
20hrs) it is essential to maximise the time and ensure pronuclear transfer is performed 
and completed before the pronuclei breakdown due to the limited number of abnormally 
fertilised zygotes often received.    
 
Therefore in order to minimise these issues experiments were performed where the 
zygotes were incubated in the cytoskeletal inhibitors prior to performing polar body 
biopsy.   This it was hoped would prevent issues surrounding lysing of the zygote, if the 
cytoskeleton was relaxed and would also allow for PNT to be performed immediately 
following polar body removal without then need to transfer the zygote between different 
drops of media within the manipulation dish.   
 
However due to the significantly reduced size of the zona drilling pipette (10µm) used 
to remove the polar bodies in comparison to the PNT biopsy pipette (28µm) and also 
issues regarding the air syringe controlling suction on the biopsy pipette, there was a 
significant lack of fine control during PB removal.  Indeed on several occasions when 
removing the polar bodies from zygotes incubated in cytoskeletal inhibitors (even 
following short periods of incubation in the cytoskeletal inhibitors <5mins) the polar 
bodies would often rush out from the perivitelline space and into the biopsy pipette, 
immediately followed by the cytoplasm of the zygote, resulting in lysing and 
degeneration of the zygote.   
 
For those zygotes which had successfully undergone polar body removal, time was able 
to be saved as both PB removal and PNT procedures were able to be performed in the 
same media.   However the presence of the cytoskeletal inhibitors did make the polar 
body removals more difficult to remove and consequently often took more time.  
Therefore it appears possible to remove the polar bodies in the presence of media 
 1 6 8  
 
supplemented with cytoskeletal inhibitors however it does also introduce additional 
complications not encountered when removing the polar bodies in non-supplemented 
G1v5plus media.   
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Overall number 
Number 
degenerating 
during procedure 
Number 
surviving 
procedure 
Polar bodies 
removed in 
G1v5plus culture 
media only  
29 2 27 
Polar bodies 
removed in 
cytoskeletal 
inhibitors and 
used for PNT 
10 2 8 
Polar bodies 
removed in the 
absence of 
cytoskeletal 
inhibitors and 
used for PNT  
 
19 5 14 
Table: 5.1 abnormally fertilised human zygotes used for polar body removal 
ad PNT  
 
Above table details the number of zygotes which were initially underwent polar 
body biopsy and later PNT.  Here the polar bodies were removed for a number of 
abnormally fertilized human zygotes (n=39).  The polar bodies were removed in 
media which was (n=10) and was not supplemented with cytoskeletal inhibitors 
(n=19) and PNT attempted.   
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Figure5. 5 Removal of polar bodies prior to performing pronuclear 
transfer in the presence and absence of cytoskeletal inhibitors  
 
Above images represent abnormally fertilised human zygotes which were 
incubated in media containing cytoskeletal inhibitors prior to removing the 
polar bodies.  (a) Here we found that this relaxed the cytoplasm to such an 
extent that during polar body removal often a small amount of cytoplasm was 
also removed with the polar body.  However if the ooplasmic membrane was 
‘nicked’ with the polar body biopsy pipette during the biopsy procedure if the 
cytoskeletal inhibitors were present the zygote did most often not go on to 
degenerate.  (b) We did attempt to remove the polar bodies when the zygote 
was placed in media without cytoskeletal inhibitors, although when the 
ooplasmic membrane was breached accidently the zygote often went on to 
lyse.  Scale bar, 50µm.   
a 
b 
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Figure5. 6 Development following polar body biopsy  
 
(a)Example of a manipulated (polar body biopsied zygote), which 
successfully developed to blastocyst stage; hatching through the hole made to 
allow the biopsy pipette to enter the zygote (as indicated by arrow) (b) 
Cultured, unmanipulated control embryo which successfully developed to a 
blastocyst stage embryo, here the zona pellucida thinned naturally.  Scale 
bars, 50µm.   
 
 
a 
 
b 
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5.4 Development following polar body biopsy 
 
Here we biopsied a total of n=39 abnormally fertilised human zygotes, a significant 
number (n=27) of which successfully survived the biopsy process and went onto cleave 
and develop in vitro.    (Note - all zygotes which did not survive the polar body removal 
procedure were not included in data analysis).  Here development was good in those 
biopsied zygotes, with 14% (n=4) (Fig5.7) developing to the blastocyst stage in vitro.   
Development was comparable to data collected for unmanipulated cultured embryos, 
where development to blastocyst rate was 16% (n=10) (Fig5.7 and Table 5.2). 
 
Due to issues surrounding premature hatching due to the presence of artificially made 
holes in the zona pellucida so as to allow the biopsy pipette to gain entry through the 
zona pellucida.  Immuno-labelling experiments were performed so as to determine if 
cell number and the integrity of the trophectoderm and ICM was affected by the hole 
and biopsy process in comparison to non-biopsied cultured control embryos.   
 
5.5 Immuno-labelling of polar body biopsied embryos 
 
Those zygotes which successfully developed to blastocyst stage embryos were fixed 
(day 5-7) in 4% PFA for 30mins.   These were then used in immuno-labelling 
experiments using DAPI to examine cell number and Nanog to examine the number of 
pluripotent cells in relation to the inner cell mass (ICM).    Cell numbers determined for 
those zygotes (n=4) which underwent polar body biopsy and successfully developed to 
blastocyst stage embryos (~79) were not found to differ significantly (p=0.7) to those of 
the unmanipulated cultured only (n=10) control embryos (~90).    The number of Nanog 
positive cells was also found to be similar between the polar body biopsied (~8) and 
control blastocysts (~10) (Fig5.9).    
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<four-cell 
Four-cell to eight-
cell stage 
>Eight-cell stage 
Polar body 
biopsied zygotes  
11% (n=3/27) 15% (n=4/27) 74% (n=20/27) 
Unmanipulated 
control zygotes 
15%(n=7/48) 15%(n=7/48) 70% (n=34/48) 
Figure5. 7 and Table5.2 Development of polar body biopsied versus 
unmanipulated control abnormally fertilised human zygotes  
 
Above graph represents development attained for those zygotes which 
underwent polar body biopsy (n=27) (dark purple bars), versus development 
observed in unmanipulated control (cultured only) (n=48) (light purple bars) 
abnormally fertilised human zygotes.  Table representing developmental stage 
attained by embryos undergoing polar body biopsy versus unmanipulated 
controls.   
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Figure5. 8 Analysis of polar body biopsied and control blastocysts  
 
Blastocysts were fixed in 4% PFA for 15-30 minutes and then stored in PBS 
until staining. Blastocysts were stained for DAPI (blue) Nanog (red) (all images 
taken at x20 magnification).   Images (a-d) represent the same blastocyst stained 
for DAPI (b) and Nanog (c) which were then overlaid in order to determine the 
number of co-expressing DAPI and Nanog cells (e).  From the DIC image there 
is a clear and distinct inner cell mass (ICM) present which contains a distinct 
population of Nanog expressing cells. However not all abnormally fertilized 
embryos exhibited restricted patterns of Nanog expression (image f).  Scale 
bars, 50µm.   
 
a b c 
d f e 
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 Total cell counts 
(DAPI) 
Nanog positive cells 
Polar body biopsied 
embryos(Manipulated) 
79 8 
Control -cultured only 
embryos(Unmanipulated) 
90 10 
 
 
 
 
 
Figure5. 9 and Table5.3 Images represent abnormally fertilised human zygotes, which 
had a small hole made in the zona pellucida (ZP) to allow for polar body biopsy.  
Blastocyst stained for DAPI (blue) Nanog (red) (all images taken at x20 magnification).   
DIC image of blastocyst (a) the same blastocyst stained for DAPI (b and d) Nanog (d) and 
then images acquired from staining for DAPI and Nanog were then overlaid in order to 
determine the number of co-expressing cells in different parts of the blastocyst (e).  From 
the DIC image there is a clear and distinct inner cell mass (ICM) present (a) (as indicated by 
arrow) which contains a distinct population of Nanog expressing cells (d and e) (as 
indicated by arrow). Scale bars, 50µm.   
 
a b 
c d 
e 
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Figure5. 10 Progressive segregation of blastocyst lineages  
 
Blastomeres first become specified to form the inner cell mass (ICM) or 
trophectoderm (TE), dependent upon the level of Oct 4 expression.  Oct4 
promotes ICM formation and inhibits TE development.  ICM cells then become 
specified to be epiblast (EPI) or primitive endoderm (PE) dependent upon the 
levels of Nanog, with Nanog acting to promote EPI and block PE development.   
(B) The choice of becoming EPI, PE or TE is not progressive, but depends on 
localized expression of both positive and negative factors.   Oct4 and Nanog 
together promote EPI formation, with Oct4 inhibiting TE formation and Nanog 
inhibiting PE formation.  Whilst Cdx2 promotes TE formation and inhibits EPI 
formation; GATA6 promotes PE formation and blocks EPI formation.   
 
 
ICM 
EPI PE 
TE 
Nanog
 
EPI PE 
Nanog
TE 
Oct4 
Cdx2  GATA6
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5.6  Discussion  
 
In this chapter I examined the feasibility of polar body removal. This was because of the 
concern that in the presence of the fusing agent HVJ-E, polar bodies could fuse back 
with the zygote in so altering the chromosomal constitution of the zygote.   HVJ-E is 
introduced into the zygote following re-introduction of the pronuclear karyoplasts into 
the (donor) recipient zygote.   If enough HVJ-E is introduced and persists within the 
perivitelline space, following karyoplast fusion, this could theoretically allow the polar 
bodies to re-fuse back with the zygote.    
 
Polar bodies are bi-products of the female meiosis and not directly involved in embryo 
development, therefore they can be safely removed through biopsy procedures 
(Mastenbroek et al, 2007; Kuliev and Rechitsky 2011; Levin et al, 2011).    These 
structures are not maintained throughout preimplantation and degrade shortly after 
formation, usually within 17–24 hr, and the resulting fragments remain entrapped within 
the zona pellucida (Longo, 1997; Ebner et al, 2000).   Therefore, due to the transient 
nature of polar bodies it is very unlikely that they would be able to fuse back with the 
zygote, even in the presence of fusing agents.   However given the concern which had 
been raised surrounding the potential for this to occur, it was important to address the 
problem and therefore assess the feasibility of polar body removal prior to performing 
the PNT procedure.   
 
Traditionally the PNT procedure is performed using media supplemented with 
cytoskeletal inhibitors (Cytochalasin B and nocodazole) (Craven et al, 2010).  The 
addition of these cytoskeletal inhibitors to routine culture media, relaxes the 
cytoskeleton allowing for the safe and successful removal of pronuclei.  As polar body 
removal was ideally performed prior to performing PNT, I set out to examine the 
feasibility of removing the first and second polar body in media supplemented with the 
two cytoskeletal inhibitors.   However I also compared this to removing polar bodies in 
un-supplemented media (without the cytoskeletal inhibitors), to determine if this 
impacted upon the removal of the polar bodies.  Ideally by removing the polar bodies in 
media supplemented with the cytoskeletal inhibitors then zygotes could be used 
immediately to perform PNT, without the need to move the zygotes between different 
types of media.   
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The first approach examined removing polar bodies in media supplemented with 
cytoskeletal inhibitors.   Removing the polar bodies in the presence of cytoskeletal 
inhibitors, did prove to slightly complicate the procedure.  This was believed to be due 
to the relaxed nature of the cytoskeleton which meant that when removing polar bodies 
which resided in close proximity to the cytoplasm of the zygote there was a 
substantially increased risk of damaging the cytoplasm of the zygote.   Also by 
removing polar bodies in media supplemented with cytoskeletal inhibitors the length of 
time embryos were exposed to these chemicals was increased.   This is a concern as 
cytoskeletal inhibitors have been shown to demonstrate cell toxicity following extended 
exposure. However brief periods of exposure to cytoskeletal inhibitors at low 
concentrations (within the range of 2.5-10µM) has been shown does not perturb 
development (Otaegui et al, 2005). Therefore provided that zygotes are not left within 
the media supplemented with cytoskeletal inhibitors for extensive periods (>9hours) no 
long term affects should be observed.    
 
The removal of polar bodies from zygotes using un-supplemented media, I found 
removed the risk of the cytoplasm of the zygote being removed during the polar body 
removal.  However as the cytoskeletal inhibitors were not present during this set of 
manipulations, if by chance we did ‘nick’ the cytoplasm of the zygote, the zygote was 
often unable to recover and degenerated as a result.  This was often due a lack of 
malleability of the zygote in the absence of the cytoskeletal inhibitors but also due to the 
presence of connections which have been shown to exist between the polar bodies and 
the cytoplasm of the zygote (Montag et al, 2012).  In order to remove the polar bodies 
successfully these ‘ties’ had to be broken, which often resulted in breaching of the 
zygote cytoplasm and the zygote degenerating.    
 
As zygotes were to be used for PNT experiments following polar body removal, this 
influenced decisions taken when removing polar bodies, including, the most optimal 
position to make a hole to perform the biopsy procedure.   The idea was that the same 
hole made to remove the polar bodies could then be re-used to remove the pronuclei.  
However the position of the polar bodies within the perivitelline space did not always 
allow for this to be accommodated.   For example in zygotes produced following 
intracytoplasmic sperm injection (ICSI), the position of the first and second polar body 
differed.    This is due to the fact that when MII stage oocytes are fertilized using the 
ICSI procedure the oocyte is orientated so that the polar bodies are located at either the 
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6 or 12 o’clock position to ensure that the spindle is not damaged as a result of the 
injection process.   This is different to the situation following routine IVF insemination, 
where first and second polar bodies can be found within a close proximity.   The 
position of the polar bodies in ICSI zygotes can often differ by 45
o
.    This therefore 
made it difficult to remove the first and second polar body from the ICSI fertilized 
zygotes, firstly using the same hole and secondly taking care as to not damage the 
zygote.   However this study did make use of abnormally fertilized human zygotes and 
therefore the location of the polar bodies may have been influenced due to their 
abnormal fertilization.   
 
The polar body biopsy (PBB) procedure is said to be one of the safest forms of biopsy 
to perform during embryonic development.   Indeed where possible PBB is now 
performed in place of conventional cleavage stage PGD in clinical practice due to the 
minimal invasive nature of the procedure (Verlinsky et al, 1990).    Therefore the impact 
of the PBB procedure upon development, embryo quality and viability is often regarded 
as minimal (Munne et al, 1999; Magli et al, 2004; Wells et al, 2002).  However given 
the complications I encountered when performing polar body it was important to 
ascertain that development was not affected by the polar body removal procedure.  I 
therefore examined development in embryos which had undergone polar body biopsy.   
The blastocyst development rate observed for PBB embryos was comparable to that 
attained by unmanipulated cultured control embryos (14% versus 16%, respectively).  
 
There is further evidence that as the degree of fragmentation found within the 
perivitelline space increases embryo quality is reduced (Ebner et al, 2000).    Indeed I 
found that development observed for embryos following polar body removal and any 
further residual fragmentation did appear to help enhance embryo developmental 
potential.   Therefore by removing the polar bodies and if possible any additional 
fragmentation present at the same site we may not only be eliminating the potential 
threat posed by fusing back of the polar bodies with the zygote due to HVJ-E mediated 
fusion but also helping to improve developmental potential and the overall embryo 
quality.    
 
There are other studies which have reported a reduction in development for embryos 
which underwent PBB.   One such study examining the effects of PBB reported the 
unfavourable effect it had on subsequent embryo development in terms of worse 
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cleavage patterns, higher fragmentation rates, and lower number of blastomeres (Levin 
et al, 2011).  However this study did examine the potential of first and second polar 
body removal and also highlighted the fact that when they initially started gathering 
data they had less experience in the technique (<100 cycles).  This ‘learning curve’ they 
said could have impacted upon the outcomes of the study.  They also commented on the 
effect of biopsying at the egg stage rather than the zygote stage alone may have 
impacted on future embryo development due to the additional intervention.  For 
example it is common practice to biopsy both polar bodies at the same time at the 
zygote stage.   
 
However the method used to perform PBB can differ between laboratories; this could 
therefore influence outcomes including developmental potential following PBB.  The 
two main techniques used to perform PBB are laser-assisted and partial zona dissection.  
Although the effect the biopsy technique alone has on subsequent embryo development 
and quality is not always easy to assess, due to the numerous other variables which 
cannot always be controlled for, including; embryo handling, exposure to non-natural 
light sources, culture media and also quality of the eggs/embryos.  
 
However the use of laser ablation of the zona pellucida, has been suggested could 
impact on embryo development potential.  Despite evidence to suggest the use of laser 
ablation minimum results in a minimal amount of heat dissipation, which is aided by the 
use of ‘isotherm rings’ it cannot always be guaranteed.  Indeed a study published in 
2011, investigated whether the viability of blastocysts developed from laser- versus 
partial zona dissection treated 1PN oocytes was negatively affected by the method of 
biopsy, which they evaluated by comparing their total cell number (TCN).    
Interestingly they found that survival and development was not affected as a direct 
result of the technique used to make the opening in the zona pellucida.  However the 
TCN of laser-derived blastocysts was significantly lower than the TCN of blastocysts 
developed from control and PZD 1PN oocytes.  They concluded therefore that viability 
of blastocysts developed from laser-treated 1PN oocytes was reduced as a result of this 
particular method of zona dissection.  However my own analysis revealed no significant 
difference (p=<0.7) in the overall cell number for those zygotes which underwent polar 
body biopsy (~79 cells) and those unmanipulated controls (~90 cells).     
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Although the study by Macas (2011) determined that blastocyst viability was reduced as 
a direct result of laser-assisted dissection of the zona pellucida.  It is difficult to see how 
the exact technique used to make the opening in the zona pellucida can be distinguished 
from the effect of the ‘size of the opening’ made in the zona pellucida and its impact on 
blastocyst viability.   Indeed artificially breaching the zona pellucida has been reported 
to alter the normal thinning process of the zona pellucida directly (shown to hatch 
through a thicker zona pellucida, while having a smaller embryo size) increasing the 
risk of premature hatching at the ‘early blastocyst stage’ (~day5) (A De (Malter and 
Cohen, 1989; Montag et al., 2000; Schmoll et al., 2003; Vos et al, 2008; Kirkegaard et 
al, 2011).    Premature hatching is not often observed during the normal hatching 
process.   This is because the zona pellucida of non-manipulated embryos demonstrate a 
unique ‘elastic’ like property which allows the zona pellucida to expand as the 
blastocyst begins to expand, with the development of the blastocoels cavity.   This is in 
turn associated with thinning of the zona during what is referred to as the ‘contraction 
cycle’ (Cohen et al, 1991).     
 
It is indeed more likely that the premature hatching-like process observed following 
partial zona dissection would explain the differences observed in TCN.   Blastocysts 
developed from the artificially breached embryos initiating a hatching-like process, with 
cells escaping from the large hole in the zona on the morning of day 5 or even earlier 
(Cohen, 1991; Macas et al, 2011; Kirkegaard et al, 2011). Studies performed to examine 
TCN in blastocysts determined to have initiated the hatching process found, no further 
increase in TCN following initiation of the process (Fong and Bongso 1998) .    This 
has led to the suggestion that mitotic activity is suspended and can only be triggered 
again if such blastocysts attach and embed among endometrial cells (Macas et al, 2011).   
This may suggest that artificial breaching of the zona pellucida regardless of the 
technique used negatively impacts upon the mitotic activity of the cells forming these 
blastocysts.   An alternative explanation has also been suggested, i.e. that the metabolic 
requirements may be inadequate at the time of hatching and that this can promote the 
process of cell death, which per se may also reduce the TCN.   Since the premature 
hatching observed in the present study mimics in some ways the mode of blastocyst 
hatching in vitro, it is concluded that a similar mechanism must also be involved in the 
decrease of the TCN of the laser-derived group of blastocysts (Macas et al, 2011).  
Indeed it is possible to perform PBB using specially designed spiked pipettes, known as 
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‘zona drilling’ pipettes.  It is often safer and easier to perform PBB with the aid of a 
hole in the zona pellucida.    
 
Although it appears that artificial breaching of the zona pellucida does not appear to 
affect the overall survival and ability of embryos to successfully develop to the 
blastocyst stage when investigated further the viability of these same blastocysts maybe 
irreversibly impaired (Cieslak-Janzen, et al 2006; Magli et al, 2004; Macas et al, 2011).   
Furthermore blastocysts hatching from artificially made biopsy holes could damage the 
integrity of the trophoblast and the ICM through expulsion through a narrow opening 
due to the fragile nature of the human blastocyst (Cohen et al, 1991).      
 
It is therefore important that blastocysts developing from embryos which have had 
artificial openings made in their zona pellucida are examined to determine that lineage 
specification is not perturbed in light of the differences observed in TCN (Macas et al, 
2011).  There are several key factors which have been identified to be essential for 
correct cell lineage specification during embryogenesis (Rossant, 2004).   One such 
factor is Nanog which is responsible for maintaining cells in a pluripotent state.    
Nanog expression gradually becomes restricted to the ICM by the blastocyst stage (~day 
5), where it is then maintained in the epiblast of the pre-gastrulation embryo until 
formation of the primitive germ cells, before it eventually becomes restricted to the 
germline (Palmieri et al, 1994; Rossant, 2004).  Nanog expression was examined in 
both manipulated and unmanipulated (control) embryos in those embryos which 
successfully developed to blastocysts.  For those blastocysts which contained a distinct 
ICM (not all did) we found there to be sufficient down regulation of Nanog in the 
trophectoderm cells compared to the ICM population of cells, with a distinct population 
of Nanog cells expressed in the ICM alone   Importantly no significant difference was 
observed in the number of Nanog positive cells we identified in the polar body biopsied 
blastocysts (~8) versus the unmanipulated controls (~10).   Despite the relative high cell 
numbers observed for these blastocysts, it is worth while remembering that these 
experiments were performed in abnormally fertilised human zygotes.   It has already 
been demonstrated that developmental potential is reduced in abnormally fertilized 
embryos and therefore it is likely that cell specification is perturbed for these embryos 
due to their abnormal chromosomal constitution (Feenan and Herbert, 2006).   
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These studies have therefore demonstrated that development to the blastocyst stage in 
vitro following polar body biopsy does not negatively impact upon development or 
indeed lineage restriction and specification.   Polar body biopsy does appear feasible 
although it does increases the length of time required to perform the PNT procedure 
which is already lengthy and performed against the clock due to the limited period of 
time pronuclei remain visible for prior to syngamy and pronuclear breakdown.   
However with the use of a double pipette holder time can be saved and its feasibility 
boosted. By removing the polar bodies the threat of possible fusion due to the use of 
HVJ-E would be completely eliminated. Therefore not only helping improve the 
developmental capacity able to be attained but also the overall embryo quality, which 
may help improve development rates achievable following PNT.  
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Chapter 6 Vitrification 
 
6.1 Introduction 
 
Since the first successful reported pregnancy from a frozen embryo in 1983 (Trounson 
and Mohr, 1983), embryo cryopreservation has become regarded as an integral part of 
the IVF process allowing couples to store excess embryos for future treatment 
(Trounson and Mohr, 1983; Valojerdi et al, 2009), thus maximising the chance of a 
pregnancy from each round of ovarian stimulation (Loutradi et al, 2007).     
 
Until recently the most commonly used approach to cryopreserve embryos within IVF 
units globally has been slow freezing or which is sometimes referred to as controlled 
rate freezing.   This utilises programmable freezers to control the rate of cooling in a 
step-wise manner, over several hours.   However more recently, the technique known as 
vitrification has begun to replace traditional slow freezing programmes within clinical 
IVF units.    The word to ‘vitrify’ literally means to turn to a glass-like state.   In order 
to achive this, vitrification requires very rapid (high) cooling rates, which in so 
substantially minimize the risk of ice crystals forming inside cells.  Together with the 
high cooling rate, vitrification also requires the inclusion of cryoprotectants within its 
vitrification solutions in order to ensure cells are dehydrated sufficiently prior to 
plunging in liquid nitrogen.   These core principles help promote improved embryo 
survival compared with conventional controlled-rate freezing (L.Hyslop unpublished 
data).    
 
In the following chapter I aim to address and explain the main principles involved in 
establishing successful cryopreservation programmes.  So as to set the scene in light of 
the work I have performed to examine the potential of vitrification in relevance to the 
nuclear transfer technique, pronuclear transfer for the purposes of preventing the 
transmission of mtDNA disease.   
 
 
 
 
 
 
(a) 
 1 8 6  
 
6.1.1 Controlled rate freezing 
 
Controlled rate freezing involves the dehydration of embryos by exposing them to 
increasing concentrations of cryoprotectants followed by a mechanically controlled 
step-wise decrease in temperature.   Controlled rate freezing is performed over several 
hours and therefore viewed as an extremely time consuming process and also requiring 
accurately controlled and expensive programmable freezing equipment.    Despite this, 
controlled rate freezing has conventionally proven the preferred option for embryo 
cryopreservation, primarily due to the relatively low concentrations of cryoprotectants 
contained in the freezing solutions (Kolibianakis et al, 2009).    However, while the low 
concentrations of cryoprotectants used for controlled rate freezing limit the potential 
toxic and osmotic damage to embryos, they are potentially insufficient to prevent 
intracellular ice crystal formation, which can lead to cell damage and developmental 
arrest (Bryant, 1995; Shaw and Jones, 2003).   
 
In general, cryoprotectants act to lower the cell’s freezing point by osmotically 
permeating through the cell membranes and slowly replacing the intracellular water 
(Shaw and Jones, 2003; Loutardi et al, 2007).  However a fine balance exists between 
the rate of water loss from a cell and extracellular ice crystal formation, as excessive 
dehydration can increase the intracellular concentrations of cryoprotectants to increase 
to potentially toxic levels (Shaw and Jones, 2003; Lane et al, 1999; Liebermann et al, 
2002; Loutardi et al, 2008).   Therefore although the concentrations of cryoprotectants 
within the controlled rate freezing solutions are relatively low compared to those found 
within vitrification solutions the total time period over which embryonic samples are 
exposed to these solutions does  
 
6.1.2 Vitrification 
 
Vitrification, literally meaning ‘to turn to glass’, is frequently referred to as a novel 
approach to embryo cryopreservation.    However vitrification has been used as an 
alternative to controlled-rate freezing’ for the past decade with significantly improved 
results (Balaban et al, 2008).  Indeed Rall and Fahy were the first to report on the 
successful vitrification of mammalian embryos back in 1985, with the first reported 
pregnancy from a vitrified embryo following in 1990 (Valojerdi et al, 2009).     Another 
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concern which has delayed the implementation of vitrification within IVF laboratories is 
potential for compromising sterility of embryonic samples due to the requirement for 
direct exposure to liquid nitrogen, key to ensuring successful vitrification (Bielanski and 
Vajta, 2009).     However significant improvements have been made in the development 
of vitrification devices and solutions, many formulated specifically for the different 
stages of embryonic development which has led to the technique replacing controlled 
rate freezing within the majority of IVF units worldwide.   
 
There are several key principles to ensure efficient and successful vitrification 
performance.  This includes firstly the inclusion of cryoprotectants at high 
concentrations in the final vitrification solutions, secondly prompt and accurate direct 
contact with liquid nitrogen and thirdly highly skilled operators.  By ensuring these 
principles are adhered to the outcomes achievable with vitrification are second to none 
and most importantly promise significantly improved survival outcomes compared to 
conventional controlled rate freezing.    
 
There are two types of cryoprotectants included within vitrification solutions 
‘permeating’ and ‘non-permeating’.   As the names suggest the ‘permeating 
cryoprotectants’ (ethylene glycol, propanediol and DMSO) are able to enter the cell and 
replace water molecules inside the cells, thereby preventing the formation of 
intracellular ice formation.  Whilst the ‘non-permeating’ (sugars e.g. sucrose) 
cryoprotectants are macromolecules which remain outside the cell acting to increase the 
extracellular osmolarity and in aid in dehydrating the cell.   Therefore the dual action of 
‘permeating’ and ‘non-permeating’ cryprotectants allows them to act like ‘antifreeze’ 
whereby they reduce the freezing temperature (due to the elimination of water) and 
increase the viscosity (Bouvet and Ben, 2003).    Furthermore by ensuring the sufficient 
elimination of water from the cells the risk posed by potential ice crystal formation is 
significantly reduced.  This is important as the induction of cryoinjuries can 
considerably reduce survival upon warming (Loutardi et al, 2008).   
 
6.1.3 Principles of vitrification  
 
6.1.3.1 The role of cryoprotectants  
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A cryoprotectant is defined as a substance that is used to protect biological tissue from 
freezing damage.   There are two types of cryoprotectants included within vitrification 
solutions ‘permeating’ and ‘non-permeating’.   As the names suggest the ‘permeating 
cryoprotectants’ (ethylene glycol, propanediol and DMSO) are able to enter the cell and 
replace water molecules inside the cells, thereby preventing the formation of 
intracellular ice formation (Kasai, 1996).  Whilst the ‘non-permeating’ (sugars e.g. 
sucrose) cryoprotectants are macromolecules which remain outside the cell acting to 
increase the extracellular osmolarity and in assist in dehydrating the cell.   Therefore the 
dual action of cryprotectants allows them to act like ‘antifreeze’ whereby they reduce 
the freezing temperature (due to the elimination of water) and increase the viscosity.  
Furthermore by ensuring the sufficient elimination of water from the cells the risk posed 
by potential ice crystal formation is significantly reduced.  This is important as the 
induction of cryoinjuries can considerably reduce survival upon warming (Loutardi et 
al, 2007).    The role of cryoprotectants in eliminating water is also key to lowering the 
freezing point and subsequently allowing the cooling rates of >25,000
o
C/min to be 
achieved (Isachenko et al, 2005; Yavin et al, 2009; Zhang et al, 2011).   
 
However the cryoprotectant often proves the predominate source of toxicity within 
vitrification (Kasai et al, 1992a, 1996).  Although by opting for cryoprotectants with 
low toxicity and good permeation properties toxicity can be minimized.   Ethylene 
glycol is commonly used as the preferred cryoprotectant due to its relatively low 
toxicity and low molecular weight giving it a high permeation ability (Gilmore et al, 
1995; Newton et al, 1998; Sommerfield and Niemann, 1999; Emiliani et al, 2000).   In 
order to further minimize the effect cryoprotectants exert on cells a combination of 
cryoprotectants is generally used, with the most common combination proving a mix of 
ethylene glycol (ETOH) and propanediol (PrOH).   By using a combination the 
concentration at which each of the cryoprotectants are included at within the 
vitrification solutions can be halved and the risk of toxicity posed to cells significantly 
reduced.    Further steps have been taken to reduce the risk further, by including an 
equilibration step prior to a final vitrification step.  The equilibration solution generally 
contains the cryoprotectants (both ‘permeating’ and ‘non-permeating’) at half of the 
concentration at which they are present at within the final vitrification solution.   Cells 
are therefore able to be left longer in the initial equilibration solutions before they are 
exposed to the final vitrification solution.   Indeed the introduction of multiple step 
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protocols for the vitrification of oocytes and embryos has proven to be one of the key 
factors in revolutionizing the vitrification procedure.    
 
6.1.3.2 Duration of exposure to cryoprotectant 
 
Exposure times are usually reduced when the cryoprotectant concentration is high and 
increased when the cryoprotectant concentration is low.    The most commonly used 
strategy adopted to avoid toxicity associated with vitrification solutions is to therefore 
to limit the duration of exposure by oocytes/embryos to the vitrification solutions 
(Kasai, 1996).  However insufficient exposure to the cryoprotectants can result in 
incomplete permeation and intracellular ice crystal formation, which cause damage 
upon thawing; whilst over exposure to cryoprotectants can result in toxic injury (Yang 
et al, 2007)..  Therefore a compromise is often made between duration of exposure and 
concentration of cryoprotectants, in order to achieve the best outcomes possible.    Often 
the deciding factor defining optimal duration of exposure often rests upon the stage of 
embryonic development the sample is vitrified at (Kasai, 1996).      
 
6.1.3.3 Single versus multiple steps  
 
The number of steps included in a vitrification protocol is also a defining factor when 
choosing a vitrification system.   Single exposure vitrification solutions may not only 
allow insufficient time for adequate penetration of the cryoprotectants but also expose 
the cells to undue toxic side-affects.    The use of two-step protocols overcomes this 
issue allowing cells to be equilibrated in initial ‘equilibration solutions’ for longer 
periods (up to 15 minutes) containing  the cryoprotectants at lower concentrations 
before a short exposure to a second ‘vitrification solution’ containing the 
cryoprotectants at a higher concentration (Liebermann et al, 2002; Kader et al, 2009).  
Allowing the cryoprotectants to more gradually and effectively penetrate the embryo; 
whilst minimizing the risk of osmotic shock and toxicity (Kader et al, 2009).   
 
6.1.3.4 Vitrification devices  
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During the past decade there has been a significant increase in commercially available 
vitrification devices, including; the cryotip (Irvine scientific), cryotop (Kitazato), 
cryolock (Bio-diseno) and cryoleaf (Origio), cryopette (Origio), cryoloop (Vitrolife), 
Rapid-I (Vitrolife).  Vitrification devices normally fall into one of two categories ‘open-
systems’ (direct contact vitrification) or ‘closed-systems’ (closed system vitrification).  
(a) Direct contact vitrification  
 
‘Direct contact’ or ‘open vitrification’ systems, have been shown significantly increase 
the cooling rate, by providing direct contact with the liquid nitrogen interface 
(24,000
o
C/min) (Palsz and Mapletoft, 1996).   Several studies have demonstrated the 
excellent survival outcomes within the order of >90% achievable when vitrifying using 
a ‘open vitrification’ device (Kuwayama et al, 2007; Liu et al, 2008; Cobo et al, 2008).   
Indeed ‘direct contact liquid nitrogen’ was and still is by some considered the ‘gold 
standard’ for vitrification.   The primary overriding concerns in light of the potential 
risk of contamination posed by microorganisms able to persist in liquid nitrogen at 
temperatures as low as -196
o
C (Bielanski and Vajta, 2009).  However in spite of these 
concerns, so far no disease transmission attributable to this mechanism has been 
documented in domestic animal or human reproductive biology (Vajta and Nagy, 2006).    
(b) Closed system vitrification  
 
Due to concerns regarding the potential risk of contamination posed by micro-
organisms ‘closed vitrification’ systems were developed.  However by avoiding direct 
contact with liquid nitrogen the cooling rate is significantly reduced to ~12,000
o
C/min 
almost half of that able to be achieved using ‘direct contact’ vitrification devices at 
~24,000
o
C/min (E Van Landuyt -  2011).  To overcome the reduced cooling rate new 
vitrification devices have been developed to maximise heat transfer incorporating 
several key features, including; the use of ultrathin material and ergonomically designed 
areas to minimise the time taken to load samples.    
 
One such device which has been developed and overcome issues associated with a 
reduction in cooling rate is the ‘Rapid-i™’ (Vitrolife) ‘closed system’ vitrification 
device.  This utilises ‘super cooled air’ to achieve rapid cooling of sample on 
submersion in liquid nitrogen, resulting in significantly improved survival outcomes 
(Larman et al, 2006).   The same device has many other unique features, including a 
 1 9 1  
 
‘50nL’ sized hole located in the tip of the flange of the device to aid in loading of 
samples in a minimal volume of vitrification media (Figure6.9).  The straw into which 
the loading device resides during storage comes with a metal rod.  This metal rod is 
placed within the outer straw when placed into the box containing liquid nitrogen.  The 
presence of the metal rod acts to create the column of ‘super-cooled air’ inside the straw, 
into which the vitrification loading device containing the oocyte/embryo is eventually 
placed.  There is now cumulative evidence both published and unpublished which 
demonstrates the highly efficient nature this device provides when vitrifying, reflected 
in the survival outcomes (Larman and Gardner, 2011; L. Saragusty and Arav, 2011; 
Hyslop, unpublished),   
 
6.1.3.5 Operator factors  
 
Vitrification outcome is highly operator dependent and requires a totally different skill 
set to slow freezing.   The embryologist should be rapidly handling the embryos in 
micro-volumes of highly viscous media.  Specific training on the use and storage of the 
vitrification device should be undertaken prior to commencing vitrification.  
Furthermore the embryologist should be fully aware of the different critical procedural 
details that can affect the vitrification outcome. This includes: the types and 
concentrations of cryoprotectants used and their toxicity threshold, the temperature of 
the vitrification solution at exposure, the duration of exposure to the final 
cryoprotectants before plunging into liquid nitrogen, rapid loading, sealing devices 
(closed-system) and system validation (loading sealing and storage).   
 
6.2 Vitrification at the Pronucleate (PN) Stage  
 
Since in some countries it is illegal to cryopreserve an oocyte after fusion of the 
pronuclei (PN) due to strictly enforced embryo legislation.    It is only possible for those 
‘fertilized oocytes’, which have not as yet undergone nuclear fusion (breakdown of 
pronuclear membranes) so as to regard them as an ‘embryo’ to be cryopreserved.  For 
example, in Germany, the ‘Embryo Protection Act 1990’ grants moral status to those 
embryos, which ‘nuclear fusion or syngamy has occurred’ (~20hrs p.f.).  As a result 
there has been a great deal of interest in developing a refined method for cryopreserving 
human pronuclear oocytes (Isachenko et al, 2004).   
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As a consequence there are is several published reports of successful cryopreservation, 
at the PN stage using both controlled rate freezing and vitrification (Damario et al, 
1999; Park et al, 2000; Isachenko et al, 2005; Orief et al, 2005; Kuwayama, 2007).   
Many have suggested the PN stage zygote as the optimal stage for cryopreservation 
(Damario et al, 1999), due to the lack of spindle apparatus, which is suggested accounts 
for its high post-thaw survival rate (Orief et al, 2005).   However as result of the lack of 
morphological criteria present at the PN stage, grading PN stage zygotes is no easy task, 
meaning vitrification at the PN stage is not widely used in clinical practice for this 
reason(Ludwig et al, 2000; Khalili and Mardanian, 2008).   However those zygotes 
which are compatible with development can be assessed upon their ability to undergo 
the first cleavage division (Orief et al, 2005).    
 
6.3 Oocyte cryopreservation  
 
The clinical interest in gamete cryopreservation has grown significantly during the last 
decade for which there are several drivers for this.   Firstly women undergoing cancer 
treatments can be rendered infertile by gonadotoxic treatments (Falcone et al, 2004; 
Gardner et al, 2007).  Secondly women are now opting to delay starting their family 
until later in life and therefore would like the potential option of storing oocytes whilst 
they are younger (Dondrop et al, 2012).  And thirdly oocyte cryopreservation is not as 
contested ethically as is embryo cryopreservation, making a more favourable stage to 
cryopreserve at (Gardner et al, 2007). 
 
In contrast to the mammalian embryo, it has proven notoriously difficult to cryopreserve 
the metaphase II (MII) stage oocyte.   One major barrier preventing successful oocyte 
cryopreservation, being the highly delicate metaphase II spindle, which is highly 
sensitive to changes in temperature (Chen et al, 2000, 2004; Mullen et al, 2004; Rienzi 
et al, 2009).   Further differences in membrane permeability and cytoplasmic 
physiological properties render oocytes much more difficult to cryopreserve 
successfully.   One such physiological aspect which has been shown to be altered as a 
result of cryopreservation procedures is intracellular calcium handling (Gardner et al, 
2007).  Where there is evidence which suggests that perturbed calcium handling in the 
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oocyte, can induce premature oocyte activation and zona hardening (Gardner et al, 
2007).   
 
Despite relatively early success (Chen, 1986; Van Uem et al, 1987), widespread 
application of oocyte vitrification was hampered for a considerable time due to the 
inefficiency of available cryopreservation methods (Oktay et al, 2006).  However 
general improvements and advancements in vitrification devices, solutions and 
techniques has now made it possible to achieve successful cryopreservation of oocytes 
(Arav, 1992; Kuwayama et al, 2005; Kuwayama et al, 2007; Ubaldi et al, 2010).  Indeed 
the technology used to perform vitrification has been so well developed and refined that 
studies conducted examining the efficiency and potential of oocyte vitrification have 
found no significant differences between fresh and vitrified oocytes (Cobo et al, 2008; 
Nagy et al, 2009).  Indeed a study performed Rienzi et al, (2009) demonstrated that 
oocyte vitrification followed by ICSI resulted in fertilization and embryo development 
rates comparable to those observed with fresh oocytes.  
 
6.4 Rationale behind investigating the feasibility and efficiency of vitrification 
at the metaphase II oocyte and pronucleate stage zygote stages of 
embryonic development in the context of preventing mitochondrial DNA 
disease.  
 
The feasibility and potential of the nuclear transfer technique pronuclear transfer (PNT) 
for preventing the transmission of mtDNA disease has been investigates using 
abnormally fertilized human zygotes (Craven et al, 2010).  The results of these studies 
published in 2010 successfully demonstrated the compatibility and potential for onward 
development of those embryos which underwent manipulation.    However it is well 
documented that abnormally fertilized human zygotes demonstrate a limited potential 
for onward development (Craven et al, 2010).    Thus, in order to progress further with 
the research and better assess development and safety concerns regarding the PNT 
technique, studies must now be performed using normally fertilised zygotes.   
 
Following the granting of the appropriate licence by the HFEA it is now possible to 
create embryos, and use those which fertilize normally to assess the PNT technique.  
Therefore we are now recruiting egg donors, through altruistic egg donor and egg 
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sharing schemes.   However this has presented a logistical problem for several reasons.   
Ideal PNT transfers are performed using oocytes obtained from two different egg 
donors.  However egg donors do not always exhibit the same response to ovarian 
stimulation resulting in potential oocyte wastage; either because one of the egg donors 
fails to respond at all or responds to well, resulting in a potential wastage of oocytes.    
This is a problem which could also potebtially present itself at a later date, if it becomes 
possible to offer PNT as a clinical treatment to mtDNA patients.  Therefore it is 
essential that strategies are developed now to allow for cryopreservation of either MII 
stage oocytes or PN stage zygotes.  I therefore set out to investigate the potential of 
vitrification at the pronucleate and metaphase II oocyte stage of embryonic 
development.  In order to ascertain which would provide the best stage to vitrify at for 
the purposes of the PNT technique.   
 
Successful cryopreservation strategies are fundamental to the development of IVF-
based treatments to prevent transmission of mtDNA disease.  Owing to variability 
between women in their response to ovarian stimulation, it will be very difficult to 
guarantee that the donor and recipient pairs will be ready to have their oocytes retrieved 
on the same day.   In context of the research and its eventual translation to clinical 
practice, it will be essential to have reliable methods for cryopreserving oocytes and 
zygotes, which are compatible with onward development and with the manipulations 
associated with pronuclear transfer and associated procedures.    
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6.5 Aims  
 
 To optimise a vitrification protocol for human zygotes 
 To determine whether PNT can be successfully performed following 
vitrification of human zygotes  
 To measure mtDNA carryover following PNT between vitrified/warmed human 
zygotes 
 To develop and optimise techniques  for vitrification of human oocytes   
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Fig6. 1 Vitrification (cooling)  
Above schematic diagram represents the two step process of vitrification 
(cooling).  Here the embryo is initially passed through an equilibration media, 
which contains the cryprotectants at reduced concentrations (7.5%) ethylene 
glycol and 1, 2-propanediol.  Embryos remain within the equilibration solution 
until they demonstrate signs of re-expansion (this can vary from 5-15 minutes).  
Once embryos have re-expanded they are transferred in a minimal volume of 
equilibration media to the second solution ‘vitrification medium’.  This 
contains the cryprotectants at double the concentration (15%, ethylene glycol 
and 1, 2-propanediol) and also sucrose which acts as a permeating molecule.  
Embryos should not be exposed to the vitrification solution for longer than 60 
seconds, including the time required to load the embryo on to the device and 
plunge it into liquid nitrogen.   
 
 
 
ES = Equilibration 
media    
Time: ~5-15 minutes  
 
 
 V = Vitrification 
media     
Time: 60 seconds  
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Warming
WS DM1 DM2 
WM1 WM2 
Gradual re-expansion 
Fig6. 2 Vitrification Warming  
Above schematic diagram represents the stages of oocyte/embryo warming, 
following vitrification.    Here the vitrification device containing the embryos is 
immediately transferred to the initial vitrification warming media following 
removal from liquid nitrogen storage container (within ~2 seconds).  Here 
embryos remain in the warming solution for up to 1 minute.  Embryos are 
sequentially passed through a series of dilution (dilution media 1 and dilution 
media 2) (each for a total of 3-minutes) and wash solutions (each for 3-
minutes) before they are transferred to an equilibrated culture dish containing 
G1v5plus media overlaid with ovoil.   
 
 
WS = Warming solution     
Time: 1 minute  
 
 
DM1 = Dilution media 1 
DM2 = Dilution media 2 
Time: 3 minutes in each  
 
 
WS1 = Wash solution 1   
WS2 = Wash solution 2  
Time: 3 minutes in each  
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6.6 Materials and Methods  
 
6.6.1 Abnormally Fertilised Human Embryos 
 
Abnormally fertilised embryos collected on day 1 of the IVF or ICSI cycle were used in 
this study. These embryos were identified as abnormal by the presence of either 1 
pronucleus (monopronucleate) or 3 pronuclei (tripronucelate) 18-19 hours after 
insemination. These embryos cannot be used in fertility treatment and are routinely 
rejected from the IVF program. 
 
6.6.2 Sources of oocytes used in study  
 
Oocytes obtained from follicle reductions (FR), together with IVM and mature 
metaphase II oocytes which failed to fertilise following IVF/ICSI were used in this 
study (Failed fertilisation was determined by lack of visible pronuclei on day1 of the 
IVF or ICSI cycle and failure to cleave by day2).  All samples used had previously been 
consented by patients undergoing fertility treatment at the Newcastle upon Tyne 
Fertility Centre at Life, following receiving the relevant research project information so 
allowing them to be used for research purposes.    
6.6.3 Vitrification  
6.6.3.1 Vitrification using an open vitrification system  
(a) Vitrification (cooling) 
 
Equilibration and vitrification solution supplied by Origio (Origio, Medicult, UK) were 
dispensed into individual wells of four-well nunc dish and left to equilibrate RT for at 
least 30 minutes prior to use.  Using a denudation pipette (vitrolife AB, kungsbacka, 
Sweden) oocytes/embryos were transferred to Equilibration medium 1 (1ml)(Origio, 
Medicult, UK) where they remained for 5 minutes before they were transferred to the 
vitrification medium (1ml)(Origio, Medicult, UK) for <1 minute.  Using the Stripper-
CC® micropipette oocytes/embryos were immediately loaded onto the tip of the McGill 
cryoleaf ™ vitrification device in a drop of less than 0.5µl (Origio, Medicult media. 
Mellehaven 12, 4040, Denmark).   The vitrification device containing the embryo was 
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then plunged directly into liquid nitrogen.  Using a pair of tweezers the protective sleeve 
was pulled down over the tip of the device before the lid of the device was also 
submerged in liquid nitrogen and the vitrification device placed into the outer cover all 
performed within the liquid nitrogen phase.  All devices were then transferred to pre-
labelled cryocaines and transferred to liquid nitrogen tanks for indefinite storage 
(Fig6.1).  
(b) Warming  
 
Vitrification warming solutions supplied by Origio (Origio, Medicult media. 
Mellehaven 12, 4040, Denmark) were aliqouted into a four-well nunc dish and allowed 
to equilibrate to RT for at least 30 minutes prior to use.   The initial warming solution 
was placed into a, non-CO2 incubator and left for minimum of 30 minutes to warm to 
37
o
C.   The vitrification carrier was collected from liquid nitrogen (LN2) storage 
container and transferred to a portable vessel containing LN2 until transfer into warming 
media.   The vitrification device was held, so the end of the device containing the zygote 
remained immersed in the liquid nitrogen whilst the device was removed from its outer 
cover.   Immediately (within 2-3 seconds), the device was transferred to the initial 
warming medium (1ml, 37
o
C) ensuring the tip of the vitrification device remained 
completely submerged in the warming solution until zygotes had been successfully 
retrieved.  Here they remained for a maximum of 1minute.  Zygotes were then collected 
and sequentially incubated in two dilution solutions (1ml) for 3 minutes in each and a 
further two wash solutions (1ml) each for 3 minutes also (Origio, Medicult media, 
Mellehaven 12, 4040, Denmark).  Zygotes were then transferred to appropriate 
equilibrated culture medium, where they were allowed time for post-warming recovery 
(Figure6.2). 
6.6.3.2 Vitrification using a closed vitrification system solutions 
and vitrification device  
(a) Vitrification - cooling  
 
Vitrification solutions supplied by (Vitrolife, Gothenburg, Sweden) were used to vitrify 
zygotes.  All vitrification and warming steps were performed at 37
o
C using 500µl of 
each solution in a four-well plate (Nunc dish).  RapidVit™ is composed of three 
separate solutions: Rapidvit1, Rapidvit2 and Rapidvit3 (Vitrolife AB, Kungsbacka, 
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Sweden).  Zygotes were initially transferred to a G-mops-like solution (RapidVit1) 
where they remained for 5-10 minutes.    Zygotes were then exposed to an initial 
solution containing ethylene glycol (RapidVit2) for 2 minutes.   The straw with the 
metal rod was placed inside the SmartBox using the magnet to keep the straw in 
position.    At 1 min 30 seconds a 20µl drop of Vitri3 was made on the bottom of a 
35mm falcon dish (BD biosciences, Franklin, USA).    At 1 min 50 seconds we began to 
collect the zygotes (from the RapidVit 2).  Zygotes were moved into the 20µl drop of 
Vitri3 as the 2 minutes elapsed. (Note: the oocytes must be exposed to Vitri3, loaded 
onto the Rapid-I and placed inside the straw (sitting in liquid nitrogen) within 25-35 
seconds).   Once the zygotes are in Vitri3 the metal rod was removed from the straw and 
the zygotes moved around the drop with the denudation pipette. At 15 seconds we 
began to collect the oocytes (keeping them at the end of the pipette).  Finally the 
zygotes were placed into the hole of the Rapid-i™ device, which was placed inside the 
polypropylene straw and sealed using the ultrasonic sealer (Vitrolife AB, Kungsbacka, 
Sweden).  
(b) Warming  
 
Vitrification solutions supplied by (Vitrolife, Gothenburg, Sweden) were used in the 
warming of zygotes.   RapidWarm™ solutions are composed of four separate solutions: 
warm solution1, warm solution2, warm solution 3 and warm solution 4.  Liquid 
nitrogen was collected and the vitrification box filled to the surface.   The first straw 
was collected from the storage tank and in its cryocaine and transferred to the 
vitrification box.  The straw was placed into one of the holding positions, here the top of 
the straw was cut just above the black end of the Rapid-I and the forceps used to lift the 
Rapid-I out of the straw (just enough to grasp with your fingertips).   The Rapid-i™ was 
transferred immediately into Warm1 (ideally this should be done within 2 seconds, 
starting from the time the rapid-I is removed from the liquid nitrogen).   The zygotes 
remained within Warming medium for 1 minute before zygotes were then moved into 
Warming medium 2 for 3 minutes, followed by Warming medium 3 for 5 minutes and 
finally into Warming medium 4 for 5 minutes.   Finally they were transferred to an 
appropriate pre-prepared culture dish containing G1v5plus culture media (Vitrolife, 
Gothenburg, Sweden).   
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6.6.3.3 Vitrification of oocytes using an open based vitrification 
system  
(a) Vitrification – cooling  
 
Equilibration and vitrification solutions were dispensed into individual wells of four-
well nunc dish and left to equilibrate RT for at least 30 minutes prior to use.  Using a 
denudation pipette (vitrolife AB, kungsbacka, Sweden) oocytes/embryos were 
transferred to Equilibration medium 1 (1ml)(Origio™, Medicult, UK) here they 
remained for 5 minutes before they were transferred to the vitrification medium 
(1ml)(Origio™, Medicult, UK) for <1 minute.  Using the Stripper-CC® micropipette 
oocytes/embryos were immediately loaded onto the tip of the McGill cryoleaf ™ 
vitrification device in a drop of less than 0.5µl (Origio™, Medicult media. Mellehaven 
12, 4040, Denmark).   The vitrification device (McGill cryoleaf ™) was then submerged 
directly in liquid nitrogen, then using a pair of large tweezers the lid of the device was 
also submerged in liquid nitrogen and placed over the tip of the device.  These were 
then transferred to pre-labelled cryocaine filled with liquid nitrogen for indefinite 
storage in liquid nitrogen tank.  
 
(b) Warming  
 
Warming media (Origio™, Medicult media Mellehaven 12, 4040, Denmark) was 
allowed to equilibrate at 37
o
C and all other media to RT for at least 30 minutes prior to 
use.   Vitrification carrier was collected from liquid nitrogen (LN2) storage container 
and transferred to a portable vessel containing LN2 until transfer into warming media. 
Using tweezers vitrification device was held with area containing the embryo immersed 
in the liquid nitrogen whilst lid was removed, as quickly as possible, device was 
transferred to warming medium (2ml, 37
o
C) here oocytes/embryos remained for 3 
minutes.  Using a denudation pipette (Vitrolife™ AB, Kungsbacka, Sweden) embryos 
were transferred and incubated in two subsequent dilution medium containing wells 
(2ml) for 3 minutes each, and a further two wash (2ml) solutions for 3 minutes each 
(Origio™, Medicult media. Mellehaven 12, 4040, Denmark).  Oocytes/embryos were 
then transferred to appropriate equilibrated culture medium, where they were allowed 
time for post-warming recovery.   
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6.6.3.4 Vitrification of oocytes using an open based vitrification 
system  
 
(a) Vitrification- cooling  
 
Solutions supplied by Vitrolife must first be equilibrated to 37
o
C prior to use (Vitrolife 
AB, Kungsbacka, Sweden).  Samples are initially incubated in the first G-mops-like 
solution where they can remain for between 5-10 mins.  Oocytes/embryos are then 
transferred to the second solution, where they remain for a further 2 minutes.   Once 
samples have been transferred to the second solution the outer-sleeve, in which the 
Rapid-I™ is placed within during storage is plunged into the liquid nitrogen containing 
tank, with a metal rod which is supplied with each device.  The metal rod remains 
within the straw.   With 30 seconds remaining a 20µl droplet is made on the bottom of a 
falcon dish. Then with 10 seconds remaining the samples are picked up from the second 
solution using a denudation pipette and transferred to the a 20µl droplet, here they are 
then washes around the drop for 15-20 seconds with 10 seconds remaining 
oocytes/embryos are collected using the denudation pipette in a minimal volume of 
vitrification media and loaded onto the Rapid-i™ vitrification device.    
 
(b) Warming  
 
Oocytes were warmed at a later date (rehydrated using a serial dilution of sucrose).  The 
straw was cut just above the black end of the Rapid-I and the forceps used to lift the 
Rapid-i™ out of the straw (just enough to grasp with your fingertips).   Quickly the 
Rapid-I was transferred into Warm1 (ideally this should be done within 2 seconds, 
starting from the time the Rapid-i™ is removed from the liquid nitrogen).   The oocytes 
remained within Warming medium 1 for 1 minute.  Oocytes were then moved into 
warming medium 2 for 3 minutes, followed by Warming medium 3 for 5 minutes and 
finally into Warming medium 4 for 5 minutes.   They were then transferred to an 
appropriate pre-prepared culture dish containing G-IVF culture media (Vitrolife™, 
Gothenburg, Sweden) for recovery.   
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6.6.4 Parthenogenetic activation  
 
Here all activations were performed in 4-well Nunc dishes.  Oocytes were initially 
incubated in G1 medium containing 1% HSA (700µl) (Vitrolife™, Kungsbacka, 
Sweden) supplemented with DMAP (7µl) (Sigma) and ionomycin (0.7µl) (Calbiochem) 
for 5 minutes, before they were transferred to the second well containing G1 medium 
containing 30%HSA(700µl) and DMAP (7µl) for a further 5 minutes, oocytes were then 
transferred to a third well containing  G1 medium containing 10% HSA supplemented 
with DMAP (7µl) here they remained for 5 hours.   Oocytes were finally transferred to 
the last well containing G1+HSA (700µl) and here they remained until they were 
checked the following morning for signs of PN development.  Successfully activated 
oocytes were cultured in G1 medium containing 10% HSA until day 3 of development 
and were then transferred to G2 medium containing 10% HSA until day 7. 
 
6.6.5 Imaging metaphase II (MII) spindle  
 
Metaphase II oocytes were transferred to a glass bottom dish containing G1v5 Plus 
medium (Vitrolife, Gothenburg, Sweden). Oocytes were immobilised with a holding 
pipette and the spindle visualized using polarized light birefringence (Oosight Meta 
Imaging System, Cambridge Research and Instrumentation, CRi). 
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6.7 Results  
 
6.7.1 Vitrification of abnormally fertilised human zygotes using an open 
vitrification system  
 
In the first part of this study I examined the ‘open vitrification’ system (McGill 
cryoleaf™ Origio) (Fig6.3).  This requires direct submergence of the vitrification device 
in liquid nitrogen before a protective sleeve, which pulls down over the sample provides 
some degree of protection with LN2 during storage.  Using this approach the cooling 
rate can reach up 23,000
o
C/min, and a warming rate of up to 42,000
o
C/min (Kuwayama, 
2007).    However the protective sleeve the device is fitted with is not heat sealed and 
therefore samples are still exposed to liquid nitrogen in a capacity which prevents this 
from being recognised as a ‘closed vitrification’ device.  
  
The open vitrification system (Origio method) utilises a two-step vitrification protocol 
to achieve successful vitrification, including an initial equilibration and a second 
vitrification solution.  The equilibration solution contains the cryoprotectants at a 
significantly lower concentration (7.5% ethylene glycol and 1, 2-propanediol) allowing 
zygotes to be exposed to this solution for an extended period of time (5-15minutes).   
Before they are then exposed to the actual vitrification solution which contains the 
cryoprotectants at a higher working concentration (15% ethylene glycol and 1, 2-
propanediol).   Exposure to the vitrification solution should not exceed 1 minute due to 
the presence of the cryoprotectants at a higher concentration.   
 
I conducted a pilot study using the open vitrification system where I vitrified a number 
(n=25) of abnormally fertilised zygotes (1PN and 3PN) for which I later assessed 
survival and development.   Initial overall survival attainable was low at 48% 
(n=12/25).   This was whilst following the protocol supplied with the vitrification 
solutions which stated embryos could be incubated for between 5-10 minutes within the 
first equilibration solution before transferring to the vitrification solution.  Following 
these guidelines once initial shrinkage (indicative of dehydration) and re-expansion of 
the embryo to its original pre-vitrified state has been observed embryos could be 
transferred to the second vitrification solution.  However the time taken for zygotes to 
shrink and re-expand often varied between zygotes and required continual monitoring.  
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On multiple occasions I observed rapid shrinkage and re-expansion of zygotes, which 
was often accompanied by ‘blebbing’ around the cytoplasmic membrane, and ultimately 
reduced survival.  Resulting in a number of zygotes degenerating during the actual 
vitrification procedure (n=20) (Fig6.4).   
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Fig6. 3 McGill cryoleaf® vitrification device  
Above images represent the ‘open system’ vitrification device, which acts to 
increase the cooling rate via direct contact with the liquid nitrogen (McGill 
cryoleaf™, Origio Mellehaven 12, 4040, Denmark).   
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Fig6. 4 Observations of embryos following exposure to the ‘open 
system’ vitrification solutions  
Several zygotes (a) failed to re-expand and (b) lysed and (d) degenerated 
following incubation in the initial equilibration solution.  Scale bars, 
50µm.   
 
  
 
a 
c d 
b 
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6.7.2 Optimization of the ‘Open vitrification system’ protocol  
 
In light of the poor survival I took several steps to optimise the protocol supplied with 
the ‘open vitrification system’.   This included; increasing the volumes of both the 
equilibration and vitrification solutions used to vitrify with from 250µl to 500µl.  The 
number of zygotes vitrified per set of solutions (500µl equilibration and vitrification 
solutions) was reduced to 4 zygotes.    This was implemented due to concerns over 
potential for dilution of vitrification solutions when transferring the zygotes in culture 
media and also between the vitrification solutions.   As this could potentially alter the 
composition of the media and in particular the active components (permeating and non-
permeating cryoprotectants) key to achieving successful vitrification could be altered 
rendering them useless.   
 
The exposure time to the equilibration solution was extended to a maximum of 15 
minutes.   If zygotes had not fully re-expanded beyond which point a note was made 
and zygotes were vitrified regardless.   However there is a consensus opinion that those 
zygotes which fail to undergo shrinkage and re-expansion during 15 minutes of 
exposure to the equilibration solution is indicative of a poor outcome and such that 
(Personal communication, Lyndon Miles) (Fig6.4 and Fig6.5).    
 
Further attempts were made to minimize the volume of vitrification medium in which 
the zygotes were loaded onto the vitrification device prior to submerging.   This was 
achieved by dragging away excess media by creating a small channel of excess media 
once the zygote had been placed onto the tip of the flange where zygotes are to be 
loaded.   This was then removed using the same glass denudation pipette used to load 
the zygotes onto the vitrification device so as to leave only a thin film of vitrification 
media covering the zygote before the final plunge into liquid nitrogen.  The volume of 
liquid nitrogen used for vitrification was increased from 0.5 litres to 1 litre.  This 
ensured that devices were completely submerged following the plunge into liquid 
nitrogen and not compromised by vitrifying in the vapour phase.   
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6.7.3 Improvements in survival outcomes following modifications to the 
‘Open vitrification system’ protocol 
 
Following implementation of the revised protocol I attempted to vitrify a further n=72 
abnormally fertilized human zygotes.   This resulted in significant improvements in 
survival, where it was possible to attain obtain overall survival of 91.6% (n=66/72) for 
all those mono- and multi-pronucleate stage zygotes which survived the vitrification 
process combined.  This was almost double the survival observed during initial 
experiments (48%) using the same device but before optimisation.   Further analysis of 
the survival data gathered following implementation of the revised protocol, revealed 
that zygotes containing 1PN demonstrated reduced survival compared to those multi-
pronucleate zygotes containing 3 PN (89.7%, n=35/39 vs 93.9%, n=31/33; P>0.05 
(Fig6.6) (Table 6.1).    The trend towards reduced survival observed for the mono-
pronucleate (1PN) zygotes may be a result of physiological differences in properties in 
the membranes rendering the mono-pronucleate (1PN) zygotes more sensitive to the 
vitrification solutions.  
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Survival Rate 
Total Number 
survived 
% Survival  
1PN 35/39 89.7 
3PN 31/33 93.9 
Overall  66/72 91.6 
 
87
88
89
90
91
92
93
94
95
Overall 3PN 1PN
% survival  
Fig6. 6 and Table 6.1 Overall survival observed for abnormally fertilised 
human zygotes vitrified using ‘open vitrification system’.  
Above figure represents survival outcomes determined for those abnormally 
fertilized human zygotes vitrified using the ‘open vitrification system’.  Overall 
survival was calculated to determine the total number of zygotes which survived 
the vitrification procedure regardless of pronucleate (PN) number.  Here overall 
survival attained using the closed system was 91.6% (n=66/72).   Independent 
survival outcomes were also calculated for 1PN zygotes as, 89.7% (n=31/33) 
and 3PN zygotes as 93.9% (n=35/39). 
n=66 
n=35 
n=31 
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6.7.4 Embryo development following vitrification using the ‘open 
vitrification system’  
 
Development was assessed for those zygotes which survived the vitrification procedure 
(n=32).    I compared development data gathered for those zygotes which survived 
vitrification (n=32) to control development data gathered for non-vitrified (fresh) 
abnormally fertilised human zygotes (n=56).    Here of those zygotes vitrified 25%, 
(n=8/32) attained development to the <4-cell stage, 44% (n=14/32) the 4-8cell stage and 
31% (n=10/32) >8cell stage.  In contrast data gathered on development for a fresh non-
vitrified zygotes revealed that; 18%, (n=10/56) attained development to the <4-cell 
stage, 29% (n=16/56) the 4-8cell stage and 53% (n=30/56) >8cell stage.   Development 
observed for those embryos developing from vitrified zygotes was therefore reduced 
compared to that observed for those embryos in the control group.  However statistical 
analysis revealed that there was no statistical significant difference in the development 
attained by those vitrified and cultured embryos versus nom-vitrified and cultured 
embryos (pvalue<0.05) (Fig6.7 and Table6.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
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Fig6. 7 Embryo development following vitrification using an ‘open vitrification 
system’ (Origio™)  
Comparison of developmental attained by embryos vitrified at the PN stage and 
cultured (n= 32) (red) using the closed vitrification system; versus non-vitrified 
(fresh) cultured control embryos.  Overall development observed for embryos vitrified 
using the open vitrification system: 25% (n=8/32), <4cell stage, 44% (n=14/32), 4-8 
cell stage and 31% (n=10/32) >8-cell stage.  Development was also determined for 
those embryos treat as fresh controls, with; 18% (n=10/56) <4cell stage, 29% 
(n=16/56), 4-8 cell stage and 53% (n=30/56).                          
n=10 
n=8 
n=16 
n=14 
n=30 
n=10 
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6.7.5 Vitrification of abnormally fertilized human zygotes using a closed 
vitrification system.   
 
The Rapid-i was developed as a vitrification device that is stored in a sealed straw under 
liquid nitrogen (Larman et al, 2011).   It consists of a ploy(methyl methacrylate) rod and 
a polyvinyl chloride storage straw(Fig6.9).   At the tip of the rapid-I is a flange that 
possesses a 50nL loading hole into which the oocytes/embryos are loaded (Larman et al, 
2011).   As a closed-system this has the advantage that it prevents direct contact with 
the liquid nitrogen in so avoiding the risk posed by open-systems of the potential risk of 
contamination by micro-organisms able to survive within liquid nitrogen  However 
studies conducted using the Rapid-i™ in mouse oocytes have successfully demonstrated 
impressive survival rates and outcomes.      Usually closed-systems are associated with 
a reduced cooling rate, which has previously been shown to negatively impact upon 
survival outcomes.   However the cooling rate achieved with the Rapid-i™ which uses 
super-cooled air to vitrify has been determined as ~ 1,2000
o
C/min.  Indeed studies 
examining the device have been able to demonstrate that regardless of the fact that this 
is a fully sealed system, cell number is not detrimentally affected (equivalent to non-
vitrified controls) as a consequence.    
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Fig6. 9 Rapid-i™ ‘Closed’ vitrification device  
Above image represent the Vitrolife Rapid-i vitrification device.  This is supplied in two 
parts consisting of a thin plastic strip containing a small hole and a plastic outer straw.  
Oocytes/embryos are loaded into the hole, (50nL) on the Rapid-I device using a 
denudation pipette in the minimal volume of vitrification solution and held in place I the 
hole by surface tension. (b) Vitrification box, designed as a holding vessel for the liquid 
nitrogen, supplied by vitrolife. The box is specially designed for vitrification with the 
Rapid-i vitrification device, due to the solenoid magnet built into the box to hold the 
Rapid-i outer straw in place whilst the device during the cooling and warming stages.   
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6.7.6 Validation of temperature for the ‘open vitrification system’  
 
Vitrification media supplied with the closed vitrification system (RapidVit oocyte™ and 
RapidWarm oocyte™ media supplied by Vitrolife™) is instructed to be used at 37˚C in 
order to maintain oocytes at physiological temperature during dehydration and re-
hydration procedures.   This therefore required all vitrification steps to be performed 
upon a heated stage in order to maintain solutions at the appropriate temperature 
throughout the process.   
 
It was essential to ensure that the heated stage upon which the 4-well Nunc dish 
containing the vitrification solutions is placed during the vitrification process was 
maintained at 37
o
C so as to ensure successful vitrification outcomes.    Therefore before 
beginning to vitrify using the Vitrolife vitrification solutions we firstly validated the 
temperature of the heated stage.   Here using a thermocouple (temperature monitoring 
device) the surface temperature was measured at varying places across the surface of the 
heated stage.   The temperature did appear to fluctuate by 1-2
o
C across the surface.    
Once the area on the heated surface, identified to maintain a steady temperature of 37
o
C 
was found an area was marked out, to ensure the dish would be placed in the correct 
position during vitrification session.  Air flow was also found to lower the temperature 
on the heated stage, therefore air-flow remained switched off whilst the vitrification 
procedure was performed.   
 
Further steps were also needed to be taken to ensure that heat loss was minimised 
during the entire vitrification procedure.   This included pre-aliqouting of the 
vitrification solutions.   Vitrification solutions were supplied in vials of 10ml and 
dispensed into 1ml aliquots sterile capped tubes).  Through creating the 1ml working 
aliquots of the vitrification solutions I was further able to minimize heat loss which 
would be encountered is dispensing solutions using a gilson pipette (personal 
communication L. Hyslop).    A further advantage of creating the 1ml aliqouts was for 
improved sterility reasons.   
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6.7.7 Survival of zygotes vitrified using a ‘closed vitrification system’  
 
Overall survival was calculated for those abnormally fertilized human zygotes which 
survived vitrification using the ‘closed system’ (n=25).   Here total overall survival was 
calculated as 96% (n=24/25) (Fig6.10 and Table 6.3).   This was higher compared to 
that previously achieved using the open vitrification system 91.6% (Fig6.6 and 
Table6.2).   However statistical analysis revealed that this was not statistically 
significant (p-value= 0.6733).   Independent survival outcomes were also calculated to 
compensate for PN number.   The total survival for 1PN zygotes was calculated as 93% 
(n=13/14) and for 3PN zygotes 100% (n=11/11) survival was possible.  However only a 
small number of zygotes (n=25) were able to be vitrified using the ‘closed vitrification 
system’ due to the inconsistent nature of sample collection.  Therefore it is difficult to 
infer if PN number affected survival outcomes.   
 
6.7.8 Development following vitrification using a ‘closed vitrification system’  
 
Potential for onward development was also assessed for those zygotes which went onto 
cleave successfully following warming (n=16).  Development obtained by those zygotes 
vitrified and warmed using the ‘closed vitrification system’ was compared to control 
data obtained for non-vitrified cultured zygotes.    Of those vitrified zygotes which 
survived and demonstrated developmental potential (n=16) a total of 18% (n=3/16) 
attained development to the <4-cell stage, 13% (n=2/16) to the 4-8cell stage and 69% 
(n=11/16) >8cell stage.   This contrasted to the control developmental data gathered for 
non-vitrified zygotes (n=56), with 18% (n=10/56) attaining development to the <4-cell 
stage, 29% (n=16/56) the 4-8cell stage and 53% (n=30/56) >8cell stage (Fig6.12 and 
6.12) (Table6.4).  Statistical analysis revealed that there was no statistical significant 
difference in the development attained by those vitrified and cultured embryos versus 
nom-vitrified and cultured embryos (p value<0.05).   
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Survival Rate 
Total Number 
survived 
% Survival  
1PN 13/14 93 
3PN 11/11 100 
Overall  24/25 96 
Fig6. 10 and Table 6.3 Overall survival observed for abnormally fertilised 
human zygotes vitrified using a ‘closed vitrification device’ 
Above figure represents overall survival obtained for abnormally fertilized 
human zygotes vitrified using the closed vitrification system.  Overall survival 
was calculated to determine survival regardless of pronucleate (PN) number 
and determined as 96% (n=24/25).  Development data was further analysed to 
compensate for PN number and its effect on survival.   The overall survival 
calculated for 1PN zygotes was 93%, (n=13/14) and for 3PN zygotes, 100% 
(n=11/11).   
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Fig6. 12 Comparison of development attained by embryos vitrified at the 
PN stage using the ‘closed’ vitrification system versus non-vitrified (fresh) 
controls. 
 Above figure represents comparison of development observed for fresh 
cultured embryos (control) (blue) versus vitrified and cultured embryos (red), 
vitrified at the PN stage using the closed vitrification system (vitrolife 
vitrification solutions and Rapid-i™).  Overall development observed for 
zygotes vitrified using the closed vitrification system was as follows; 18% 
(n=3/16), <4cell stage, 13% (n=2/16), 4-8 cell stage and 68% (n=11/16).  
Development was also determined for those zygotes treat as fresh controls, 
with; 18% (n=10/56) <4cell stage, 29% (n=10/56), 4-8 cell stage and 53% 
(n=30/56) (p value>0.05).   
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6.8  Premature pronuclear (PN) breakdown observed following warming of 
abnormally fertilized zygotes vitrified using an ‘open’ versus ‘closed’ 
vitrification system  
 
Following initial studies it soon became apparent that the time the pronuclei remained 
visible following warming and recovery (~2hours) varied considerably between the 
abnormally fertilised human zygotes vitrified.  This we believed was influenced by the 
time they were able to be vitrified and which was subsequently dependent upon the time 
they were inseminated/fertilized the previous day and finally the time fertilisation 
checks were conducted and the zygotes able to be consented for use in the research 
study.   From the initial study I conducted using the open vitrification system a 
significant number underwent pronuclear breakdown within a short time immediately 
following warming (n=22) or whilst in the recovery dish (n=15).  This subsequently 
dictated the overall number of zygotes which could be considered to attempt 
manipulations with so as to determine if this was still possible to perform using zygotes 
which had been vitrified.  Overall n=15 zygotes still contained visible pronuclei 
following warming and recovery for the open vitrification system.  This compared to a 
total of n=14 zygotes using the closed vitrification system.  Therefore despite the good 
overall survival able to be achieved for zygotes vitrified using both the open and closed 
vitrification systems, the potential to manipulate zygotes following warming and 
recovery is significantly compromised due to the limited time which pronuclei are 
visible for before they undergo PN breakdown.  This is a factor which I did try to 
compensate for by making efforts to vitrify the zygotes as soon as from the time I 
received them however despite these efforts the overall number of zygotes which 
retained pronuclei was still relatively low.  Given the risk that this might compromise 
the use of vitrified zygotes for the purpose of the pronuclear transfer technique, we did 
also explore the potential of vitrification at the MII stage (as discussed in chapter) to 
determine if this may provide an alternative route to bank oocytes from patients for 
future use when the technique has been established for clinical use (Fig6.12).  
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Open vitrification 
system  
Closed vitrification 
system  
% of zygotes containing visible 
PN immediately following 
warming  
69% (50/72) 87.5% (21/24) 
% of zygotes containing visible 
PN following ~2hr recovery 
period 
50% (15/30) 66.6% (14/21) 
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warming
% of zygotes containing visible
PN following ~2hr recovery
period
Open vitrification systen
Closed vitrification system
Fig6. 13 and Table 6.5 Comparison of PN breakdown following warming 
and recovery of abnormally fertilised human zygotes vitrified using the 
‘open’ versus a ‘closed’ vitrification system  
 Above figure depicts the percentage of zygotes which retained visible pronuclei 
immediately following warming and those zygotes for which pronuclei could 
still be observed within after the 2hour minimum recovery period.  This was 
analysed for zygotes vitrified using both the open vitrification system (blue) and 
closed vitrification systems (red).   
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6.9 Vitrification of oocytes  
 
6.9.1 Vitrification of oocytes using a ‘open’ vitrification system  
 
Initially a small number of oocytes (n=15) were vitrified using the open vitrification 
system.   However the overall number of oocytes which survived upon warming was 
low, with a number of the oocytes noted to have suffered cryoinjuries, most likely as a 
result of sub-optimal vitrification.    Here cryoinjuries are defined as visible 
morphological damage, which include the; vacuole-like structures within the cytoplasm, 
shrinkage of the cytoplasm away from the zona pellucida and granularistion and 
darkening of the cytoplasm (Fig6.14).   
Previous studies have shown that these cryoinjuries result from either increased 
exposure time to the cryoprotectants during the cooling process.   In an attempt to 
prevent cryoinjuries occurring and improve survival, several modifications were made 
to the vitrification protocol supplied with the open vitrification system.   This included 
increasing the time the oocyte was incubated within the first equilibration solution.  
Upon warming we adjusted the time spent in each of the warming wash solutions, in the 
hope that by increasing the time spent in the wash solutions this may help to improve 
removal of the permeating cryoprotectants from the oocytes.   
Following implementation of the modifications overall survival increased from 46% 
(n=7/15) to 60% (n=30/50).    
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Fig6. 14 Images of oocytes which did not survive the vitrification process when 
vitrified using the initial protocol supplied with the ‘open’ vitrification system. 
Above images represent the various types of cryoinjuries which were encountered in 
the initial attempts undertaken to vitrify failed to fertilize oocytes.  These included 
degeneration upon warming(a) vacuole-like structures within the cytoplasm of oocytes 
and embryos(b), cytoplasmic disturbances, most likely as a result of ice crystal 
formation within the cytoplasm (d) and(e) .   
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Fig 6. 15 Observing the spindle in vitrified and warmed MII stage oocytes  
Above image confirms presence of intact spindle (indicated by red arrow) (a) 
imaged for a vitrified and warmed mature oocyte, using Oosight. (X40, 
magnification)  (b) DIC image of the same vitrified oocyte. 
a b 
  
 2 2 9  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fresh Oocytes 
(21) 
Vitrified and Warmed 
Oocytes (30) 
Overall survival  
30  50  
Overall survival  
- 30/50 (60%) 
spindle  Present 
12/21 (57%) 20/25 (80%)   
Activation potential 
8/12(66.6%) 12/20(60%) 
Table6.8 Survival outcomes following vitrification using an open based 
vitrification system (Origio™ method) 
 
 The above table represents the current outcomes with regards to the vitrification of 
metaphase II stage oocytes.  Here we vitrified a total of 30 oocytes, which we 
subsequently warmed at a later date.  Upon warming these embryos were graded 
upon the morphological criteria we have previously described (Fig4.3).  Oocytes 
vitrified using the open vitrification system demonstrated 60% survival.   A select 
number of oocytes which survived (n=30) were then examined for the presence of a 
spindle using polarized light birefringence (Oosight Meta Imaging System, 
Cambridge Research and Instrumentation, CRi).    A number (n=20) of those 
oocytes which were found to contain a spindle were the n considered for 
parthenogenetic activation (n=12/20).   We also non-selectively allocated a number 
of oocytes to a control group, which were also checked using polarized light 
birefringence and once again a select number found to contain visible spindles 
parthogenetically activated.   
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6.9.2 Parthenogenetic activation  
 
Those mature oocytes which survived the vitrification and warming process and later 
found to contain a spindle when imaged using polarized light birefringence (Oosight 
Meta Imaging System, Cambridge Research and Instrumentation, CRi).were then 
considered for parthenogenetic activation (n=20)(Fig6.15 and Fig6.16) and (Table 6.8).  
Parthenogenetic activation can be induced in mammalian oocytes by a diverse range of 
chemical compounds and physical conditions (Gook et al, 1995).  A number of these 
chemicals contain hydroxyl (–OH) groups, and our commonly employed as 
cryoprotectants including propane-2-diol (PROH), which has previously been shown to 
be a potent parthenogenetic activator of mouse oocytes (Cuthbertson, 1983; Shaw and 
Trounson, 1989; Van der Elst et al, 1992; Gook et al, 1995).  Several Metaphase II 
(MII) stage oocytes were determined to have undergone spontaneous activation 
following warming without intervention (n=8). However we did attempt to activate a 
number of oocytes (n=20) vitrified using the open vitrification system which were 
known to have retained their spindle.   Indeed we were successfully able to activate a 
number of the vitrified oocytes, which we determined by the appearance of a pronuclei 
the following day (n=12/20(60%) (Table6.8).   Unfortunately in vitro development 
observed following parthenogenetic activation was poor, although we cannot be sure if 
this was related to the vitrification process or the parthenogenetic activation and 
exposure to chemicals used for this purpose.  However several demonstrated an attempt 
to cleave, and some even developing to morula stage (n=2).  However due to the high 
degree of fragmentation and poor morphology of these embryos cell number was often 
difficult to judge.   
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6.9.3 Vitrification of oocytes using a closed vitrification system   
 
A closed vitrification system was also investigated for its potential to vitrify oocytes and 
determine if this could further improve on survival attained when vitrifying oocytes 
using an open vitrification system.   Initially survival was low with a significant number 
of oocytes degenerating during the warming procedure.  This was believed to be due to 
issues involving oocytes floating to the surface of the warming media attached to 
bubbles which were believed to be introduced during the loading of oocytes onto the 
vitrification device.    This ultimately resulted in suboptimal warming conditions as 
oocytes were not fully exposed to the warming media and therefore degenerated as a 
result.   Those oocytes which were attached to bubbles were unable to be visualized 
upon submersion of the vitrification device into the initial warming solution.   In order 
to overcome this issue greater care was taken when loading the oocytes onto the 
vitrification devices in order to avoid the introduction of bubbles.   Attention was also 
paid when warming oocytes and in particular transferring the vitrification device 
containing the oocyte into the first well containing the initial warming solution.   Here 
the device was fully submerged in the well and not removed until the oocyte was 
visualized to have left the device, residing within the warming solution.    
 
6.9.3.1 Oocyte survival using a closed vitrification system 
 
Here we vitrified a number of oocytes (n=42) which included follicle reduction, in vitro 
matured (IVM) and failed to fertilize oocytes.  These were then warmed (over a period 
of 3months) resulting in overall survival of 95.2% (n=40/42) (Table6.9).    Oocytes 
were judged to have survived if they regained their pre-vitrified state, which included a 
fully intact zona pellucida,   homogenous cytoplasm, lack of apparent incremental 
increase in inter-membrane space and no apparent cryoinjuries.     
 
6.9.3.2 Examining for the presence of a spindle in vitrified 
oocytes using the imaging software Oosight™ 
 
Where possible oocytes were imaged using the Oosight™  imaging software (CRI, ) to 
check for the presence of a spindle prior to vitrification however this was not always 
possible (if oocytes were vitrified within the clinical laboratory).   A significant number 
 2 3 3  
 
of those oocytes which were found to contain spindles prior to vitrification were also 
found to contain spindles when checked following warming, 87.5% (n=35/40)(Fig6.17).   
 
6.9.4 Fertilisation potential of vitrified oocytes obtained from follicle 
reductions  
 
A number of oocytes (n=13) obtained from follicle reductions were also warmed, and 
following adequate recovery time (~2hours) were imaged to check for the presence of a 
spindle using oosight (Research Instruments, Cornwall).    Those oocytes which had 
good general morphology ad found to contain an intact spindle were then used to 
attempt fertilisation with (n=13).  Here intracytoplasmic sperm injection (ICSI) was 
used to fertilize warmed follicle reduction oocytes, in favour of regular in vitro 
fertilization (IVF) due to the hardening of the zona pellucida regarded as an artefact of 
the cryopreservation process. (ICSI was performed by embryologists (L.Hyslop and 
S.Byerley).     Fertilisation checks were performed the following morning (8am) to 
check for the presence of pronuclei (PN).   A number of oocytes (n=8), which 
underwent ICSI, underwent normal fertilization as deemed by the presence of 2 
pronuclei (n=6).   
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 Vitrified oocytes 
Number oocytes vitrified 42 
Total number of oocytes 
warmed  
100% (42) 
Survival rate following 
vitrification  
95.2% (40/42) 
Total number containing 
spindle after warming  
87.5% (35/40) 
Table 6.9 Vitrification outcomes for those oocytes vitrified and warmed 
using a closed vitrification system (Vitrolife™ oocyte vitrification 
specific solutions and Rapid-I™ vitrification device) 
 
Here a number of oocytes were vitrified (n=42), these included failed to 
fertilise (0PN) and in vitro matured oocytes in order to determine the 
efficiency and feasibility of the closed vitrification system.  Overall 
recovery following warming of vitrified oocytes was encouraging with 
100% recovery achieved and overall survival of 95.2% (n=40/42).  All 
oocytes which survived following warming were also examined for the 
presence of a spindle (n=40) >80% (87.5%, n=35/40) were found to contain 
a spindle when imaged using polarized light birefringence (Oosight Meta 
Imaging System, Cambridge Research and Instrumentation, CRi). 
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Fig6. 17 Images of vitrified and warmed Metaphase II (MII) stage oocytes 
using a closed based vitrification system (Vitrolife™ vitrification 
solutions and Rapid-I™ vitrification device)  
Above images represent a follicle reduction oocyte which was vitrified using 
the closed vitrification system (Rapidvit oocyte and then warmed using 
Rapid-warm oocyte media, Vitrolife™).  Following ~2hours recovery the 
warmed MII oocyte was examined using oocyte to check for the presence of a 
spindle (a) The MII oocyte was then fertilised using ICSI (vitrification causes 
hardening of the zona pellucida, making conventional IVF not possible) (c) 
The following morning fertilisation checks were made and two pronuclei 
identified.   
 
a b c 
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6.10 Discussion  
 
The ultimate purpose of this study was to examine the efficiency and feasibility of 
vitrification at the metaphase II versus the pronucleate (PN) stage zygote.    
 
In 2010 a paper was published which demonstrated the feasibility of the nuclear transfer 
technique pronuclear transfer (PNT) for preventing the transmission of mtDNA disease 
(Craven et al, 2010).    All of the studies performed to date to examine the technique 
have used abnormally fertilized human zygotes, which are known to demonstrate a 
limited potential for onward development due to their abnormal chromosome 
complement (Personal communication L.Hyslop).    Thus, in order to progress further 
with the research and better assess development and safety concerns regarding the PNT 
technique, studies must now be performed using normally fertilised zygotes.   
 
Following the granting of the appropriate research licence by the HFEA it was made 
possible to create embryos, and use those which fertilize normally to assess the PNT 
technique.  A recruitment drive is now underway to attract potential egg donors.   
However this has presented a logistical problem, for several reasons.  As in order to 
perform PNT and assess mtDNA carryover to assess the success of the procedure, 
oocytes from two different egg donors would be required on the same day.  This would 
therefore require to egg donors to undergo synchronous ovarian stimulation, so as to 
acquire oocytes from two different patients on the same day.   However it is known that 
each individual’s response to ovarian stimulation programmes differs considerably and 
therefore it is highly unlikely that both patients would be ready for egg collection on the 
same day.   There is also likely to be a discrepancy in the number of oocytes retrieved 
from patients and therefore a high degree of wastage if we are not able to maximize 
their use.   It is therefore imperative that a successful cryopreservation strategy is in 
place so as to be in a position to store either the pre-fertilized ‘metaphase II’ stage 
oocyte or following fertilization at the ‘PN zygote’ stage. I therefore set out to 
investigate the potential of vitrification at both the metaphase II oocyte and pronuclear 
(PN) stage zygote, in order to determine which would provide the highest post-thaw 
survival outcome.   
 
Initially I investigated vitrification at the PN zygote stage.    The PN stage is a unique 
stage during embryonic development which marks the transition from oogenesis to 
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embryogenesis.  Here upon successful fertilization of an MII stage oocyte, the maternal 
and paternal nuclear DNA become visible as round membrane bound strictures, referred 
to as pronuclei.    The presence of DNA within ‘membrane bound structures’ at the PN 
stage had led to the suggestion that it could potentially prove to be the optimal 
embryonic stage to cryopreserve embryos clinically (Damario et al, 1999; Orief et al, 
2005).    Indeed several studies have now examined cryopreservation, at the pronucleate 
stage using both controlled rate freezing and vitrification with much reported success 
(Veeck et al, 1993; Damario et al, 1999; Park et al, 2000; Damario et al, 2000; 
Isachenko et al, 2005; Orief et al, 2005; Kuwayama, 2005, 2007).   However the PN 
stage zygotes unfortunately lacks distinctive morphological features which allow for 
successful grading prior to vitrification.   Attempts have been made in the past to try and 
help establish a set of criteria which could be used in the establishment of a grading 
scheme for the PN stage zygote.  Criteria which have been suggested could be used 
include; the position of the pronuclei in relation to the second polar body , the size and 
number of nucleoli within the pronucleus (Garello et al, 1999; Wittemer et al, 2000; 
Scott et al, 2000; Balaban et al, 2001; Payne et al, 2007).   
 
Although even using these suggested schemes (Zygote scoring or Z-scoring) to grade at 
the PN stage, the grades agreed are not always highly accurate and the process can 
prove extremely time consuming.  It therefore proves an incredibly difficult task to 
select zygotes for cryopreservation, compared to the selection of embryos at other 
embryonic stages (for example the cleavage and blastocyst stage) where successful 
grading schemes have been established.  This has therefore limited the establishment of 
PN stage vitrification programmes in clinical practice as a result (Ludwig et al, 2000; 
Khalili et al, 2008).   As the majority of IVF laboratories prefer to only cryopreserve 
those embryos which have good morphology prior to vitrification and therefore are 
likely to best survive the cryopreservation procedure, there are also cost and storage 
implications too.    However my main reason for exploring vitrification at the PN stage 
was for the purpose of the PNT project.  The idea that oocytes could be obtained from 
egg donors, fertilized and then cryopreserved until they could be used optimally.  
Therefore given the reports of success of cryopreservation strategies at the PN stage, it 
seems logical to explore the potential to vitrify at this stage.    
 
However the methods used in the reports published describing successful outcomes 
differ a great deal.   As there are many different approaches which have been used to 
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cryopreserve at the PN stage, including; controlled rate freezing, ultra-rapid freezing 
and more recently vitrification (Veeck et al, 1993; Damario et al, 1999; Park et al, 2000; 
Damario et al, 2000; Isachenko et al, 2005; Orief et al, 2005; Kuwayama, 2005, 2007).  
Not only did the majority of these studies use different cryopreservation strategies, 
many also used in-house designed vitrification devices and solutions, it therefore was 
not possible to adopt the same approaches previously utilised.  Furthermore due to the 
recent resurgence in vitrification within IVF laboratories, new commercially available 
devices and vitrification solutions are continually being launched onto the market each 
promising improved survival and developmental outcomes.   
 
Indeed there are many different types of vitrification systems now available 
commercially, including ‘open’ and ‘closed’ devices.    It was therefore important as 
part of this study to examine both ‘open’ and ‘closed’ vitrification systems so as to 
determine how this affected survival outcomes.   There is much evidence in the 
literature to suggest that the use of open based vitrification devices results in improved 
survival due to the higher cooling rate achieved from the direct contact with liquid 
nitrogen the devices permit (Mukaida et al, 2003; Kuwayama et al, 2005).   However 
there is a disadvantage associated with the use of ‘open’ vitrification devices as they 
introduce a potential risk of contamination by micro-organisms able to persist within the 
liquid nitrogen even at temperatures of -196
o
C (Bielanski et al, 2000, 2003, 2009).    
Therefore ‘closed’ vitrification devices offer an increased degree of safety and prevent 
the potential for contamination possible with ‘open’ based systems.  I therefore also 
investigated the potential of a closed based vitrification device known as the Rapid-I.   
This is a unique ‘closed’ vitrification device which makes use of super-cooled air in 
order to achieve survival outcomes similar in the order to those only once able to be 
achieved using ‘open’ vitrification devices.     
 
Initially I examined the open vitrification system which makes use of the McGill 
cryoleaf (Origio™). This solutions supplied with this open system comprises of a two-
step vitrification protocol, which includes an initial ‘equilibration solution’ (ES) and a 
second ‘vitrification’ (V) solution.    Zygotes/embryos are initially exposed to an 
equilibration solution containing the active cryoprotectants at a reduced concentration 
(7.5% ethylene glycol and 1, 2-propanediol) before they are incubated in a second 
solution (vitrification solution) again containing both active cryoprotectants but at an 
increased concentration (15% ethylene glycol and 1, 2-propanediol).  
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Following initial attempts at vitrifying zygotes using the open vitrification system I 
found that a considerable number of zygotes failed to fully regain their previous pre-
vitrified state within the maximum exposure time of 10 minutes to the ES.   As a result 
these zygotes proceeded to degenerate upon warming or survived but with ‘poor’ 
morphology and limited potential for onward development.     A significant number of 
embryos were also observed to have lysed and also exhibit membrane ‘blebbing’ upon 
warming.    There is evidence within the literature which have reported observing 
similar ‘membrane blebbing’ following extended exposure to vitrification solutions 
containing ethylene glycol (EG) (5mins), however this usually only occurred at high 
concentrations (>4M) (Hotamisligil et al; 1996; Valojerdi and Salehnia, 2005; 
Pogorelov et al, 2007).     It is possible therefore that the initial poor survival I observed 
for zygotes following warming was a result of prolonged exposure to the 
cryoprotectants.    However it is also likely that operator error and lack of experience 
with the technique also contributed to the reduced survival I observed.   Indeed 
vitrification is a highly skilled procedure and requires great skill and manual dexterity in 
order to ensure zygotes/embryos are not over-exposed to the vitrification solutions and 
also loaded onto the vitrification devices within time constraints and minimal volume of 
vitrification media in order to achieve high survival outcomes.  However following 
further experience with the technique and also optimisation of the conditions for the 
zygote stage of embryonic development a significant improvement in survival was able 
to be accomplished.   Here previously survival was <45% however following the 
implemented improvement survival rose to 91.6%.     
 
I therefore looked to examine the potential of a relatively new vitrification device 
known as the ‘Rapid-i™’ (Vitrolife). This uses super cooled air to improve survival 
outcomes once only able to be achieved using ‘open’ vitrification devices (Gardner and 
Larman, 2011).    In order to achieve this, the Rapid-i is inserted into the super-cooled 
air found within the straw for instantaneous vitrification before it is finally sealed at the 
open end of the straw (occasionally referred to as the post-sealing method).   This 
device also makes use of another novel adaptation a, 50nL hole present within the 
loading tip of the device.  This I found aided greatly in the loading of zygotes, allowing 
the zygotes to be loaded in the minimal volume of vitrification media and excess media 
drawn off.   Indeed minimizing the volume of vitrification solution the embryo is 
exposed to during storage, which has been shown to be result in improved survival 
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outcomes (Vajta et al, 1998; Lane et al, 1999; Kuwayama et al, 2007; Larman and 
Gardner, 2010; Zhang et al, 2011).  Here it was possible to achieve over 96% survival 
(n=24/25) with the closed based vitrification system, which was slightly higher than that 
previously achieved when vitrifying using the open vitrification system (91.6%, 
n=66/72). However a substantially greater number of zygotes (n=72) were vitrified as 
part of the study examining the potential of the open vitrification system in comparison 
to the number vitrified using the closed vitrification system (n=25).   However the 
overall survival I was able to achieve when vitrifying zygotes using both an ‘open’ and 
‘closed’ system was comparable to those previously published data (Park et al, 2000; 
Isachenko et al, 2004; Kuwayama et al, 2007)  
 
It was also important to ascertain that developmental potential was not jeopardized by 
the vitrification process. Therefore potential for onward development was assessed for 
zygotes vitrified using both systems.  Interestingly developmental potential of those 
zygotes vitrified using the ‘open vitrification system’ was lower than that able to be 
achieved by zygotes vitrified using the ‘closed vitrification system’.  Here the number 
of embryos which attained development to the >8cell stage when vitrified using the 
‘open vitrification system’ was less than half of that able to be achieved using the 
‘closed vitrification system’ (31% (n=10/32) versus 69% (n=11/16) respectively).   
Furthermore development obtained by those zygotes vitrified using the ‘closed’ 
vitrification system was comparative to the control development data with 69% 
(n=11/16) versus 53% (n=30/56) attaining development to the >8cell stage (Fig6.18) 
However it must be noted that there were differences in the number of embryos within 
each of the three groups (‘open’, ‘closed’ and non-vitrified), which may have slightly 
biased the data.   
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Fig6. 18 Comparison of embryonic development attained by embryos vitrified at 
the PN stage using an ‘open’ versus ‘closed’ vitrification system and in contrast to 
that observed for non-vitrified (fresh) cultured controls   
Comparison of development attained by embryos vitrified at the PN stage using a 
‘closed’ (n= 16) (red), versus ‘open’ (n=32) (green) vitrification system and how this 
compared to non-vitrified (fresh) cultured control embryos.  Overall development 
observed for zygotes vitrified using the closed vitrification system was as follows; 18% 
(n=3/16), <4cell stage, 13% (n=2/16), 4-8 cell stage and 68% (n=11/16).  Overall 
development observed for zygotes vitrified using the closed vitrification system was as 
follows; 25% (n=8/32), <4cell stage, 44% (n=14/32), 4-8 cell stage and 31% (n=10/32) 
>8-cell stage.  Development was also determined for those embryos treat as fresh 
controls, with; 18% (n=10/56) <4cell stage, 29% (n=16/56), 4-8 cell stage and 53% 
(n=30/56).                          
 
 
 
 
 
0
10
20
30
40
50
60
70
80
<4-cell 4-8cell >8-cell
Cultured fresh controls
Vitrified (using 'closed'
vitrification system) and
cultured
Vitrified (using 'open'
vitrification system) and
cultured
n=10 
n=3 
n=16 
n=2 
n=30 
n=11 
n=8 
n=14 
n=10 
 2 4 2  
 
However the lower survival observed with the open vitrification system was somewhat 
unexpected as open based systems are often praised for their high cooling rates, which 
promote high survival outcomes.   However there are several explanations which may 
explain the difference observed in survival development attained by zygotes vitrified 
using the ‘closed’ versus ‘open vitrification’ systems.   Firstly this may be a result of 
operator based errors.  As the those zygotes vitrified using the ‘open’ vitrification 
system were the first zygotes I had attempted to vitrify, it is therefore likely that due to 
inexperience with the technique, survival and developmental potential was 
compromised as a result.  These were said to be suitable to use at every stage of 
embryonic development from the oocyte to the blastocyst, their non-specific nature may 
have impacted on survival therefore.   It is also possible that system were not optimal 
for the vitrification of abnormally fertilized human zygotes.  Another possibility is the 
solutions used to vitrify with the open system.  This also poses the question if the 
reduced survival was a result of the starting quality of the abnormally fertilized zygotes 
used.   
 
As embryos obtained following abnormal fertilization may not have the same 
cryobiological properties and developmental potential as embryos obtained after normal 
fertilization (Noto et al, 1991; Joris et al, 1999; Park et al, 2000; Macas et al, 2011).   
However due to the scarcity and ethical issues associated with using normally fertilized 
human zygotes for validation and research purposes, the use of abnormally fertilized 
human zygotes as a model to evaluate different cryopreservation strategies is often the 
only option available.   However multi-pronuclear zygotes are known to more closely 
resemble normally fertilized (2PN) zygotes and therefore often these demonstrate 
increased potential for development compared to their 1PN counterparts (Park et al, 
2000; Isachenko et al, 2004) 
 
Another interesting finding from this work revealed a difference in the overall survival 
observed for those 3PN zygotes (93.9%) versus 1PN zygotes (89.7%) vitrified using the 
‘open’ vitrification system.    Interestingly the same observation was also made for 
those zygotes vitrified using the ‘closed’ vitrification system (1PN (82%) and 3PN 
(90%)).     Although these differences observed in survival between the 1PN and 3PN 
zygotes was not found to be statistically significant, given the low sample sizes used in 
this study, it must be considered when assessing the outcomes of this study.  Indeed 
there are reports of similar observations regarding differences in survival and 
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developmental potential between mono and multi-pronucelate stage zygotes following 
cryopreservation (Park et al, 2000; Isachenko et al, 2004; Macas et al, 2011).   It is 
possible that the slightly reduced survival observed for those 1PN zygotes is related to 
physiological differences which renders mono-pronucleate zygotes oocytes more similar 
in nature to oocytes rather than fertilized embryos (zygotes), potentially making them 
more sensitive to the vitrification process in comparison to their 3PN zygote 
counterparts.   Therefore solutions employed to vitrify oocytes best suited vitrification 
of 1PN zygotes.   However the media supplied with the ‘open’ vitrification system is 
described as a ‘one media suits all’ and can therefore be used from the oocyte right up 
to the blastocyst stage of embryonic development.   It is possible that the non-specific 
nature of the vitrification medium used when vitrifying zygotes using the ‘open’ 
vitrification system may have been altered outcomes.   
However despite the success I was able to achieve with regards to the successful 
vitrification of abnormally fertilized human zygotes, there were several issues which I 
had not previously accounted for, when assessing vitrification at this specific stage of 
embryonic development.   This included the premature breakdown of pronuclei.   This 
presents the biggest problem, as the reason for exploring vitrification at the PN stage 
was for in order to explore the potential of cryopreserving zygotes obtained from egg 
donors and mitochondrial patients.   It is also important that a cryopreservation strategy 
is optimised and in place in order to allow for zygotes to be stored until a time to allow 
for optimal PNT transfers to be performed.   This is in order to overcome issues 
surrounding synchronization and discrepancies in egg numbers.    
I found that following warming of the vitrified zygotes and allowing for adequate 
recovery time prior to manipulating it became increasingly difficult to visualize the 
pronuclei.  This was a major problem as the pronuclei in the majority of zygotes were 
breaking down before I had time to remove the pronuclei.   In some instances it was 
possible but incredibly difficult to remove the pronuclei due to the faintness of their 
membranes.   This therefore presented several problems and significantly reduced the 
overall number of vitrified zygotes I was able to use for PNT experiments with fresh 
zygotes.   
There are several explanations which may explain why I observed the premature 
breakdown of pronuclei upon warming.   The timing of the mitotic cycle can vary 
between fertilised oocytes, with the pronuclei becoming visible anywhere from 3 up to 
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20 hours after sperm entry into the oocyte and the pronuclear membrane breakdown 
occurring between 22 to 34 hours (Feenan and Herbert, 2006).      It is reasonable to 
postulate therefore that this might account for some of the variability we observed in the 
expanse of time pronuclei were visible for in zygotes following warming.  Another 
factor which may have contributed is the fact that this study made use of abnormally 
fertilised PN stage human zygotes which were only obtained once all fertilisation 
checks had been completed, and therefore the pronuclei  in some zygotes were close to 
PN breakdown prior to vitrifying.     However vitrification has previously been reported 
to impact on zygote morphology, with around 15% of zygotes failing to maintain 
pronuclear integrity after warming, which has been associated with poorer outcome).  It 
is therefore possible that the vitrification procedure was also involved in the breakdown 
of pronuclei, due to chemicals found within the vitrification solutions (e.g. 
cryoprotectants).  Cryoprotectants included within the vitrification solutions have 
previously been shown to contribute to parthenogenetic activation of oocytes upon 
warming (Gardner et al, 2007).  It is therefore possible that the cryoprotectants may 
have induced PN breakdown biologically.    
 
Due to issues encountered with premature PN breakdown upon warming I then set out 
to investigate the potential of vitrification of oocytes as an alternative to PN stage 
vitrification.   Following this approach oocytes would be stripped of cumulous cells to 
asses maturity and then vitrified if mature.  The MII stage oocytes could then be 
warmed at a later date at which time they would then be fertilized using ICSI (due to 
hardening of the zona pellucida, which prevents routine In vitro fertilization being used 
to inseminate).   This would allow greater control over the time at which oocytes could 
be fertilized, the time and day the transfer could be performed and ultimately help 
overcome the issues regarding pronuclei breakdown encountered following zygote stage 
vitrification.  
However until recently, the cryopreservation of oocytes has in the proven elusive.  This 
is due to the unique physiology of the oocyte rendering them extremely sensitive to 
changes in their external environment in particular changes in temperature which can 
lead to osmotic shock.   However recent advances in both vitrification solutions and 
devices has now made it possible to successfully cryopreserve oocytes and achieve 
good survival outcomes.   Successful cryopreservation strategies can result in overall 
survival of >90% being attained in comparison to the 50-65% with conventional slow-
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freezing (Chian et al, 2009).    Here as with the PN stage vitrification experiments I 
examined two different commercially available systems; an open vitrification system 
and later a closed vitrification system.    
 
Initial investigations using the open vitrification system (Origio™) and solutions again 
yielded poor survival outcomes.   In the initial stages it was only possible to achieve 
overall survival 45%.    Here the same solutions used to vitrify the PN stage zygotes 
supplied with the ‘open’ based vitrification system were used.  These solutions were 
formulated to allow vitrification from the oocyte all the way through to the blastocyst 
stage embryo.  Allowing clinics to invest in media which could be utilised for all stages 
of embryonic development and in so allow for the vitrification process to be streamlined 
within clinics and avoid issues surrounding confusion over different vitrification 
solutions only able to be used for specific stages of embryonic development.  The only 
aspect required to be tailored to the stage of embryonic development for which the 
solutions are to be used is the timings.   Here the time required within the equilibration 
solution (ES) differs between whether you are vitrifying oocytes, zygotes, cleavage 
stage embryos or blastocysts.  But the time required within the final vitrification 
solution remaining unchanged despite the embryonic stage.    
A similar phenomenon observed when using the same solutions to vitrify the PN stage 
zygotes was ‘membrane blebbing’ observed for several different oocytes whilst 
incubated within the first equilibration solution.  This was despite this incubation period 
within the ES solution not exceeding the recommended time given within the 
manufacturer’s protocol supplied with the solutions.   However it is possible that the 
concentration of the cryoprotectants included within the ES solution was not appropriate 
for the oocyte.   However having previously observed similar ‘membrane blebbing’ 
when vitrifying the PN zygotes using the same solutions it is more likely that this is an 
issue associated with the solutions and not the oocytes or zygotes.  In attempts to 
overcome the issues associated with ‘membrane blebbing’ I looked to alter the time 
oocytes were incubated within the ES solutions, ensuring solutions were mixed 
thoroughly before aliqouting, the temperature of the media and surface was optimal at 
the procedure was being performed at.       
There are other steps that can be taken to help improve survival outcomes. This includes 
observing oocyte shrinkage and re-expansion whilst exposure to the equilibration 
solution.   It is recommended that oocytes should be completely shrunken after 3–6 
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from initial exposure to the equilibration solution. After this, oocyte shape should start 
to recover, with full recovery expected within 9–15 min.   For human oocytes, full-size 
recovery seems to be extremely important for the success of the warming procedure: if 
they have still not re-expanded to at least >75% of their original size, survival prognosis 
is low (Personal communication, Lyndon Miles).    
I was only able to achieve 60% survival when vitrifying oocytes using the ‘open’ 
vitrification system.  This survival was good but still not optimal and would result in 
great oocyte wastage.  Therefore it was essential to examine other approaches in ana 
attempt to achieve higher survival outcomes.  I therefore examined the potential of a 
closed vitrification system, for oocyte vitrification (Vitrolife™ vitrification solutions 
and Rapid-I™ vitrification device). This provided the same benefits as described 
previously when using this system to vitrify at the PN stage.    Indeed using the ‘closed’ 
vitrification system and oocyte specific vitrification solutions it was possible to achieve 
92.5% overall survival for those oocytes vitrified using this system (Fig6.19).     
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Fig6. 19Comparison of survival observed for oocytes vitrified 
using an ‘open’ versus ‘closed’ vitrification system  
 
Above graph depicts the percentage survival obtained for oocytes 
vitrified using an ‘open’ (n=30/50) 60% versus ‘closed’ vitrification 
system (n=40/42) 95.2%.   
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There are several explanations as to why I was able to achieve higher overall survival 
when vitrifying using the ‘closed’ vitrification system.   It is possible that this increase 
was attributable to the oocyte specific formulated equilibration and vitrification 
solutions supplied by the same manufacturer.   This may therefore explain the lower 
survival outcomes achieved when vitrifying with the ‘open’ system as the vitrification 
solutions non-stage-specific.   Allowing them to be used to vitrify; oocytes, zygotes, 
cleavage and blastocyst stage embryos.  This is because each stage of embryonic 
development is known to possess different and unique physiology, therefore where one 
solution might best suit one stage of embryonic development it may not be best suited to 
all stages inclusively.   It is therefore likely that the main reason for the difference in 
survival able to be achieved when using the different vitrification systems was 
influenced by the vitrification solutions.    
 
Oocytes are known to exhibit differences in membrane permeability compared to 
embryos, which may affect the diffusion of cryoprotectants into the oocyte (Gardner et 
al, 2007).   This is also a problem encountered with blastocyst stage vitrification and 
negatively affects survival outcomes (Vanderzwalmen et al, 2003; Kader et al, 2009).  
Oocytes are also known for their high water content which may also impact upon the 
time oocytes are required to be incubated within the ES solution in order to ensure that 
the cryoprotectants have been able to fully penetrate the oocyte and avoid the potential 
for ice crystal formation if not fully re-hydrated prior to vitrification.   It is therefore 
incredibly likely that due to a combination of using oocyte specific vitrification 
solutions and performing the vitrification process at 37
o
C improvements in overall 
survival were achieved.  
It is possible that survival outcomes could be improved further in attempts to achieve 
100% survival and minimize oocyte wastage by employing strict pre-freeze 
morphological criteria in order to assess oocyte quality prior to cryopreservation and 
ensure only good quality oocytes are selected.    Screening criteria can include; zona 
pellucida thickness, size of perivitelline space, oocyte shape, cytoplasm colour and 
granularity, presence of vacuoles and first polar body morphology. It has also been said 
that those high-quality MII oocytes suitable for cryopreservation are colourless and of 
regular shape, with regular zona pellucida and small perivitelline space without debris, 
homogeneous cytoplasm and no vacuoles or granulations (De Sutter et al., 1996, Xia, 
1997, Ebner et al., 2003, Parmegiani et al., 2008, Parmegiani et al., 2011).  
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At metaphase II, the maternal chromosomes are held suspended close to the cortex of 
the oocyte by a network of microtubules, called the meiotic spindle (Gardener et al, 
2007).    It is critical to ensure correct physical segregation of the chromosomes 
following polar body extrusion and the successful completion of meiosis in so ensuring 
the oocyte has the correct complement of genetic material (Gardner et al, 2007).    It 
was therefore important to ascertain for those oocytes which survived with good 
morphology that they had also retained a spindle upon warming.  Another reason it was 
important to ascertain that oocytes retained a visible spindle upon warming was due to 
concerns that the cryoprotectants included in the vitrification solutions, predominately 
the alcohols (ETOH and PrOH), are able to induce microtubule depolymerization 
(Vincent et al, 1990; Gook et al, 1993; Zenzes et al, 2001).    
In order to examine the presence of a spindle within the oocytes following warmed I 
used polarized light birefringence (Oosight Meta Imaging System, Cambridge Research 
and Instrumentation, CRi)    Polarized light microscopy uses liquid crystal optics to 
allow visualization and imaging of the meiotic spindle in living, unfixed MII stage 
oocytes, without compromising viability (Liu et al, 2000; Wang et al, 2001a; Rienzi et 
al, 2004; Gardner et al, 2007).    This technique has therefore made it possible to 
visualize changes which can occur in the meiotic spindle following freezing and 
thawing, which may have been missed previously using conventional fixation and 
staining procedures.   More importantly it allows for those oocytes for which a spindle 
has been visualized to be fertilized using ICSI and development assayed, which would 
not be possible if oocytes had to be fixed using PFA to examine the spindle.     
Indeed upon warming I was able to observe a spindle in a high percentage of oocytes I 
vitrified using the ‘open’ (80%) and ‘closed (87.5%) vitrification systems.    I also 
found that in those oocytes I vitrified using the ‘closed’ vitrification system the spindle 
was visible almost immediately following warming and occasionally even appeared 
brighter than its pre-vitrified spindle.   Indeed studies have shown that when human 
oocytes are vitrified involving an exposure to vitrification solutions at 37
o
C, the meiotic 
spindle remains intact (Larman et al, 2006).     It may therefore be the fact that 
combined effect of the super-cooled air used and the temperature (37
o
C) the solutions 
are held while vitrifying and warming encourage spindle integrity and therefore further 
suggest are best suited to achieve successful oocyte vitrification.    
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A number of oocytes which survived following vitrification and warming with good 
observable morphology and a visible spindle were then considered for parthenogenetic 
activation. Parthogenesis is considered as the growth and development of embryos 
without fertilization by a male (Taupin, 2011). It occurs naturally in some species and 
can be induced artificially in vitro through the use of chemicals (Taupin, 2011). A 
significant number of those oocytes which I attempted to activate parthenogentically, 
went onto develop pronuclei. However development was often perturbed and ‘blastic’ in 
nature. The perturbed development I observed was most likely due to issues relating to 
current parthenogenetic activation protocols and the chemicals used to achieve this 
artificial activation. The imaging software used to image the spindle within the oocytes 
has a very low resolution, only allowing it to only be visualized as a flashing light 
within the oocyte.   Therefore due to the low resolution it is possible that the spindle 
may have been scattered in some of the oocytes I attempted to activate using the 
chemical activation protocol, which would also explain the perturbed development I 
observed for some of these oocytes.  Indeed similar studies who have examined in vitro 
development following parthenogenetic activation of oocytes also reported lower 
morphological grade embryo development following chemical activation, with a 
significantly lower proportion going onto cleave on day 3 (Paffoni et al, 2007).    As 
fresh oocytes were not available to perform this study it is also worth noting that the 
oocytes I used in this study to examine oocyte vitrification were either in vitro matured 
(IVM) oocytes matured overnight or failed to fertilize oocytes, obtained three days 
following fertilization checks.   This may have also affected outcomes in particular 
spindle integrity in failed to fertilize oocytes may have been compromised and likely 
prone to scattering by the time they were used.   
At a later date we did also attempt to fertilize a number of oocytes which we had 
vitrified using the vitrification solutions, supplied by Vitrolife. This was only possible 
to now perform following receiving an HFEA license to perform ICSI for training 
purposes. Therefore those oocytes which were deemed to have good visible 
morphology, no observable cryoinjuries and visible spindle were used to attempt 
intracytoplasmic injection (ICSI). A number of these oocytes successfully went onto 
develop pronuclei, when fertilization checks were made the following morning. Almost 
all those embryos which successfully developed PNs went onto cleave, however 
development to the blastocyst stage was low. However when considering the 
development we observed with these embryos there are several factors we must allow 
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for. The rig that was used to perform the ICSI procedure was not equipped with 
Hoffman optics. The Hoffman Modulation Contrast system is designed to increase 
visibility and contrast in unstained and living material by detecting optical gradients (or 
slopes) and converting them into variations of light intensity 
(http://www.olympusmicro.com/primer/techniques/hoffman.html). This aids in the 
selection process of single sperm, to be used in the ICSI procedure, which is usually 
performed using morphology based criteria. Therefore the sperm selected for injection 
for those vitrified oocytes in this study was done so under sub-optimal conditions and 
may have impacted upon in vitro development observed. Furthermore the media used to 
hold the warmed oocytes and sperm preparation in during the ICSI procedure under 
normal circumstances would be G-MOPS (within the clinical lab) however this was 
substituted and G1v5plus used instead. G-MOPS is a HEPES buffered medium which 
allows for samples to be held at room temperature safely, G1v5plus however is not 
HEPES buffered and therefore requires to maintained in a modified environment which 
is held at 37
o
C and supplied with C02. Therefore in substituting the media used to hold 
the samples during ICSI sperm quality may have been impaired and in future it may 
well be more appropriate to use G-IVF culture media instead of G1v5plus as this is 
specifically formulated for the handling of gametes. Although development was reduced 
in the vitrified and ICSI oocytes it was significantly better than that previously observed 
following parthenogenetic activation of oocytes.  
Oocyte vitrification followed by ICSI has been shown is not inferior to fresh 
insemination procedures, with regards to both fertilization and embryo development 
rates and has been reported following several similar independent studies (Kuleshova et 
al, 1999; Yoon et al, 2003; Kuwayama et al, 2005; Rienzi et al, 2010). This study 
published examined embryo development in fresh versus vitrified mature oocytes 
following ICSI through a prospective randomized sibling-oocyte study. Here the 
fertilization rate obtained with fresh oocytes was determined as 83.3% (100/120) in 
comparison the fertilization rate (2PN) achieved with the vitrified and warmed group 
per sibling oocyte was determined as 76.6% (95/124). In all cases for both the fresh and 
warmed oocytes a total of three oocytes were made available for ICSI procedures. Fifty 
four patients (43.2%) were confirmed to have obtained a clinical pregnancy following a 
fresh cycle, of these 48 are on-going (beyond 12 weeks) (38.8%). Of the confirmed 
clinical pregnancies recorded in the vitrified and warmed group (37.5% per cycle and 
38.5% per embryo transfer) 12 were currently on going at the time of publishing (as 
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given beyond 12 weeks of gestation) (30.0% per cycle and 30.8% per embryo transfer). 
This study utilized the cryotop vitrification device and media also supplied by the same 
company as the vitrification device Kitazato, which is marketed on the premise of its 
specific formulation for the vitrification of oocytes. The sample size of oocytes included 
in this study was much larger than our study however it does successfully demonstrate 
the strong potential of vitrified oocytes. 
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Chapter 7 Pronuclear Transfer (PNT) performed between vitrified 
and fresh abnormally fertilized human Zygotes 
 
7.1 Introduction  
 
After establishing it was possible to vitrify abnormally fertilized PN stage zygotes, the 
next aim was to determine if it was possible to manipulate using vitrified zygotes.  It 
was also important to establish if mtDNA carryover was affected when using vitrified 
zygotes.  Therefore for those zygotes which survived the manipulation process and 
showed onward development, mtDNA carryover analysis was performed.     
 
7.1.1 MtDNA Heteroplasmy following Pronuclear Transfer performed using 
mouse embryos 
 
Studies have examined the PNT technique using mice carrying a large-scale mtDNA 
deletion (mito-mice) (Nakada et al, 2001).  The average level of mtDNA carryover was 
determined as 35% for the mice generated following nuclear transplantation (Sato et al., 
2005).  Here polar bodies were used as biopsy samples to determine carryover.  
However as we know now from more recent studies, polar bodies do not provide an 
accurate representation of the mutation load observed in the zygote, when sampled to 
analyse mtDNA mutation loads (Gigarel et al, 2011).   It is therefore likely that this 
from of sampling did not provide a completely accurate account of the mtDNA 
carryover.   Although the resultant progeny had an average of 11% mutated mtDNA in 
tail samples and did not develop any clinical symptoms associated with the mtDNA 
mutation. This therefore demonstrates that pronuclear transfer can be an effective 
method to prevent transmission of mtDNA disease. 
 
Other studies have completed pronuclear transfer between embryos from different 
strains of mice and investigated the level of mtDNA carry-over in reconstructed 
embryos.  One such study revealed that pronuclear transfer embryos analysed following 
manipulation contained on average 19% mtDNA of karyoplast origin, ranging from 16 
to 23% (Meirelles and Smith, 1997). Most progeny derived from these embryos were 
found to contain less mtDNA from the pronuclear karyoplast but with some variation in 
heteroplasmy levels between tissues, ranging from 6% (lung) to 69% (heart). 
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Another study used the same approach and determined the level of karyoplast mtDNA 
in reconstructed embryos cultured to the blastocyst stage following pronuclear transfer 
(Brown et al., 2006). This study reported a similar level of 16.3±8.4% mtDNA of 
karyoplast origin and confirmed that it is possible to generate mice with low levels of 
mtDNA carry-over. Variation in heteroplasmy between tissues was also revealed, with 
levels ranging from 10% (muscle) to 37% (liver). 
 
7.1.2 MtDNA Heteroplasmy following Pronuclear Transfer between human 
embryos  
 
Having established that pronuclear transfer was compatible with onward development 
of human embryos, carry-over of donor mtDNA genotype was examined in 
reconstituted human pronuclear-transfer embryos (Craven et al 2010).    Last hot cycle 
PCR restriction-fragment length polymorphism (RFLP) assays were developed for 
identified mtDNA variants and used to analyze mtDNA extracted from whole embryos. 
We found that there was variation in the amount of mtDNA genotype from the donor 
zygote transferred to the embryos receiving two transferred pronuclei (8.1% ± 7.6 
(mean ± s. d.), n = 8).   
 
Analyses were also performed to determine whether the proportion of donor mtDNA 
genotype also varied between blastomeres in the reconstituted embryos after transfer of 
two pronuclei.   In one out of eight embryos no donor mtDNA was detected in any 
blastomere.   In the other seven embryos analyzed, there was variation in the level of 
donor mtDNA genotype between blastomeres.  Although the variation observed was 
similar to previous reports on heteroplasmic human embryos (Steffan et al, 2006; 
Tajima et al, 2007).    However attempts made to further minimize the carry-over of 
donor zygote mtDNA, involving techniques to reduce the amount of cytoplasm 
contained within the pronuclear karyoplast.    Analysis of donor mtDNA genotype 
carryover following improvements to the technique demonstrated that the mtDNA 
carry-over was significantly lower (P < 0.005), with four out of nine embryos now 
found to contain undetectable levels of mtDNA carry-over.   The average mtDNA carry-
over in all remaining embryos was less than 2% (1.68 ± 1.81% (mean ± s.d.), n = 9). 
These same embryos also revealed much less variation in mtDNA carry-over between 
individual blastomeres.   
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7.1.3 Mitochondrial distribution in cryopreserved human embryos  
 
Studies examining mitochondrial distribution in human abnormally fertilized pronuclear 
stage zygotes and cleaved embryos frozen using ultra-rapid freezing have demonstrated 
its similarity to that observed for controls (Noto et al, 1993; Nottola et al, 2007).  
However other studies also examining mitochondrial distribution in vitrified abnormally 
fertilized human zygotes, reported observing the formation of large SER vesicles 
associated with mitochondria following ultra-structural analysis performed using 
electron microscopy (EM).  These were said likely to be a result of the cryopreservation 
process and possible caused as a result of defects or damage to Ca
2+
 -regulation 
(Sathananthan and Trounson, 1989; Sathananthan et al, 1988b; Liu et al, 2001; 
Isachenko et al, 2003).  There is also evidence that mitochondria ultrastructure and 
viability (as assessed by analysis of mitochondrial polarity) may be adversely affected 
by the cryopreservation procedure (Jones et al, 2004).   
 
7.1.4 Manipulation of cryopreserved oocytes and embryos  
 
 
There is a single report of a study performed to evaluate the feasibility of using 
cryopreserved oocytes for maternal spindle transfer (MST), using the nonhuman 
primate model.   They used a commercially available vitrification kit (CRYOTOP) and 
determined high post-thaw survival and recovery of rhesus macaque MII oocytes. 
Furthermore following ISCI, 72% formed pronuclei, but only 6% developed to 
blastocysts. Thus, this cryopreservation method was suggested compromised blastocyst 
development, because blastocyst formation of fresh oocytes from the same cohort was 
52%.     
 
The same study also examined the ability to perform reciprocal MST between fresh and 
frozen-thawed monkey oocytes and examined fertilization and embryo development.  
When fresh spindles were transplanted into vitrified cytoplasts, fertilization after ICSI 
was impaired (50%) compared to controls (91%).   Furthermore all embryos in this ST 
group arrested before reaching blastocysts, whereas 57% controls progressed to 
blastocysts.   These MST results were similar to those seen with frozen-thawed intact 
controls.    However, when spindles from vitrified oocytes were transferred into fresh 
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cytoplasts, fertilization (88%) and blastocyst formation (68%) rates were similar to 
fresh controls.   These results suggested that vitrification causes damage primarily 
within the cytoplasm rather than to the spindle apparatus. 
 
7.2 Materials and Methods  
 
7.2.1 Pronuclear karyoplast removal 
 
Zygotes were incubated in G1v5 Plus medium (Vitrolife) containing cytochalasin B 
(5μg/ml) and nocodazole (10μg/ml) at 37ºC with 7% CO2 for 10 or 30 minutes prior to 
manipulation and during the procedure. Manipulations were performed using an 
inverted microscope (Nikon Eclipse TE2000-U) equipped with a micromanipulation 
system (Integra Ti, Research Instruments). Zygotes were immobilised with a holding 
pipette and a small ablation made in the zona pellucida using a microsurgical laser 
(Saturn Active, Research Instruments).   A customised biopsy pipette with an inner 
diameter (ID) of 28μm was inserted under the zona pellucida.  The pronucleus and 
surrounding cytoplasm were then aspirated into the biopsy pipette as a membrane bound 
karyoplast.   For transfer of a single pronucleus, a pronuclear karyoplast was removed 
from either a monopronucleate or tripronucleate donor zygote and transferred to a 
recipient zygote containing only one pronucleus. The recipient zygote was either 
a pronucleate zygote, which required no manipulation prior to transfer, or a 
tripronucleate zygote from which two pronuclei had been removed. Thus, the 
reconstituted zygotes contained two pronuclei. In experiments involving transfer of two 
pronuclei, pronuclei were removed either as two individual pronuclear 
karyoplasts or a single karyoplast containing both pronuclei. These karyoplasts were 
then transferred to an enucleated recipient zygote such that the reconstructed zygote 
contained two pronuclei. 
 
7.2.2 Pronuclear karyoplast fusion 
 
Pronuclear karyoplasts were transferred within a biopsy pipette to a 1μl drop of HVJE 
(GenomONETM-CFEX HVJ Envelope Cell Fusion Kit, Cosmo Bio Co) and a small 
volume of the suspension approximately equal to the volume of the karyoplast aspirated 
into the pipette. The pipette was then moved to a drop containing a recipient zygote. 
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The pipette was inserted into the zygote through a small ablation in the zona pellucida 
and the HVJ-E and pronuclear karyoplast aspirated into the perivitelline space, ensuring 
good contact between the karyoplast and plasma membrane.  Fusion of the pronuclear 
karyoplast with the recipient zygote was confirmed visually and usually occurred within 
10 minutes up to 1 hour after transfer.  Manipulated zygotes were transferred to G1v5 
Plus medium (Vitrolife) and cultured at 37ºC with 7% CO2.  Embryos were transferred 
to G2v5 Plus medium (Vitrolife) on day 3 of development and cultured at 37ºC with 7% 
CO2 up to day 7. Embryos for mitochondrial DNA analysis were then transferred to 
sterile 0.5ml microfuge tubes and stored at -20ºC until DNA extraction. 
 
7.2.3 MtDNA Sequencing 
 
7.2.3.1 PCR amplification of the non-coding control region 
 
The non-coding control region of the mitochondrial genome was amplified using two 
rounds of PCR amplification as described previously (Taylor et al., 2001) with the 
following modification: secondary PCR reactions were performed with 4 sets of 
overlapping M13-tailed primers (primer nucleotide positions: D1F: 15758-15777 and 
D1R: 019-001, D2F: 16223-16244 and D2R: 129-110, D3F: 16548-16569 and 
D3R:389-370, D4F: 323-343 and D4R: 771-752) with an annealing temperature of 58ºC. 
 
7.2.3.2 Purification of PCR products for sequencing 
 
PCR products were purified using ExoSap-IT (GE Healthcare) according to the 
manufacturer’s instructions. 5μl PCR product was transferred to a 96-well plate on ice 
followed by 2μl ExoSap-IT. The plate was vortexed and incubated at 37oC for 15 
minutes followed by 80
o
C for 15 minutes to inactivate the enzymes. 
 
7.2.3.3 Cycle-sequencing reactions 
 
For the cycle sequencing reaction, the following was added to each sample: 9μl dH20, 
3μl 5 x sequencing buffer, 1μl Universal forward primer and 2μl BigDyes v3.1. The 
reaction plate was placed on a thermal cycler and subjected to the following conditions: 
96
o
C for 1 minute then 25 cycles of 96
o
C for 10 seconds, 50
o
C for 5 minutes and 60
o
C 
for 4 minutes. 
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7.2.3.4 Precipitation and sequencing 
 
PCR products were precipitated by adding 2μl 125mM EDTA, 2μl 3M sodium acetate 
and 50μl 100% ethanol to each sample. The plate was inverted several times to mix and 
left at room temperature for 15 minutes before being centrifuged at 2090g for 30 
minutes. The supernatant was discarded and the pellets washed with 70% ethanol.  The 
plate was then centrifuged at 1650g for 15 minutes and the supernatant discarded.  The 
plate was allowed to air dry in the dark before 10μl HiDi formamide was added to each 
sample. Following a, 2 minute incubation at 95ºC, the samples were then sequenced on 
an ABI3170 Genetic Analyser (Applied Biosystems) with BigDye Terminator cycle 
sequencing chemistries (v3.1, Applied Biosystems). Sequences were directly compared 
to the revised Cambridge Reference Sequence for human mtDNA (Andrews et al., 
1999) (GenBank Accession number: AC_000021.2) using SeqScape software (v2.1.1, 
Applied Biosystems). 
 
7.2.4 Restriction Fragment Length Polymorphism (RFLP) to Determine 
mtDNA 
 
Carry-over in Nuclear Transfer Embryos Level of donor zygote mtDNA carry-over was 
determined by last hot cycle PCR restriction fragment length polymorphism (RFLP) 
analysis. Separate assays were developed for each discriminatory mtDNA sequence 
variant identified and were performed as described previously (Taylor et al., 2003, 
McFarland et al., 2004), with modifications as listed in Supplementary Table 2a 
(Appendix 3). 
 
7.2.4.1 Last hot cycle (LHC)-PCR 
 
Fragments containing the sequence variants of interest were amplified by PCR using 
primers listed (see supplementary table 1) and a last hot cycle performed with 1μl 
forward and reverse primer (20μM), 0.25μl Amplitaq Gold DNA polymerase and 5μCi 
[α-32P]-dCTP (3,000 Ci/mmol). LHC-PCR conditions were: 94oC for 5 minutes, the 
optimised annealing temperature for the specific primer pair for 2 minutes (see 
supplementary table 1) and 72
o
C for 8 minutes. The radiolabelled DNA was precipitated 
by adding 2μl Pellet Paint™ Co-precipitant (Novagen), 50μl 7.5M ammonium acetate 
and 200μl 100% ethanol to the sample. The sample was left to precipitate at room 
temperature for a minimum time of 1 hour and was then centrifuged at 13,000rpm for 
10mins. The supernatant was removed and the pellet washed with 70% ethanol. The 
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centrifugation was repeated and the supernatant removed. The pellet was then left to air 
dry at room temperature for ~10mins and the number of counts per second in the sample 
measured using a gamma counter. The pellet was then re-suspended in a volume of 
dH20 to give 1000 counts in 17μl of radiolabelled sample. 
 
7.2.4.2 Restriction digests of radiolabelled PCR products 
 
Restriction digests were completed by adding 16.8μl radiolabelled PCR product to 0.2μl 
100X BSA, 1μl assay-specific restriction enzyme and 2μl of the appropriate 10 x 
restriction enzyme buffer (New England Biolabs, UK). The digests were left at 37
o
C 
overnight. An additional 0.5μl restriction enzyme was added to the digest the following 
morning and the reaction left at 37
o
C for an additional 1 hour. 
7.2.4.3 Polyacrylamide gel electrophoresis 
 
Vertical 12% polyacrylamide gels were prepared by adding 12ml 40% acrylamide (29 
acrylamide: 1 bis) to 4ml 10 x TBE and 24ml dH20. The acrylamide was polymerised 
by addition of 75μl 25% ammonium persulfate (APS) and 75μl TEMED (Sigma) and 
the solution applied between glass plates and allowed to set at room temperature. 3μl 10 
x loading dye was added to the digested products and the restriction fragments 
electrophoresed in 1 x TBE at 100V for 1hr and then at 150V for an appropriate length 
of time to allow clear separation of the products. The gel was dried onto a support using 
a gel dryer at 66
o
C for ~1.5 hours. The gel was then exposed to a PhosphoImager screen 
(Molecular Dynamics, Eugene, Oregon) and left at room temperature overnight. The 
Phosphoimager screen was then imaged using the STORM Phosphoimager (Molecular 
Dynamics) and analysis completed using ImageQuant software (Molecular Dynamics). 
Carry-over donor zygote mtDNA was calculated as the percentage of total mtDNA in 
the recipient embryo. 
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7.3 Results  
 
7.3.1 Potential to manipulate zygotes vitrified using an open versus closed 
vitrification system  
 
The ultimate purpose of this study was to determine the potential to manipulate zygotes 
which had been vitrified.  This is extremely important as it is highly likely that if 
pronuclear transfer were to become available as a clinical treatment one day that it 
would be difficult to ensure that both the embryo donor and embryo recipient would 
both be ready to undergo egg retrieval on the same day.  Vitrification will allow zygotes 
to be stored from both the oocyte donor and mitochondrial patient following fertilisation 
at the PN stage of development.    Those zygotes which retained their pronuclei after the 
minimum 2 hour recovery period were used to determine the feasibility for use in 
pronuclear transfer procedures (please refer to 4.3Materials and Methods for the full 
PNT protocol).  Those embryos which were successfully able to be manipulated were 
then cultured so as to determine potential for onward development in vitro.   
 
7.3.2 Potential to manipulate zygotes vitrified using an open vitrification 
system  
 
Here I initially explored the potential to manipulate zygotes vitrified using the open 
vitrification system (Origio™).  Unfortunately due to premature pronuclear breakdown 
(As covered previously in section 6.8) it was only possible to attempt manipulations for 
a small number of zygotes (n=25).   
 
7.3.3 Differences in ability to manipulate zygotes following vitrification as 
opposed to fresh zygotes 
 
This is the first known report which has attempted to manipulate s vitrified zygotes.    
All zygotes were given at least 2 hours to recover following warming before they were 
moved to manipulation dishes.   Zygotes were then incubated within the cytoskeletal 
inhibitors for the same time fresh embryos would be incubated (15-30 minutes).  Holes 
were made within the zona pellucida using a minimum number of laser pulses, no 
apparent differences were noted when performing this with the vitrified as opposed to 
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fresh zygotes.  Upon introducing the biopsy pipette into the embryo, the cytoplasm of 
the zygote did move around more within the zona pellucida compared to what would 
normally be observed for fresh zygotes.  This did make it more difficult to orientate the 
zygote in order to attempt to remove the pronuclei. The cytoplasm of the zygote did 
offer greater resistance when the biopsy pipette was introduced into the zygote.  This 
subtle difference in the composition of the cytoplasm following vitrification did suggest 
that the vitrification process did slightly alter the physiological properties of the zygote 
however not enough to prevent the zygotes being manipulated.  On several occasions it 
was possible to remove pronuclei from the zygotes intact despite the observed 
differences in the nature of the cytoplasm however it did make it slightly more difficult 
to remove excess cytoplasm from the karyoplasts once removed from the zygotes.   
 
In all 20 zygotes (n=20/25) were able to be enucleated and the pronuclear karyoplasts 
transferred to enucleated fresh (nom-vitrified) abnormally fertilized human zygotes.   
From the 20 successful PNT transfers is was possible to perform, 15 of the embryos 
resulting from these transfers survived with only 5 embryos degenerating immediately 
or on the following day.   The 15 embryos which survived were then cultured and 
development monitored.   
 
7.3.4 Development of vitrified (using the open vitrification system) and 
manipulated zygotes   
 
Development for those zygotes vitrified using the open vitrification system and then 
manipulated and cultured was good, with; 20% (n=3/15) <4-cell stage, 47% (n=7/15) 
the 4-8cell stage and 33% (n=5/15)>8cell stage (Figure7.16 and Table7.9).   This was 
compared to control data gathered for development attained by fresh embryos which 
underwent PNT manipulations; 25% (n=24/89) <4-cell stage, 44% (n=37/89) the 4-8cell 
stage and 31% (n=28/89) >8cell stage.   Despite the small sample size of the vitrified 
and manipulated development attained by those zygotes which survived the procedure 
demonstrated developmental potential similar to that achieved by fresh manipulated 
embryos.    
 
However given the vast differences in the sample size in the vitrified and manipulated 
embryo group (n=15) compared to the sample size of the non-vitrified (fresh) 
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manipulated embryos (n=89) (Fig7.2) and (Table7.1) it is difficult to make unbiased 
comparisons accurately compare and contrast fairly.  The discrepancies in sample size 
can be explained by both the variability and unpredictability in obtaining samples and 
the impact of the vitrification process, including pronuclear breakdown during warming 
and recovery, which all acted to significantly reduce the number of zygotes which could 
be used to attempt manipulations upon following vitrification and warming.   
 
7.3.5 Potential to manipulate zygotes vitrified using a closed vitrification 
system  
 
I also examined the potential to manipulate abnormally fertilized human zygotes 
vitrified using the closed vitrification system (Vitrolife).    It was only possible to 
attempt manipulations with a small number of zygotes (n=6).  This was due to issues 
regarding the number of zygotes which t pronuclei were present in following warming 
and adequate recovery time prior to attempting manipulating (~2hours).   Given these 
constraints it was possible to remove intact PN karyoplasts from n=6 zygotes (as 
depicted in Fig7.1).   
 
Those zygotes which were manipulated, had their own PN karyoplasts fused back with 
them (reciprocal transfer) before they were then returned to fresh culture dishes and 
development monitored.  Several of the manipulated zygotes did go onto cleave (n=4/6) 
to at least the 2-cell stage (Fig7.2).   However given the small sample size, it is difficult 
to extrapolate our findings from this study using the closed vitrification system and 
contrast them to data we previously obtained for the closed vitrification and fresh 
manipulation and culture experiments (control data)(Fig7.2 and Table7.1).    
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Fig7. 2 Comparison of development achieved for vitrified and manipulated, 
vitrified and cultured and fresh (non-vitrified) controls (abnormally fertilised 
human zygotes). 
 
Figure represents development stages attained by fresh- vitrified manipulation and 
manipulated zygotes using the open vitrification system (red) fresh-vitrified 
manipulated using the closed vitrification system (green) and non-vitrified 
manipulated fresh control zygotes.  Several zygotes vitrified using the open 
vitrification system (red) and manipulated demonstrated compatibility with onward 
development; 20% (n=3/15) <4-cell stage, 47% (n=7/15) the 4-8cell stage and 33% 
(n=5/15)>8cell stage.   This was compared to development obtained from zygotes 
originally vitrified using a closed vitrification system (green) which were 
manipulated and cultured to assess developmental potential, with ; 33.3% (n=2/6) 
developing to <4-cell stage, 33.3% (n=2/6) the 4-8cell stage and 
33.3%(n=2/6)>8cell stage.   Development obtained by vitrified zygotes which were 
manipulated was compared to development obtained by fresh (non-vitrified) 
manipulated zygotes (blue) 25% (n=24/89) <4-cell stage, 44% (n=37/89)  the 4-8cell 
stage and31%(n=28/89) >8cell stage.    
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7.3.6 Mitochondrial DNA Carry-over in vitrified reconstituted 
Pronuclear Transfer Embryos  
 
Experiments were completed to determine if the proportion of mtDNA carry-over 
varied between blastomeres obtained from reconstituted embryos following the transfer 
of pronuclei from vitrified zygotes (vitrified using the open vitrification system) to fresh 
enucleated (non-vitrified) zygotes.  To do this, pronuclear transfer embryos were 
cultured up to day 3 and then disaggregated into individual blastomeres (refer to chapter 
3) to determine the level of donor mtDNA in each cell.  This analysis revealed that there 
was limited variation in the level of mtDNA carry-over between blastomeres obtained 
from reconstituted embryos (n=4), ranging from <1-4% (Fig7.4). This analysis also 
revealed that one embryo contained no detectable levels of mtDNA from the pronuclear 
donor embryo in any blastomere (n=3).  The average mtDNA carry-over in all embryos 
analysed was 5.5% (n=5).   
 
However increased levels of donor embryo mtDNA were determined for individual 
blastomeres (n=5) obtained from one single embryo.  Resulting in its average mtDNA 
carry-over calculated as 13.4%.    Here the mutation loads ranged from 10-20% for each 
of the five individual blastomeres which were able to analyse for this particular embryo 
(Table 7.2).    However this was an embryo which I manipulated whilst still in the initial 
stages of learning the PNT technique, therefore this may have contributed to the higher 
levels of mtDNA carried over to the recipient zygote.  As with further experience and 
time spent performing the PNT technique I was better able to reduce the size of the 
karyoplast removed, and importantly minimise the volume of cytoplasm removed 
together with the pronuclei (Figu7.4).  This is encouraging and further demonstrates the 
potential of vitrification as a potential means by which to successfully store human 
zygotes for the purpose of the PNT project.   
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191bp  
175bp 
   42bp 
34bp 
Uncut  B1
nc
B2 B3 FF 
Mutant 
16,270T>C 
 
Wild Type  
16,270T>T 
175bp 34bp 
34bp 133bp 42bp 
Fig7. 3 Mitochondrial DNA (mtDNA) carryover analysis (Last-hot cycle 
RFLP) of individual blastomeres disaggregated from vitrified pronuclear 
transfer embryos  
 
Schematic diagram representation of the RFLP designed for the 16,270 mtDNA 
sequence variant identified following sequencing of follicular fluids obtained for 
the donor and recipient.     
133bp 
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Development                              
stage  
1 2 3 4 5 6 
Three-cell n.d. n.d. n.d.    
Five-cell n.d. 3 3 2 3  
Four-cell 2 3 4 2   
Six-cell n.d. 3 1 2 2 3 
Five-cell 20 15 12 10 10  
Fig7. 4 andTable7. 2 Levels of donor mtDNA carry-over for 5 embryos vitrified 
and used for pronuclear transfer  
(a)Images of pronuclear karyoplasts before and after further manipulation, so as to 
minimize the volume of cytoplasm carried over to the recipient zygote with the donor 
pronuclei.   (b) Table represents levels of mtDNA carry-over determined for those 
embryos which were vitrified and warmed and following recovery used for PNT.  
Sequencing analysis was performed and single nucleotide sequence variants identified 
for each recipient and donor sample.  RFLPs were accordingly designed following 
identification of sequence variants.    
  
Karyoplasts prior to further 
manipulation to remove cytoplasm 
Karyoplasts following further 
manipulation to remove cytoplasm 
Blastomere number  
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7.4 Discussion 
 
This study is the first study to examine pronuclear transfer between vitrified and fresh 
abnormally fertilized human zygotes.    Studies performed previously were successfully 
able to demonstrate the use of nuclear transfer techniques with the potential to prevent 
transmission of mtDNA disease in humans (Craven et al, 2010).    These initial studies 
were performed using fresh abnormally fertilized human zygotes.   Here they were able 
to demonstrate that these manipulated zygotes maintained potential for onward 
development and importantly the level of mtDNA carried over with the ‘karyoplast’ 
was low. This technique would ameliorate the risk that the mtDNA mutation would 
cause disease in the child resulting from the reconstituted zygote.   
 
In the previous chapter I demonstrated that it is possible to vitrify abnormally fertilised 
human zygotes and upon warming and adequate recovery time perform pronuclear 
transfer between zygotes.   In this chapter I set out to determine if indeed it was possible 
to manipulate using vitrified abnormally fertilized human zygotes initially.   The second 
aim of this chapter was to determine if these embryos were compatible with 
development.  Finally I set out to determine if mtDNA carryover was adversely affected 
by the vitrification procedure and would therefore make it not feasible to vitrify zygotes 
to be used for PNT.    
 
I found there were several minor differences I observed when attempting manipulations 
upon the vitrified zygotes, which were not encountered when working with fresh 
zygotes.  This included increased resistance to the biopsy pipette by the zona pellucida, 
indeed it is known that cryopreservation does induce hardening of the zona pellucida. I 
also found more difficult to manipulate the zygote.   This we found slightly altered the 
ease at which the biopsy pipette was able to enter the zygote, resulting in a larger hole 
having to be made so as to not compromise the integrity of the zygote during the 
manipulation procedure.   However it is quite possible that this may have been due to 
inadequate recovery time prior to attempting manipulations, which meant that the 
cytoplasm had still not yet fully recovered following warming.  It is also possible that 
this may have been due to factors independent of the vitrification process, for example 
inadequate incubation within the cytoskeletal inhibitors prior to attempting 
manipulation procedures.   
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This study also demonstrated that not only is it possible to vitrify PN stage zygotes and 
successfully use them to perform PNT, they also demonstrate potential for onward 
development following manipulation.     Development observed for zygotes vitrified 
using both the open and closed vitrification systems following manipulated was 
comparable to that observed for fresh manipulated control zygotes (33% versus 31% 
<8cell stage).  
 
This is extremely encouraging as it demonstrates that it is feasible to use vitrified 
zygotes to perform PNT and the reconstituted zygotes are still compatible with 
development.    However given the issues I encountered regarding PN breakdown the 
overall number of zygotes which I was able to attempt PNT with a small number of 
vitrified zygotes, therefore when performing the manipulations using zygotes vitrified 
with the open vitrification system I often used a fresh (non-vitrified) zygote as the 
recipient, to which the vitrified PN karyoplasts were fused back with to create the 
recipient zygote.  This may have slightly altered outcomes.  As the reconstituted zygotes 
contained fresh cytoplasm and only the vitrified ‘nuclear’ component.  It is therefore 
possible that the cytoplasm helped to support development of the reconstituted zygote.  
This is consistent with the only other published report of attempts to manipulate 
vitrified non-human primate oocytes (Tachibana et al, 2012).    This study failed to 
disclose the overall survival it was able to achieve using a device similar to the open 
vitrification device I used initially.    They did state that using the particular 
cryopreservation method they opted for that development to the blastocyst stage was 
compromised for those cryopreserved oocytes which fertilized successfully following 
ICSI.   However they did, none the less investigate the potential of spindle transfer (ST) 
between fresh and frozen-thawed non-human primate oocytes, for they which they 
examined fertilization and developmental potential.      They noted that when fresh 
spindles were transplanted into vitrified cytoplasts, not only was fertilization following 
ICSI impaired to controls by almost half (50% versus 91%).   Moreover all embryos in 
the vitrified ST group arrested development before reaching the blastocyst stage, 
whereas 57% of control embryos attained development to the blastocyst stage.    
However when they transplanted the vitrified spindle into a fresh cytoplast both 
fertilization (88%) and blastocyst (68%) formation were similar to those able to be 
achieved for fresh controls (91% and 57%).   
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It was also important to ascertain that mitochondrial DNA carryover was not affected by 
the vitrification process.  Here I was able to examine mtDNA for individual blastomeres 
disaggregated from a number of fresh-vitrified PNT embryos.  The levels of mtDNA 
carryover detected was generally low.   Indeed non-detectable levels of mtDNA 
carryover were determined for some of the embryos I gathered from later into my 
experiments.  This was extremely encouraging and demonstrated that vitrification was 
not exerting a detrimental effect on mtDNA carryover.  This is encouraging as the 
average level of mtDNA carry-over detected in pronuclear transfer embryos reported by 
Craven et al (2010) were very low (ranging from <0.5 to 4.3%) and well below the level 
of mutated mtDNA associated with the onset of clinical disease (usually >60% of total 
mtDNA).   However the levels of donor mtDNA detected in reconstituted embryos prior 
to improvements in my ability to manipulate karyoplasts before fusing with the 
recipient embryo were higher.   Indeed the average level of mtDNA carryover detected 
for one embryo was ~13.4%, with one blastomere found to contain 20% mtDNA 
carryover.   However higher levels of mtDNA carryover were also detected by L. 
Butterworth prior to improvements in performing the technique and manipulating the 
karyoplasts to minimize carryover (ranging from <0.5 to 25.3%).  
 
It was extremely important to ensure that vitrification did not adversely affect the 
distribution of mitochondria in abnormally fertilised human embryos, as several studies 
have, demonstrated mitochondrial clustering around the pronuclei at the PN stage (Noto 
et al., 1993, Van Blerkom et al., 2000, Van Blerkom et al., 2002).   If this were true we 
would expect to see high levels of mtDNA carry-over due to the increased numbers of 
mitochondria likely to be present within the pronuclear karyoplast.    However, this was 
not observed in this study, which examined mitochondrial carryover in reconstituted 
embryos created by the transfer of pronuclei between fresh and vitrified embryos.      
 
Furthermore unpublished work performed work has examined mitochondrial 
distribution in at the PN stage in both mouse and human zygotes and found 
mitochondria appeared uniformly distributed throughout the cytoplasm with no obvious 
mitochondrial aggregation around the pronuclei (unpublished data, L. Butterworth).    
However this same work did note that the distribution changed slightly in the presence 
of cytoskeletal inhibitors, with a clearing of cytoplasm observed in the cortical region 
almost immediately after exposure, however this did not result in an aggregation of 
mitochondria around the pronuclei. 
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Chapter 8 Final Discussion 
 
Mitochondrial DNA is inherited through strict maternal inheritance and mutations in 
this genome are a common cause of inherited disease.  However many mtDNA 
mutations are heteroplasmic and due to the genetic bottleneck during development, 
there is variable transmission to the offspring.    It is therefore recommended that 
mothers with mitochondrial DNA mutations who want to have children should seek 
specialist advice from doctors who have experience of counselling specifically about 
mitochondrial genetic disorders.  Indeed there are several different reproductive options 
available to these patients including; oocyte donation, preimplantation genetic diagnosis 
(PGD) and prenatal diagnosis (PND).     This thesis therefore set out to examine the 
potential and feasibility of currently available  IVF based techniques (PGD) aimed at 
minimizing the risk of transmission and those options currently being explored  to 
prevent the transmission of mtDNA disease (PNT and MST) from mother to child. 
Preimplantation genetic diagnosis (PGD) has only recently been recognized as a 
feasible option for women who carry heteroplasmic mtDNA mutations, due to the 
uncertainty surrounding mtDNA transmission and inheritance.   The PGD technique 
involves the creation and identification of suitable embryos that have ‘undetectable’ or 
‘low levels’ of mtDNA mutation and so are associated with a lower risk of the offspring 
developing severe disease.   In recent years the technique has been successfully applied 
to a small number of maternally inherited mtDNA mutations (Steffan et al, 2006, 
Thorburn et al, 2009, Monnot et al, 2011, Treff et al, 2012, Sallevelt et al, 2013).  
Although experience is still limited and more information is required to determine the 
suitability of PGD for different pathogenic mtDNA mutations.   
Studies conducted as part of this thesis were successfully able to perform mutation load 
analysis for a number of oocytes, cleavage and blastocyst stage embryos obtained from 
patients with six different mtDNA mutations (m.14709T>C, m.14487T>C, m.9176T>C, 
m.8993T>C, m.10158T>C and m.3688G>A).  The results of which were encouraging 
and allowed for several important questions to be addressed. Firstly, does the mutation 
load observed in the biopsied blastomere accurately reflect the mutation load in the 
remaining cells of the embryo? Secondly does the mutation load observed at the point 
of blastomere biopsy remain consistent throughout embryonic development?  Thirdly 
are there any apparent mutation specific differences regarding mtDNA segregation 
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within the same embryo? Finally, finally how does mutant mtDNA species segregate 
between embryonic and extra-embryonic cells within blastocyst stage embryos?  
The results of my studies were in-line with the few previous which have revealed that 
mutation load is comparable between blastomeres (Thorburn et al, 2009, Treff et al, 
2012), with interblastomere variations reported as 6% for the m.3243A>G mutation 
only (Monnot et al, 2011) and <10% for the m.3243A>G and m.8993T>G mutations 
(Sallevelt et al, 2013) in the majority of embryos examined.  This is extremely 
important in order to guarantee the feasibility and efficiency of PGD for mtDNA 
inherited disorders.  However, some variation in mutation load has been reported 
between blastomeres within a minority of embryos.   This may occur more frequently in 
certain individuals, implying that genetic factors could be involved in mitochondrial 
segregation during embryogenesis (Vandewoestyne et al, 2012; Sallevelt et al, 2013).  
Therefore care must be taken when performing PGD assessing each case on an 
individual basis.    
However although the mutation load determined in the biopsied blastomere appears to 
be representative of the mutation load in the remaining cells of the embryo, does this 
reflect the mutation load of the cells which will go on to give rise to the ‘embryo 
proper’?  Unfortunately there is currently very little information available regarding the 
segregation of mutant mtDNA between embryonic and extra-embryonic cells within 
blastocyst stage embryos.  This study was able to provide an insight into mutation load 
segregation within the blastocyst, detecting similar mutation loads in cells origination 
from the ICM are highly comparable with those of the TE (for mutations m.14487T>C 
and m.3688G>A).  There is one other single report which examined mutations loads 
from embryos carrying the m.3243A>G mutation, reporting a maximum variation of 9% 
mutant load between the ICM and TE (Treff et al, 2012).  In addition, multiple biopsies 
from the ICM and TE of the same embryos revealed highly consistent heteroplasmy 
levels across the embryos, with mutation loads differing by 2-4% in the ICM and 3-11% 
in the TE (Treff et al, 2013).  The low variation within the ICM supports the 
observation that mutant load remains relatively stable across fetal tissues (Matthews et 
al, 1994, Ferlin et al, 1997, Cardailoi et al, 2000, Monnot et al, 2010) and suggests that 
the mutant load determined at the time of biopsy will remain unchanged during embryo-
fetal development.   
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The similarity in mutation loads observed in samples obtained from the TE and ICM 
also act to support the procedure of trophectoderm biopsy for mitochondrial PGD (Treff 
et al, 2012).   Indeed there are many advantages of performing biopsy at this stage,  
including demonstration of developmental competency with embryos attaining 
development to the blastocyst stage, the increased number of cells acquired at point of 
biopsy for testing, less invasive procedure, and cells removed are not involved in 
contributing to the embryo proper so likelihood of compromising development is 
significantly reduced.   
Another reproductive screening technique which has been proposed as an alternative 
reproductive screening approach is polar body biopsy.  Polar body biopsy of mature 
oocytes prior to fertilisation avoids the need to create embryos for testing and is 
routinely performed for a number of nuclear-encoded genetic disorders (Munne et al, 
1998; Wells et al, 2002; Magli et al, 2004; Montag et al, 2004; Kuliev et al, 2006; 
Mastenbroek et al, 2007).  Its application in mtDNA disorders, however, has been 
disputed due to the apparent poor predictive value of the polar body in relation to the 
oocyte (Gigarel et al, 2011, Vandewoestyne et al, 2012).  This was inferred from a study 
of over 50 oocytes obtained from patients with three different mtDNA mutations, as 
only 50% of polar bodies were reported to contain similar mutant loads (±10%) to the 
corresponding oocyte or embryo (Gigarel et al, 2011).  The variation in mutant load 
observed between the polar body and oocyte appeared greater in polar bodies with 
higher levels of heteroplasmy (>60% mutation load) (Gigarel et al, 2011).  My own data 
revealed a high correlation in mutant load between the oocyte and the first polar body 
for a very limited number of oocytes carrying the m.3688G>A and m.10158T>C 
mutations, supporting the observation that mutation load determined in the polar body 
corresponds to the mutant load in the oocyte at least for low levels of heteroplasmy.  
However, exceptions may still occur as reported in the m.3243A>G embryo that 
revealed mutation-free polar bodies but higher levels of mutation (up to >50%) within 
blastomeres of the cleavage stage embryo (Vandewoestyne et al, 2012).  Therefore, 
polar body based PGD may be considered unreliable for mtDNA mutations irrespective 
of the mutant load. 
In light of the current reproductive options available which can be used to minimize the 
likelihood of conceiving a child severely affected by a mtDNA defect there is still at 
present no way to completely preventing the transmission completely.  However 
recently two nuclear transfer based techniques have been suggested as a means, by 
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which to prevent the transmission of mtDNA disease from mother to child (Tachibana 
et al, 2009; Craven et al, 2010).  Both techniques involve the transfer of the nuclear 
component but at two comparatively different stages of development: Metaphase II 
(MII) spindle transfer (MST) utilises unfertilised metaphase II stage oocytes whilst 
pronuclear transfer (PNT) requires one cell zygotes (embryos).  Indeed studies 
examining MST in the primate model have resulted in the birth of healthy live 
offspring, demonstrating the promise of this procedure (Tachibana et al 2009).    
When introducing a new reproductive technique into IVF clinics it is critical that the 
technique is able to be reproduced by other operators.   This has been demonstrated for 
the MST technique previously and as part of this study I was able to demonstrate the 
reproducibility of the PNT technique.  Both potential for onward development and 
levels of mtDNA carryover were found to be similar to those previously attained in the 
initial proof of principle studies (Craven et al, 2010).   All of these studies were 
performed in abnormally fertilised human zygotes (Craven et al, 2010).    
However abnormally fertilized human zygotes are known demonstrate a limited 
capacity for development due to their abnormal chromosomal constitution (Herbert and 
Feenan, 2006).     Therefore although current PNT experiments have been able to 
demonstrate the feasibility and potential of the PNT procedure using abnormally 
fertilized human zygotes in order to accurately assess development obtainable following 
PNT and address further concerns regarding the safety of the procedure it is imperative 
that studies are reproduced using normally fertilized zygotes (2PN).   
Indeed following an amendment to the HFEA embryology act bill in late 2010 the 
creation human zygotes for the purpose of the mitochondrial study was permitted.  The 
first altruistic donors were recruited for the PNT project in November 2010 and since a 
significant number of furtherer donors have been recruited.   However the likelihood of 
two donors both being ready for egg retrieval on the same day was foreseen to be highly 
unlikely due to discrepancies in each individuals responses to the stimulation 
programme and adherence to the treatment plan they are given as altruistic donors.    It 
is essential that there be a means by which to cryopreserve oocytes immediately 
following retrieval or following fertilization at the single cell zygote stage.   
Embryo cryopreservation is a routine procedure performed within IVF laboratories 
globally allowing couples to store supernumerary embryos created from their fresh IVF 
cycle, which can be used to attempt frozen embryo transfer (FET) with.   Slow freezing 
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was primarily used as the method used to cryopreserve embryos however due to 
advances in technology, the ultra-rapid freezing technique, known as vitrification has 
now replaced slow freezing.  Vitrification is a much more efficient method of 
cryopreserving, less time consuming and promises high survival outcomes.  This study 
also examined the potential of the vitrification for both oocytes and PN stage zygotes.   
Cryopreservation at the PN stage has been demonstrated previously using both slow-
freezing and more recently vitrification, with predominately good outcomes (Troup et 
al, 1991; Al-Hasani et al, 1986; Liebermann et al, 2002; Isachnko et a, 2005; 
Kuwayama et al, 2007).  Indeed there is much interest in PN stage cryopreservation in 
Germany due to the laws which prevent embryo cryopreservation for those embryos 
which have undergone syngamy (Ludwig et al, 2000; Liebermann et al, 2002; 
Isachenko et al, 2004).   However there are several stage specific limitations which 
restrict the suitability of vitrification at the pronucleate stage for the purposes of the 
PNT project.   This is primarily due to the time which pronuclei remain visible for, 
before undergoing PN breakdown, given they are temporary structures and are therefore 
only present for a limited amount of time.   
Indeed it is known from studies examining pronucleus formation following ICSI that 
extrusion of the second polar body occurs between 2-4 hours following injection, 
followed by the first appearance of pronuclei within 6-8 hours after fertilization (Nagy 
et al 1994, 1998).    These studies also found that disappearance of pronuclei occurred in 
a synchronous manner, with PN breakdown occurring ~20 hours hpi.  As fertilization 
checks are routinely performed between 16-18 hours following fertilization it is likely 
that some PN stage zygotes are on the cusp of undergoing PN breakdown, when the 
zygotes are transferred to research.   However as the studies performed in these were 
performed using abnormally fertilized human zygotes, it is likely that this further 
complicated matters.  As the appearance and disappearance of PN has been shown to 
vary somewhat in abnormally fertilized zygotes with up to a 10 hour delay between the 
appearance of the first and third pronuclei, which is not observed for normally fertilized 
zygotes (Nagy et al, 1994, 1998).    This may help to explain why experiments 
performed as part of this study found that PN only remained visible long enough to 
perform PNT in a limited number of warmed zygotes.   However it cannot be 
guaranteed that this phenomenon was simply due to timing issues associated with the 
PN stage, the use of abnormally fertilized zygotes or a side effect of the 
cryopreservation procedure and the cryoprotective chemicals employed.  
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Given the time constraints associated with PN appearance, it is essential that alternative 
stages of vitrification are explored, this includes oocyte vitrification.   However 
cryopreservation of oocytes has proven elusive for the best part of the past decade due 
to the incredibly fragile physiological nature of the oocyte, rendering it vulnerable to 
cryodamage during the cryopreservation procedure (Gok et al, 1993; Chen et al, 2004; 
Boneti et al, 2011).   However following the re-invention of vitrification it is now been 
made possible to successfully cryopreserve at this stage and achieve good overall 
survival.  Indeed several studies have now demonstrated the high recovery and survival 
rates which can be achieved following vitrification at the MII stage (Lucena et al, 2006; 
Ciotti et al, 2009; Capalbo et al, 2010; Rienzi et al, 2010).     
The criteria normally used to assess oocyte survival following warming is very limited 
involving assessment of morphology and developmental potential.  However in the last 
few years the meiotic spindle has been investigated in an attempt to assess oocyte 
viability more accurately (Santis et al, 2005).   The spindle is a highly delicate structure, 
which can be damaged as a result of the cryopreservation procedure.  This is because 
the spindle becomes depolymerised during the vitrification process and subsequently 
requires adequate recovery time following warming to allow the spindle time to 
reassemble (Sathananthan et al, 1988; Aman et al, 1994; Wang et al, 2001; Larman et 
al, 2007; Gomes et al, 2008; Ciotti et al, 2009).     Following the introduction of the 
optical system referred to as Polscope®, it is now possible to assess oocyte viability in 
living oocytes.  This is piece of microscopy apparatus that uses polarized light to allow 
observation of highly ordered subcellular structures, such as the spindle microtubules in 
mammalian oocytes (Liu et al, 2000; Moon et al, 2003; Konc et al, 2004; Navarro et al, 
2005; Rienzi et al, 2005; Santis et al, 2005; Hyun et al, 2007; Larman et al, 2007; 
Coticchio et al, 2010).  The Polscope offers the unique advantage of being totally non-
invasive, preserving oocyte viability (Keefe et al., 2003).   The Polscope device was 
used in this study to examine for the presence of spindles in oocytes following warming, 
affirming the success of the vitrification procedure for oocytes.   
However as a result of the cryopreservation procedure the zona pellucida hardens, 
therefore it is not possible to perform routine IVF insemination and ICSI must be used 
instead (Vanderzwalmen et al, 2003; Lucena et al, 2006; Ko et al, 2008). Oocyte 
vitrification followed by ICSI has been shown is not inferior to fresh insemination 
procedures, with regards to both fertilization and embryo development rates and has 
been reported following several similar independent studies (Kuleshova et al, 1999; 
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Yoon et al, 2003; Kuwayama et al, 2005; Rienzi et al, 2010).   As part of this study a 
small number of vitrified and warmed oocytes were used to attempt ICSI, which did 
prove successful. This would therefore suggest that vitrification at the metaphase II 
stage followed by fertilization using ICSI upon warming may prove the best approach to 
bank samples obtained from altruistic egg donors.   Given that this overcomes issues 
associated with vitrification at the PN stage and allows for great control with regards to 
experimental procedures.   
This study set out to address issues regarding the reliability and efficiency of current 
reproductive based techniques used to minimize the risk of transmission of mtDNA 
mutations.   However it also set out to investigate the reproducibility of new techniques, 
which have the potential to prevent the transmission of mtDNA mutations, which is not 
possible with current techniques.   However there is still much work which must be 
conducted before such nuclear transfer based approaches can be fully translated into a 
clinical treatment.   However if the nuclear transfer techniques are demonstrated to be 
safe, they will offer hope to those mtDNA patients, whom have exhausted all options 
currently available to allow them to conceive and carry a child genetically and 
biologically their own.   
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Future work 
 
There is indeed an ever growing demand for PGD by mitochondrial patients.   
Consequently it provides a potential source of embryonic samples which allows for 
examination of mutation loads for different mtDNA inherited mutations.  Work 
undertaken as part of this thesis has so far been able to examine mutation load 
segregation in various embryonic samples for six different mtDNA inherited mutations.  
However this only represents a tiny proportion of the currently reported known 
pathogenic mtDNA mutations.   It would therefore prove interesting and important from 
both a scientific and clinical standpoint to gather mutation load segregation data for as 
many other mtDNA mutations as possible to help build a picture of how this differs.  
This will certainly determine the value of PGD for women that carry these mutations.   
I think it would also prove important to analyse mtDNA mutations in individual cells of 
the blastocyst obtained from both the trophectoderm and the ICM.  This would allow us 
to determine if the mutation load indeed differs between individual cells of the ICM 
(mosaic) in contrast to the mutation load determined for the homogenate trophectoderm 
population.   Furthermore in light of recent proposals suggesting the importance of the 
ICM in initiation of the bottleneck it would be of interest to attempt to perform analysis 
for individual cells of the ICM.   It would be important however to ensure that these 
cells were not contaminated by any other neighbouring cells which may lead to 
inaccurate determination of mutation load for that cell.   
These studies would involve developing assays which would allow for efficient 
separation of cells.   Current approaches used in the laboratory involve manually 
dissecting the ICM from the trophectoderm cells.   This does allow for the ICM 
population to be distinguished from the trophectoderm cells however this does not 
ensure that the ICM population is completely dissociated from all trophectoderm cells.   
However other approaches have been reported including enzymatic digestion of non-
specific adhered cells, followed by separation and these could be used if samples are 
available.   
Given the work which has been conducted so far to examine the potential of pronuclear 
transfer for the prevention of transmission of mtDNA disease and recent events 
concerning the licensing and permitting of the technique for clinical purposes; the 
implementation of this technique now seems more a of a reality.  Much work has yet 
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still to be undertaken to fully assess the safety of the technique and its efficacy and 
efficiency.   
One of the primary areas optimisation is ensuring that embryos attain development to 
the blastocyst stage following PNT.   Several different aspects of the PNT procedure 
require refinement in order to achieve this.   Currently cytoskeletal inhibitors are used to 
allow for embryos to be manipulated safely.   Cytoskeletal inhibitors relax the 
cytoskeleton allowing for the biopsy pipette to safely remove the pronuclei, however 
these do possess some cytotoxity and it therefore important that exposure to such 
compounds is minimized and those with low cytotoxity are utilised.  This has involved 
investigating a range of cytoskeletal inhibitors to determine which poses the least harm 
to the embryo.   It will also be important that if the PNT procedure is to be made 
available as a clinical treatment that efforts be made to source a cytoskeletal inhibitor 
which is of clinical grade.   Further experiments also need to be conducted to determine 
the effects of the new cytoskeletal inhibitors and the effects this may have in turn on 
mtDNA carryover.  Another aspect of the procedure which requires attention is the 
effect of the hole made in the zona pellucida to allow entry of the biopsy pipette.  This 
is due to concern that this could be allowing premature hatching of blastocysts on day 5 
as opposed to day 6, which consequently negatively affects blastocysts quality.   
Various modifications have been developed to try and overcome this issue including 
using smaller pipettes to remove the pronuclei (which subsequently do not compromise 
the integrity of pronuclear karyoplast), making a smaller hole and using a sharp ended 
pipette.   However despite these interventions blastocysts continue to hatch on day 5, 
which has (L.Hyslop- unpublished data) may result in reduced blastocyst quality.  
Indeed analysis of fixed PNT embryos for several key cell type markers has 
demonstrated that many of these blastocysts contain lower cells counts which has been 
suggested could be a consequence of premature hatching.    There are still some options 
to be explored which might allow this issue to be overcome including the use of a 
nanomaterial to patch up the hole made for entry of the biopsy pipette.  Another 
possibility is the use of a currently commercially available compound known as 
‘embryo glue’.  These are both viable options which need to be investigated.   
Further work is also required to be performed to examine the blastocysts which result 
from the PNT embryos.   Following a report published by the scientific advisory 
committee (a panel of experts selected from relevant backgrounds to guide the decision 
making with regards to the awarding of a license to perform the PNT procedure when 
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safety and efficacy have been demonstrated) emphasis was placed on the need to ensure 
that blastocysts resulting following PNT embryos are not adversely affected.   To 
address this issue a number of key lineage specific markers (Nanog, Gata6 and Cdx2) 
have been examined in the limited number of PNT embryos which attained 
development to the blastocyst stage in order to demonstrate that the PNT procedure 
does not affect lineage specification.   The aim now therefore is to examine these 
markers and other useful cell lineage specific markers to fully examine the resulting 
blastocysts.   
The scientific advisory committee also suggested that attempts be made to derive stem 
cells from the ICM cells of the PNT blastocysts.    This would allow differentiation and 
proliferation to be examined.     It was also suggested that mtDNA carryover resulting 
from the PNT transfer procedure should also be examined.   It was therefore suggested 
that stem cells could be derived from the ICM cells of these PNT embryos and mtDNA 
carry-over examined via this method.   This would also allow for mtDNA carryover to 
be examined at different cell passages to determine if it remained consistent.    
Work covered as part of this thesis briefly touched upon the vitrification of oocytes.  
However work needs to be conducted to ensure that the meiotic spindle is not affected 
or disrupted by the vitrification process.    This will involve using imaging based 
techniques and possibly comparative genome hybridization (CGH) to ensure that the 
spindle is not harmed as a result of the vitrification process.  Karyotyping would also 
provide useful information on the chromosomal constitution.   
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Appendix 1 
 Comparison of vitrification protocols  
 
Open method (Origio™) Closed method (Vitrolife™) 
  
Cooling Rate  20,000°C/min 1,220
o
C/min  
Warming Rate   7,700
 o
C/min 
Temperature vitrification is  
performed at 
Room temperature (18-25
o
C) 
Performed on heated stage and 
solutions pre-warmed to 37
o
C (set 
point 42
o
C) 
Are solutions buffered? 
HEPES buffered  to help 
maintain pH during vitrification 
and warming procedures 
Solutions consist of a MOPs buffered 
medium to help maintain pH during 
vitrification and warming procedures 
Cryoprotectants equilibration 
solutions 
(7.5%)1,2-propanediol (PROH), 
ethylene glycol(EG) 
ethylene glycol 
Cryoprotectants in vitrification 
solution 
(15%)1,2-propanediol (PROH), 
ethylene glycol(EG) and 
0.5MSucrose 
ethylene glycol(EG), 
propanediol(PROH), 
ficoll and sucrose 
Number of solutions used to  
vitrify 
Two-step protocol Three-step protocol 
Exposure time to vitrification 
(final solution) 
60 seconds max exposure 30 seconds max exposure 
Number of solutions included 
in the warming protocol 
Five-step protocol Four-step protocol 
Time in initial warming 
solution  
3 minutes 10-30 seconds 
Initial temperature warming 
solution is equilibrated and 
held  
37
o
C 37
o
C 
Temperature remaining 
dilution steps are carried out at 
Room Temperature 37
o
C 
 
Comparison of the open and closed vitrification systems utilised as part of this study 
Table illustrates the main differences between the ‘open’ and ‘closed’ vitrification systems used 
in this study.   
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Appendix 2 
 
Supplementary 
 table 1 
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Supplementary table 2a 
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